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Maternal obesity is an increasing concern in the obstetric population. It 
confers increased morbidity and mortality to the mother and offspring 
during pregnancy and delivery as well as potential long-term increase in risk 
of ill health to the offspring. There are currently few effective interventions 
and no pharmacological therapies. Potential mechanisms to account for ill 
health in obese non-pregnant individuals include excess inflammation, both 
systemically and within specific tissues such as adipose, as well as alterations 
in metabolic regulation including hyperglycaemia, reduced sensitivity to 
insulin and altered adipokine expression. In healthy pregnancy, there are 
significant adaptations to maternal metabolism, including the development 
of profound systemic insulin resistance. We hypothesize that there exists an 
interaction between the metabolic adaptations of pregnancy and those 
occurring in obesity which could provide a physiologically plausible 
mechanism which could contribute to the pathogenesis of adverse outcomes 
associated with obese pregnancies. In this thesis, we sought to understand 
and define the metabolic adaptations to pregnancy in severely obese women. 
Anthropometric characteristics are described in a longitudinal case-control 
study of apparently healthy obese (BMI > 40kg/m2) pregnant women. 
Systemic adipokine and pro- inflammatory cytokine profiles were measuring 
using ELISA. Indices of insulin sensitivity were assessed at three time points 
in pregnancy. In a cohort study of healthy pregnant women in the third 
trimester, transcript levels of adipokines and inflammatory cytokines in 
paired subcutaneous and omental adipose tissue biopsies were quantified 
and correlated these transcript levels with booking body mass index (BMI). 
Obese pregnant women gained less weight in pregnancy compared to lean 
women, but had significantly elevated fasting third trimester glucose, as well 
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as elevated blood pressure and fasting insulin resistance throughout 
pregnancy. Fasting leptin was elevated throughout pregnancy in obese 
compared with lean pregnancy women; however, in the third trimester there 
was no correlation between adipose tissue leptin mRNA levels and BMI. 
Transcript levels of IL-6 were positively correlated with BMI in subcutaneous 
but not omental adipose tissue; no other positive correlations with BMI were 
shown. 
Hyperinsulinaemic euglycaemic clamps with concomitant use of stable 
isotope tracers were carried out in a case-control study of healthy obese 
pregnant women to characterise in detail whole body insulin sensitivity, 
endogenous glucose production and rate of lipolysis. In contrast to the 
original hypothesis, by the third trimester, there were few differences 
between lean and obese pregnant women in whole body glucose disposal 
(WGD) and endogenous glucose production. Compared with non-pregnant 
women, lean pregnant women demonstrated approximately 60% decrement 
in WGD; in contrast, obese non-pregnant women were already significantly 
insulin resistant but did not develop further insulin resistance in response to 
pregnancy.  
3-Tesla (3T) Magnetic Resonance Imaging (MRI) and 1H-Magnetic Resonance 
Spectroscopy (1H-MRS)was used to assess abdominal fat distribution, hepatic 
and skeletal muscle lipid content in a case-control study of healthy pregnant 
women in the third trimester. As expected, obese pregnant women have 
greater adipose accumulation in both subcutaneous and intra-abdominal 
adipose depots and greater lipid accumulation in skeletal muscle. However, 
hepatic lipid content was low in both groups and there were no significant 
differences between lean and obese pregnant women. This was not expected 
as both groups are profoundly insulin resistant at this at this gestation, and 
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in non-pregnant individuals, insulin resistance at this level would be 
expected to drive hepatic lipid accumulation, and may point to a pregnancy-
specific hepato-protective mechanism. 
In conclusion, in this thesis, it has been shown that while obese women are 
insulin resistant with an adverse metabolic profile, that there does not appear 
to be the expected worsening of this profile in response to pregnancy and 
that by the end of pregnancy, lean women have a similar phenotype. Instead, 
while lean women are exposed to this environment only towards the end of 
pregnancy, obese women and their offspring are exposed throughout 
gestation, including key periods of fetal development in early pregnancy. 
This prolonged exposure may account for the excess pathologies in such 
pregnancies, potentially by exhausting what physiological reserve such 
women have pre-pregnancy. Potential therapies must therefore be optimally 
timed to improve the metabolic profile of obese women in early pregnancy, 
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‘If we knew what it was we were doing, it would not be called research, would it?’ 
Attributed to Albert Einstein 
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Chapter 1  Introduction 
 
Obesity is a disorder of excess adipose tissue, and in pregnancy, it is 
associated with a number of adverse short- and long-term outcomes for both 
mother and offspring. The incidence of obesity is increasing in the UK, in 
parallel with the global situation; in particular, the long term impact of the 
maternal metabolic environment on offspring outcomes such as obesity and 
cardiovascular disease in later life is just beginning to be recognised, 
contributing to a huge burden of disease for the future.  
 
The therapeutic interventions available for obese pregnant women and their 
care providers are currently limited by three broad factors: firstly by an 
incomplete understanding of the function and regulation of adipose tissue in 
health, this area having undergone a significant paradigm shift in the last 
two decades; secondly, by a rapidly evolving appreciation of the effects of 
obesity on adipose tissue function; and thirdly, by our limited understanding 
of maternal metabolism in normal pregnancies and the complex interactions 
of the fetomaternal unit. While it is clear that interventions are required to 
prevent propagation of ill health to subsequent generations, the combined 
complexities of the combination of obesity and pregnancy are therefore a 
significant challenge.  
 
This thesis will examine the role of adipose tissue in the metabolic 
adaptations of pregnancy in obese women. Firstly, methods employed to 
assess body fat content and distribution, as well as functional aspects of 
obesity including assessment of insulin sensitivity are reviewed. Pregnancy 
impacts not only the practicalities of employing some of these techniques 
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which are widely used in the general population but also their applicability. 
In this thesis, several complementary methods of assessment of adipose 
tissue accretion and distribution and of insulin sensitivity were employed to 
address these issues. Secondly, the normal structure and function of adipose 
tissue in health is reviewed, focussing on the regulation of lipolysis, the 
endocrine function of adipose tissue and followed by coverage of the 
evidence for the disruption of adipose tissue homeostasis by obesity in non-
pregnant individuals. In this thesis, the metabolic and adipose tissue 
characteristics of severely obese pregnant women are described and 
contrasted with those of healthy weight pregnant women. Thirdly, the 
normal adaptation of lipid metabolism and its regulation by insulin by 
pregnancy is addressed. Lastly, the impact of maternal obesity in pregnancy 




1.1. Obesity  
1.1.1. Incidence & impact in pregnancy 
 
Obesity is defined as ‘abnormal or excessive fat accumulation that may 
impair health’ (World Health Organisation (WHO), 2000). The International 
Classification of Disease (ICD-10) code E66 includes several subgroups 
including morbid obesity (E66.8) and extreme obesity with alveolar 
hypoventilation (Pickwickian syndrome, E66.2) 
 
The incidence of obesity is increasing worldwide, although there is some 
evidence to suggest that incidence may be reaching a plateau, more so 
among women than men (Flegal, Carroll et al.  2010). In the UK, it was 
estimated that approximately 24% of men and women were obese 
(BMI>30mk/m2) in 2007 (WHO). In Scotland in 2008, it was estimated that 
approximately 66% of men and 59% of women aged 18-65 were obese. In the 
obstetric population, the incidence of obesity (BMI>30kg/m2) has increased 
from 7.6% to 15.6% in England from 1989 to 2007, with greatest increases in 
the percentage of women with morbid obesity (BMI>40kg/m2) (Heslehurst, 
Rankin, et al. 2010). In Scotland, the incidence of women with booking BMI 
>30kg/m2 was estimated at approximately 20% in 2005 (Kanagalingam, 
Forouhi, et al. 2005). 
 
Pre-gravid obesity is associated with adverse outcomes for mother and 
neonate, including maternal and fetal mortality (Cnattingius, Bergstrom, et 
al. 1998; Castro, Avino, et al. 2002; Jensen, Ovesen, et al. 2005; Denison, Price, 
et al. 2008). Women who are obese have reduced fertility, and in the event of 
conception, have an increased risk of miscarriage (Lashen, Fear, et al. 2004). 
4 
 
They are at increased risk of the major morbidities of pregnancy: gestational 
diabetes, pre-eclampsia, obstetric cholestasis and venous thromboembolism 
as well as increased mortality, largely due to thromboembolic events 
(CMACE, 2005-2008). 
Obese women are also at increased risk of minor complications of pregnancy 
including chest infection, symphysis pubis dysfunction (SPD), oesophageal 
reflux, and carpal tunnel syndrome (Denison, Norrie, et al. 2009). The excess 
financial cost to the NHS is high.  
At the end of pregnancy, obese women are at increased risk of post-dates 
pregnancy (Denison, Price, et al. 2008); approximately one third of women 
with BMI>35 undergo induction of labour in the UK (CMACE), compared 
with one fifth of the general population. This is associated with an elevated 
risk of late stillbirth. Operative or instrumental delivery is also increased, 
almost 40% of women with BMI>35 deliver by caesarean section compared to 
25% in the general population. This is important because operative deliveries 
are associated with increased morbidity including haemorrhage, anaesthetic 
complications, and post-partum complications including thromboembolism 
and wound infections. Anaesthetic complications include difficulty in siting 
regional analgesia, increased requirement for general anaesthesia and 
increased risk of Mendelson syndrome.  
Fetal issues include increase risk of congenital anomaly (Rasmussen, Chu, et 
al. 2008; Stothard, Tennant, et al, 2009; Mills, Troendle, et al. 2010). This is 
possibly due to a true ‘metabolic’ teratogenesis similar to that observed in 
diabetic pregnancies (Suhonen, Hiilesmaa, et al. 2000) and nutritional defects 
such as folate deficiency (Kaidar-Person, Person, et al. 2008), as well as 
decreased sensitivity of antenatal screening tests such as ultrasound (Dashe, 
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McIntire, et al. 2009). Fetal loss is increased, both first trimester miscarriage 
and late stillbirth. Neonatal admission rates are also increased (Sarkar, et al. 
2007), as is the likelihood of pre-term delivery (Smith, Shah, et al. 2007; 
McDonald, Han, et al. 2010). There can also be difficulties with achieving 
acceptable fetal monitoring in labour; a low threshold for use of a fetal scalp 
electrode is recommended by the Royal College of Obstetricians & 
Gynaecologists (CMACE/RCOG, 2010).  
More importantly, the impact of the maternal metabolic environment on 
long-term offspring outcome is beginning to be recognised, with increased 
risk of obesity in later life in the offspring of obese mothers (Whitaker, 2004; 
Oken, Taveras, et al., 2007.). However, these relationships are complex and 
are affected by postnatal environmental factors. 
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1.1.2. Assessing Body Fat content and distribution 
The most commonly used method to quantify ‘fatness’ is the Body Mass 
Index (BMI). This is a means to describe weight relative to height, is 
expressed in kg/m2, and is calculated as follows: 
BMI = weight (kg) / [height (m)]2 
 
The World Health Organisation defines BMI as follows: 
Category BMI Range (kg/m2) 
Underweight <19.9 
Normal 20.0 – 24.9 
Overweight 25.0 – 29.9 
Obese Class I 30.0 – 34.9 
Obese Class II 35.0 – 39.9 
Obese Class III (morbid obesity) >40.0 
 
BMI has the advantage of being easily and reproducibly measured, simply 
calculated and universally accepted, thus facilitating comparison between 
data from different countries. However, there are a few caveats which should 
be considered. The first is international variation on the basis of ethnicity. For 
example, South East Asian and Japanese populations use different ranges to 
categorise BMI: BMI > 23.0 is considered overweight in these populations as 
there is evidence that this ethnic group have elevated cardiovascular risk 
even if BMI is low compared to those of European ethnicity (Razak, Anand, 
et al. 2007).  Secondly, as BMI is a simplistic estimation of total body fatness, 
the assumption that relative proportions of muscle, water and fat mass 
remain constant leads to overestimation of adiposity in individuals with 
increased lean body mass e.g. athletes. Therefore while in population based 
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studies BMI is a useful comparator, in more detailed studies, greater 
description of body composition is required.  Thirdly, it is increasingly 
evident that it is not simply total body fat which determines risk of 
cardiovascular disease, but body fat distribution, particularly excess central 
or abdominal adiposity (Kannel, Cupples, et al, 1991). Thus additional 
assessment of body composition and distribution is required. There are many 
approaches to this which can be broadly classified as either direct or indirect 
methods. Indirect methods infer body composition; reference methods 
involve direct measurement from which body composition, commonly 
expressed as percentage body fat, can be calculated. Indirect methods 
include body mass index, anthropometric measurements such as waist/hip 
ratio and skinfold thicknesses, and use of bioimpedance to estimate body 
composition using electrical conductivity. Direct methods involve more 
complex techniques such as underwater weighing (UWW) or air-
displacement plethysmography (ADP), Dual Energy X-ray Absorptiometry 
(DEXA) and stable isotope tracer methods. All of these approaches require 
certain assumptions to be made and application of a generalisable model of 
body composition, the simplest of which is the 2-compartment model, which 
splits the organism into Fat Mass (FM) and Fat Free Mass (FFM). Fat free 
mass is most commonly estimated by assessment of total body water, using 
the assumption that fat is relatively anhydrous. The second assumption that 
it uses is that FFM is composed of 73% water, 20% protein and 7% bone 
mineral. Models of body composition can be employed; the simplest is the 2-
compartment model, which divides the body into FM and FFM; a 4-
compartment model divides FFM into water, bone mass and muscle mass. 
The choice of applied model depends on the question of interest, size and 
nature of the study as well as resources available. 
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1.1.2.1. Indirect Methods 
 
Anthropometric measurements 
The simplest measurement of body distribution uses the ratio of waist 
circumference to hip circumference, the waist-hip ratio (WHR). A high WHR 
(>0.85) has been associated with increased central distribution of adipose 
tissue, which in turn has been associated with increased risk of 
cardiovascular disease and type II diabetes mellitus (Kannel, Cupples, et al, 
1991). 
 
A more detailed assessment of body fat distribution uses measurement of 
skinfold thickness using callipers at specific anatomical locations, commonly 
including triceps, biceps, subscapular and supra-iliac regions. These 
measurements can be used to calculate the total body fat as a percentage of 
total body weight. There are a number of different equations for calculating 
body fat; commonly used are the Jackson-Pollock 3- and 7-site equations 
(Jackson, Pollock, et al., 1980) and Durnin/Womersley (Durnin & Womersley. 
1974) equations and their variations. The advantages of these types of 
measurements are that they are cheap to use, accessible and acceptable to 
patients, which makes them very useful for ‘field’ studies of large 
populations. The major drawback is that obtaining the measurements can be 
extremely operator dependent, both in identifying the correct site for 
measurement and in use of the callipers to obtain measurements. While 
intra-observer variability can be minimised with training and repetition, 
there is significant variability in estimation of total body fat depending on 
the choice of equation used to calculate body fat. There is also an additional 
source of variability where the gender and ethnicity of the population being 
measured differs from the characteristics of the study cohort used to develop 
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those equations, or where body fat content is at the extremes of the Gaussian 
distribution i.e. extremely obese or extremely lean. For example, some 
studies have shown a consistent 3-8% overestimate of total body fat when 
anthropometric measurements were compared with underwater weighing in 
a group of females with predominantly upper body fat distribution (Swan & 
McConnell, 1999).   Additionally, skinfold derived estimations of body fat 
can be inaccurate compared with other methods. However, while assessment 
of absolute body fat may be inaccurate, skinfold measurements can be used 
to assess longitudinal changes in body composition. In pregnancy, while 
calliper measurements are highly correlated with ultrasound measurement 
of subcutaneous adipose depth, they also consistently overestimate the true 
skinfold thickness compared to ultrasound. This is thought to be due to 
altered compressibility of subcutaneous tissue in pregnancy (Stevens-Simon, 
Thureen, et al. 2001). 
 
Bioelectrical Impedance 
Bioelectrical impedance analysis (BIA) makes use of measurement of the 
degree of impedence of tissues to conductivity of an electrical current to 
calculate the relative water content of a living organism and thus the relative 
proportion of fat and fat free mass can be subsequently estimated. 
Bioimpedance measurements have been validated against other Total Body 
Water (TBW) approaches, and correlate closely in the studied populations 
(Kushner & Schoeller, 1986). In addition, the equipment required is easily 
used and portable. However, BIA can be unreliable in conditions where 
generalisable equations for the derivation of TBW have not been validated or 
hydration status is not known. In pregnancy, the contribution of amniotic 
fluid volume and altered total body water is variable, although some small 
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studies have suggested that BIA is comparable to isotopic dilution methods 
(Lukaski, Siders., et al 1994). 
 
1.1.2.2. Direct Methods 
 
Total body water 
Assessment of total body water (TBW) can be used to infer fat mass by the 
application of the 2-compartment model. There are a number of methods for 
measuring total body water: isotopic dilution methods and volume 
displacement techniques. Isotopic dilution methods make use of stable 
isotope tracers such as deuterium (2H, or D) and oxygen -18 (18O); deuterated 
water (D2O) can be used alone to calculate total body water, or doubly 
labelled water (D218O) can be used to calculate metabolic rates. This method 
works by introducing a sample of labelled molecule, e.g. deuterated water, of 
known concentration into a system (eg an organism) and then measuring 
how much that sample has been diluted in the total population of water 
molecules present in that system (Schoeller, Santen, et al. 1980). The total 
mass of water is therefore calculated as follows: 
 Nmol = Mmol / pM 
Where Nmol is the total number of water molecules, Mmol is the number of 
molecules introduced and pM is the proportion of marked molecules in the 
sample obtained after a period of time.  
 
These methods are straightforward to carry out, but can be expensive and 
require access to mass spectrometry equipment to analyse samples, which 




Water displacement (underwater or hydrostatic weighing) and air 
displacement methods rely on calculation of body density to estimate fat 
content, by making a precise measurement of weight and body volume based 
on volume or pressure change. This data can then be used to calculate total 
body density and thus estimate % body fat based on the equations of Siri 
(Siri, 1961):  
%Fat = 495/density-450 
 These methods are more accurate than simple anthropometric 
measurements, have good agreement with other methods of assessing body 
composition and have been accepted as the gold standard method of 
assessing body composition. However, they require access to specialised 
equipment and training, are time-consuming to carry out, and are therefore 
less suitable for large population studies. Air displacement plethysmography 
(ADP) is generally more acceptable to patients than underwater weighing 
and can be useful for assessment of specific subgroups of patients such as 
infants, in whom other methods of assessing body composition are not 
suitable.  
 
Total Body Potassium 
 Total body potassium can be used to estimate the cellular contribution to 
body composition, by measuring gamma radiation emission from 40K, a 
naturally occurring  potassium isotope, present at constant concentrations of 
approximately 0.0118% of total potassium. Measurement of this isotope can 
be used to calculate total body potassium, and thus FFM and FM. Two 
assumptions are required: firstly that the potassium content of FFM is 
constant; secondly, that potassium is located almost exclusively in the FFM. 
(Forbes, Gallup, et al. 1961; Burmeister, 1965). This approach requires 
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expensive specialist equipment, but with access to equipment, it is relatively 




Imaging techniques have the advantage of not only measuring body fat 
content in the whole organism, but also provide detailed information on fat 
distribution. The main approaches make use of dual energy x-ray 
absorptiometry (DEXA), computed tomography (CT) and magnetic 
resonance imaging (MRI) modalities. 
 
DEXA makes use of the differential attenuation of X-ray radiation by bone, 
adipose and non-adipose soft tissue. The advantages are that it is quick to 
carry out and is relatively operator independent. It also provides information 
on total adipose tissue including both specific adipose depots and also any 
other fatty tissue in ectopic sites. Measurement of bone mass allows a more 
accurate assessment of body composition using the 4-compartment model. 
However, it can be expensive and requires exposure to ionising radiation. X-
ray exposure is low, but this still limits its usefulness in certain populations 
such as children or pregnant women. 
 
Whole-body CT imaging provides similar information; the relative 
attenuation of X-rays in different tissue types allows generation of images in 
grey-scale. The relative ‘greyness’ of each pixel in the image corresponds to 
the number of Hounsfield units (HUs) of that tissue. Adipose tissue appears 
white, with HUs between -190 to -30; muscle is denser, appears darker and 
has HUs in the positive range. It is therefore possible to use image analysis 
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software to set an arbitrary cut-off to identify which areas of the image have 
low attenuation and vice versa. The advantage of whole-body CT is that 
smaller discrete adipose depots can be quantified, such as intra-muscular 
lipid infiltration, in addition to measurement of specific adipose depots; data 
analysis is relatively operator independent, although it does require regions 
of interest to be identified and thresholds to identify adipose to be set. 
However, it can be very costly, with significant data analysis requirements 
and also requires significant exposure to x-ray radiation.  
 
Magnetic Resonance Imaging allows similar assessments of adipose tissue 
volume and organ lipid content but avoids radiation exposure. Similar image 
analysis techniques can be applied to MR images as those used for analysis 
of CT-derived data. MR allows increased resolution of soft-tissue and thus 




1.1.3. Assessment of body composition in pregnancy  
 
Changes in maternal body weight and composition have been associated 
with adverse pregnancy outcomes, particularly in obese women (Kiel, 
Dodson, et al., 2007). It is therefore important to have a robust means of 
determining body composition during pregnancy. However, many 
commonly used means of assessment of body composition rely on 
determination of total body water, and are thus influenced by the relative 
hydration status of the subject. During pregnancy there is expansion of 
maternal body water due to increased blood volume, tissue growth and 
amniotic fluid, estimated to contribute 6-10L (Hytten., 1985). Consequently, 
methods which rely on accurate assessment of total body water are not valid. 
Although equations have been generated to account for a gestational change 
in composition and density of fat-free mass (van Raaj, Peek, et al. 1988); these 
were derived from a small number of normal weight women based on 
underwater weights at increasing gestation. Their applicability to a 
heterogeneous population is not clear and may be affected by differing body 
compositions at different gestations (Jaque-Fortunato, Khodiguian, et al. 
1996). 
 
An additional issue is that change in body composition requires an accurate 
assessment of a baseline measure. There are few data on early changes in 
body composition; it is likely to be slightly altered by early gestation, with 
small contributions from fetus and placenta, as well as expanded total body 
water, although some studies have suggested that there is in fact little change 
in body composition over the first trimester (Fattah, Farah, et al. 2010). Post-
partum measurements are also unlikely to reflect a true pre-pregnancy state.  
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One approach has been to use a more complex model for body composition, 
with up to 4 compartments (fat mass, and fat-free mass composed of bone 
mass, body water and protein or muscle mass). Use of the 4-compartment 
model requires assessment of the bone mass of subjects; this can be done by 
DEXA and is therefore unsuitable unless subjects are assessed pre-
pregnancy, as DEXA is unsafe to use in pregnancy. There is good correlation 
between 3- and 4-compartment models (Hopkinson, Butte, et al. 1997; Koop-
Hoolihan, Van Loan, et al. 1999). Three compartment models have the 
advantage of not requiring assessment of pre-pregnancy bone mass. 
However, all approaches require certain assumptions to be made and are 
subject to a significant degree of variability within populations. 
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1.1.4. Quantifying intra-organ lipid content  
 
In addition to quantification of adipose tissue depots, intra-organ lipid 
content is of increasing interest due to the observed association between 
intra-hepatic and intra-myocellular lipid content and insulin resistance, 
particularly in the context of obesity (Seppälä-Lindroos, Vehkavaara, et al. 
2002). Biopsy is the current gold standard for direct quantification of intra-
hepatic and intra-muscular lipid content. However, this is an invasive 
technique which places a high burden on research participants and is less 
suitable for longitudinal studies.  
 
Imaging allows accurate, non-invasive quantification of organ lipid content, 
in particular ultrasound, CT and MR techniques including 1H-MR 
spectroscopy. Ultrasound is commonly used to assess lipid infiltration in 
organs such as liver and to grade hepatic steatosis. Data can be very operator 
dependent but the technique is relatively cheap and accessible, which makes 
it a clinically useful modality for the assessment of patients with conditions 
such as hepatic steatosis (Ma, Holalkere, et al. 2009). CT images can be used 
to determine the relative lipid content of organs as well as identifying 
adipose depots. Lower mean attenuation of an organ correlates with lipid 
content, however, a high glycogen content can also affect attenuation and so 
relative rather than absolute lipid content is often generated (eg the ratio of 
attenuation of liver to that of spleen). Both ultrasound and CT provide 
qualitative rather than quantitative information about organ lipid content. 
 
1H-MR spectroscopy makes use of differing resonance frequencies of protons 
which are components of different molecules, usually metabolites such as 
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amino acids or creatine, and generates a plot of proton resonance relative to a 
known reference standard e.g. water. Peaks which correspond to specific 
molecules are identifiable at specific resonance frequencies, corresponding to 
the degree of shift from the standard. Data is generated from a specified 
voxel or region of interest within the organ, with signal intensity relative to 
the quantity of metabolite present in that voxel. Thus quantitative data 
regarding organ lipid content is obtained by the use of magnetic resonance 
spectroscopy (MRS). MRS has been thoroughly validated: MRS data 
correlates closely with lipid content of phantoms containing known lipid 
concentrations (Goodpaster, Stenger, et al. 2004) as well as with biopsy data 
from specific organs (Szczepaniak, Babcock, et al. 1999; Sharma, Kitajima, et 
al. 2011; Springer, Machann, et al. 2010). The main drawback of MRS is that it 
is costly to carry out, limiting its use to research studies rather than routine 
clinical practice.  
 
Certain practical limitations can also influence the use of MRS. Firstly, MRS 
requires a uniform magnetic field, and uneven loading of the subject within 
the field can affect data capture. The process of shimming can compensate 
for this to a certain extent, however, patient positioning can also have a 
significant effect on magnetic field distortion. Therefore if a specific patient 
position is required, the acquisition of spectroscopy data can be affected. 
Secondly, data must be acquired from as homogeneous a voxel as possible. 
In liver, this requires avoidance of vessels, but also avoidance of lateral 
placement to avoid inclusion of subcutaneous or lung tissue in the voxel, 
particularly taking breathing motion into consideration.  
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1.1.5. Assessing Insulin Sensitivity/Resistance 
 
A major consequence of excess adiposity is dysregulation of metabolism 
culminating in systemic resistance to the action of insulin. Insulin resistance 
(IR) contributes to the pathophysiology of several clinical conditions 
including metabolic syndrome & type II diabetes mellitus (Reaven, 1988), 
and can be defined as a reduction in the effectiveness of insulin at lowering 
extracellular glucose. Insulin resistance has been defined clinically as ‘a 
syndrome that is associated with a clustering of metabolic disorders, 
including non-insulin-dependent diabetes mellitus, obesity, hypertension, 
lipid abnormalities, and atherosclerotic cardiovascular disease’ (De Fronzo & 
Ferrannini, 1991). 
 
Assessment of insulin sensitivity/resistance is essential as it is central to the 
diagnosis of specific conditions but also because identification of insulin 
resistant subjects at higher risk of development of frank disease facilitates 
early intervention and therapy. A large number of definitions of metabolic 
syndrome exist from a number of national and international institutions such 
as WHO, IDF, EGIR, ADA, SIGN, and NICE, each making use of differing 
measures of insulin resistance. However, common to all definitions is the 
concept that insulin resistance underpins the pathogenesis of type II diabetes 
mellitus, and is associated with an adverse metabolic and cardiovascular 
phenotype, and clinical features such as hyperlipidaemia, hypertension and 
obesity (Alberti, 2005). 
 
Multiple methods of quantification of insulin resistance exist; the gold 
standard is the Hyperinsulinaemic Euglycaemic Clamp (HEC). The choice of 
19 
 
assessment depends on the study context, time available and cost. While 
clamp techniques provide an accurate assessment of IR, they are moderately 
invasive and time-consuming; therefore other methods have been developed 
which are simpler to conduct and have increased applicability at a 
population level.   
 
Firstly, single measurements can be employed, at their most basic making 
use of measures of fasting glucose and insulin. These can be diagnostic in 
their own right, for example, fasting glucose > 7.0mmol/L is diagnostic of 
diabetes mellitus (World Health Organization criteria).  An elevated fasting 
insulin can be indicative of insulin resistance (Laasko, 1992) although caution 
has to be taken in certain clinical circumstances, eg type 2 diabetes mellitus, 
where beta cell failure and reduced insulin secretion is a feature. Improved 
correlation with clamp assessments of IR can be derived from a combination 
of fasting glucose and insulin measurements, using models such as the 
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) 
(Matthews, Hosker, et al. 1985) and QUantitative Insulin sensitivity Check 
Index (QUICKI) (Katz, Nambi, et al. 2000). These methods make the 
assumption that hepatic and peripheral IR are equivalent. 
 
HOMA-IR is calculated as follows: 
(Fasting glucose (mmol/L) x Fasting insulin (μU/mL))/22.5  
 
QUICKI is calculated as follows: 




Both of these indices have been evaluated against HEC and show reasonable 
correlation with clamp-derived IR. Their major advantage is that they require 
only a single fasting sample from the patient, and are thus more suitable for 
use in the general population. 
 
A further index which can be used is that of Matsuda (Matsuda & deFronzo, 
1999), which uses measurements obtained during an oral glucose tolerance 
test, ie fasting and 2 hour samples. This has the advantage of assessing both 
hepatic IR (fasting state) and peripheral IR (fed state post-glucose challenge) 
and is calculated thus: 
10,000/√([fasting glucose(mg/dL) x fasting insulin(μU/mL)] x [mean 
glucose(mg/dL) x mean insulin during OGTT(μU/mL)]) 
 
This index correlates closely with that of HOMA-IR (r = 0.92) and with SIclamp 
(r = 0.74) (Matsuda & deFronzo, 1999), and provides a more detailed 
assessment of whole body insulin sensitivity from easily obtainable samples 
during an OGTT rather than a snapshot of the fasting state alone. 
  
More detailed assessments of IR can be derived by the use of minimal 
modelling techniques (Saad, Anderson, et al., 1994). These include the 
Frequently Sampled IV Glucose Tolerance Test (FSIVGTT) and the 
Continuous Infusion of Glucose with Model Assessment (CIGMA). These 
techniques make use of multiple samples to more accurately model glucose 
disposal in both hepatic and peripheral compartments using mathematical 
algorithms. These are useful in the context of a research study but are less 




The use of both and glucose and insulin challenge provides further 
assessment of metabolic regulation; techniques includes the insulin tolerance 
test, involving measuring the decline in circulating glucose concentrations 
following an insulin bolus, and the insulin sensitivity test (Greenfield, 
Doberne, et al. 1981) which uses octreotide, a potent somatostatin analogue, 
to suppress endogenous insulin followed by a fixed infusion of insulin with a 
defined glucose load. The advantage of this technique is that it negates the 
beta-cell contribution to peripheral insulin sensitivity. 
   
As previously stated, the hyperinsulinaemic euglycaemic clamp remains the 
gold standard method for assessing insulin sensitivity. A constant insulin 
infusion provides supra-physiological plasma insulin concentrations; this has 
the effect of stimulating glucose uptake peripherally, suppressing 
endogenous glucose production by the liver as well as affecting other 
insulin-sensitive pathways. A concomitant glucose infusion is titrated to 
maintain plasma glucose concentrations at euglycaemia (a common target is 
4.7mmol/L). The rate of glucose infusion in steady state conditions is a direct 
measure of whole body glucose disposal and represents basal glucose uptake 
as well as uptake by all insulin-sensitive tissues. The greater the rate of 
glucose infusion, the greater the subject’s sensitivity to insulin. This is 
expressed as M, in mg glucose/kg/min. M can also be expressed as mg/kg fat 
free mass/min (mg/kgFFM/min). Fat free mass is largely composed of skeletal 
muscle, which is the biggest contributor to insulin-sensitive glucose uptake; 
therefore expressing whole body glucose uptake in this way is more specific 
for insulin sensitive tissues. This has to be interpreted with caution in 
pregnancy as estimates of fat mass and fat free mass are less accurate in 
pregnancy as discussed in section 1.1.3; while expressing M per kg fat free 
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mass expresses substrate utilisation by insulin sensitive tissues, this could be 
influenced by less accurate assessment of total body fat, particularly in the 
third trimester due to the influence of the fetoplacental unit. However, 
expression of M per kg total body mass could lead to a potential 
underestimation of insulin sensitive glucose disposal, particularly in lean 
women, as they have proportionately greater lean body mass per kg 
compared to obese subjects.  
  
An index of insulin sensitivity can also be derived from the M value, by 
expressing glucose disposal as a function of insulin concentration, M/I. This 
expresses insulin sensitivity relative to the quantity of glucose disposal 
achieved per unit insulin. 
 
Clamp studies also provide the means to study additional metabolic 
pathways such as endogenous glucose production, lipolysis and also energy 
expenditure by the concomitant use of techniques such as isotopic tracers or 
indirect calorimetry. Tracer studies utilise either stable or radiolabelled 
isotopes. Stable isotopes include 6,6-d2 glucose and 1,1,2,3,3-d5 glycerol 
which contain deuterium labels and are thus identifiable using mass 
spectrometry techniques.  Lack of radioactivity makes them particularly 
suitable for use in most study populations, including pregnant women. In 
the work described in this thesis, we have employed glucose and glycerol 
stable isotope tracers in the context of a hyperinsulinaemic euglycaemic 
clamp to quantify insulin resistance, endogenous glucose production and 
rate of lipolysis in obese pregnant women.  
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1.2. Adipose tissue biology in health 
 
Adipose tissue is an organ of mesodermal origin whose primary function 
was until recently considered to be purely one of energy storage as fat in the 
form of triglyceride. However, it has become apparent in recent years that 
adipose tissue is not only a highly active endocrine organ, but has specific 
functions depending on its anatomical location. 
 
1.2.1. Anatomy 
There are two types of adipose, brown adipose tissue (BAT) and white 
adipose tissue (WAT). WAT is the major type of adipose in human adults, 
and is the depot which is expanded in obesity. In humans, BAT is 
predominantly found in the fetus and neonate and is principally involved in 
thermogenesis. BAT shares a common embryological origin with myocytes, 
is multilocular and dense in mitochondria (Seale, Bjork, et al. 2008). BAT 
comprises less than 1% of total adipose tissue in adult humans, but it may 
have a role in maintaining energy homeostasis. However, it has recently been 
shown that brown adipose tissue is present in adults (Cypess, Lehman, et al.  
2009), can be activated in adults in response to cold (Virtanen, Lidell, et al.  
2009) and that the amount of BAT present is inversely proportional to body 
mass index which may reflect a reduction in the requirement for non-
shivering thermogenesis in obese subjects or a predisposition to adipose 
accumulation via a pre-existing defect in the ability to dispose of excess 
calories (Cypess, Lehman, et al.  2009; Vijgen, Bouvy, et al.  2010). It has also 
been shown that there is a population of beige or ‘brite’ adipocytes which 
arise from white adipose  but express low levels of UCP-1, a classical marker 
of brown adipocytes. These cells respond to stimulation in a similar manner 
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to brown adipocytes and may be the origin of cold-responsive brown 
adipose in humans (Wu, Boström, et al. 2012). 
 
Composed of adipocytes, supporting stromal cells and a vascular network, in 
humans, the major WAT depots are subcutaneous and visceral, although 
there are also some smaller adipose deposits in bone marrow and 
intramuscular. Subcutaneous adipose tissue displays regional characteristics, 
depending on anatomical location, e.g. abdominal, gluteal, or thoracic. 
Adipocytes in WAT derived from mesenchymal stem cells begin to form 
around week 17 of fetal development, though the majority of fetal adipose 
tissue deposition occurs in the third trimester (Symonds, Mostyn, et al. 2003). 
While fetal adipose displays characteristics of both WAT and BAT, in adult 
life, the majority is WAT. Adipose tissue also contains lymph nodes with a 
locally adaptive immune cell content and stromal cells: macrophages, 
fibroblasts and endothelial cells. These cells are thought to have a local 
regulatory role in adipose tissue function, and along with adipocytes 




1.2.2. Biochemical properties of adipose tissue 
 
1.2.2.1. Lipid storage & release 
 
One of the major functions of the adipocyte is to store energy as intracellular 
triglyceride. Circulating protein-bound lipid in the form of chylomicrons or 
very low-density lipoprotein (VLDL) is hydrolysed by lipoprotein lipase 
(LPL), bound to the endothelial surface of adipose tissue capillaries via 
heparin sulphate proteoglycans. Following hydrolysis, non-esterified fatty 
acid is taken up by the adipocyte by a number of binding proteins, e.g. fatty 
acid transport protein (FATP), converted to fatty acyl CoA and subsequently 
re-esterified with glycerol-3-phosphate in the endoplasmic reticulum to form 
triacylglyceride (TAG). The rate limiting step in TAG synthesis is catalysed 
by diglycerol acyl transferase (DGAT), an endoplasmic reticulum membrane 
bound protein.  TAG is stored usually in a single large anhydrous lipid 
droplet within the cytoplasm of the adipocyte.   
 
Lipid storage is under endocrine regulation which controls the relative rates 
of lipid synthesis and lipolytic mechanisms through regulation of lipid 
turnover at the intracytoplasmic lipid droplet.  
26 
 
Access to the lipid droplet is regulated by perilipins, which prevent access to 
triglyceride by hormone-sensitive lipase (HSL), initially considered the rate-
limiting enzyme in the lipolytic cascade. Under basal conditions, HSL is 
located diffusely throughout the cytoplasm, however, upon phophorylation, 
which occurs physiologically in response to fasting, it is translocated to the 
surface of the lipid droplet (Egan, Greenberg, et al. 1992; Brasaemle, Levin, et 
al. 2000)), where interaction with phosphorylated perilipin allows access to 
the lipid droplet (Sztalryd, Xu, et al. 2003). HSL has specificity for both TAG 
and DAG; glycerol and the last remaining fatty acid are released by the 
action of monoacylglycerol lipase. A third lipase, adipose triglyceride lipase 
(ATGL), has also been identified and has a role in the initiation of lipolysis. 
Both ATGL and HSL are required for normal full induction of lipolysis 
(Zimmerman, Strauss, et al. 2004). Following sequential hydrolysis of a 
molecule of triglyceride, one molecule of glycerol and three of fatty acid are 
released into the circulation. Fatty acid binding protein (FABP) is important 
in intracellular transport and release of FFA from the lipid droplet to the 
plasma membrane (Baar, Dingfelder, et al. 2004); FFA are subsequently 
exported to the liver bound to albumin, where they undergo beta-oxidation; 
glycerol is exported from the adipocyte via aquaporin 7 (Maeda, Funahashi, 
et al. 2004), and can be used as a substrate for gluconeogenesis in the liver 
following uptake and phosphorylation by glycerol kinase.  
 
The regulation of lipid turnover is under significant hormonal control and 
which pathway dominates depends on whether the individual is in an 




The principle hormone promoting lipid storage is insulin. Insulin acts via a 
membrane-bound tyrosine kinase receptor. Phosphorylation of the intra-
cellular domains upon insulin binding activates the phosphoinositide-3-
kinase (PI3K) signalling cascade, resulting in the translocation of the Glucose 
Transporter (GLUT)4 to the cell surface, enhanced lipid esterification and 
inhibition of lipolytic enzymes. Insulin-dependent glucose uptake is 
increased following translocation of GLUT4 (Slot, Geuze, et al. 1991); upon 
entry to the adipocyte, glucose is phosphorylated by glucokinase and enters 
the lipid synthesis pathway. Enhanced production of glycerol contributes to 
lipid accumulation as it esterifies with the accumulating free fatty acid. 
Phosphorylation of insulin-receptor substrate-1 (IRS-1) promotes association 
between the plasma membrane and PI3K, leading to activation of PI3K and 
subsequently the activation of protein kinase B/Akt. PKB activates 
phosphodiesterase 3b which inhibits HSL by reducing cAMP levels. 
 
The principal hormones promoting lipolysis are the catecholamines, of which 
the principle adrenoceptors of adipocytes are beta 1 and 2; beta-3 
adrenoceptors are also capable of promoting lipolysis but are thought to be 
of less importance in humans. Adrenaline and noradrenaline signal via 
cAMP, and activate PKA. This kinase then rapidly phosphorylates and 
activates HSL.  Polymorphisms in the adipocyte beta-2 adrenoceptor have 
been linked to obesity (Large, Hellström, et al. 1997). 
 
A number of other hormones have regulatory activity in the adipocyte. 
Glucagon stimulates lipolysis in vitro (Langslow & Hales, 1969); however, in 
vivo studies using microdialysis in humans have not shown an effect on 
lipolysis (Bertin, Arner, et al. 2001; Gravholt, Møller, et al. 2001). Atrial 
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natriuretic peptide (ANP) stimulates lipolysis in a cGMP dependent 
mechanism via cGMP-dependent protein kinase (PKG) in response to 
exercise (Moro, Pillard, et al. 2008). Thyroid hormones can also act to enhance 
the effect of catecholamines on lipolysis by increasing receptor availability 
and reducing secondary messenger turnover via reduced phosphodiesterase 
activity (Hellström, Wahrenberg, et al. 1997). 
 
Glucocorticoids also have a role in maintaining lipid storage: in vitro, 
treatment of isolated adipocytes with cortisol reduces basal and isoprenaline-
stimulated lipolysis (Ottosson, Lönnroth, et al. 2000); dexamethasone has a 
stimulatory effect on LPL mRNA synthesis and activity (Fried, Russell, et al. 
1993). There are regional variations in response to glucocorticoid; omental 
adipose has a greater density of glucocorticoid receptors than subcutaneous 
aidpose (Pedersen, Jønler, et al. 1994). Recent evidence has highlighted the 
importance of local regulation of availability of glucocorticoids through the 
activity of 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This 
enzyme converts inactive cortisone to active cortisol (and also the reverse 
reaction) and thus enhances local tissue availability of active glucocorticoid 




1.2.2.2. Endocrine functions of adipose tissue 
 
In the last 20 years there has been a paradigm shift from adipose tissue being 
viewed as an inert lipid storage organ to that of an active endocrine organ. 
Many hormones, with endocrine and paracrine actions are produced by 
adipose tissue, both by adipocytes themselves and also by the supporting 
stromal cells. Secretory products of adipose tissue are collectively known as 
adipokines, and include a diverse range of proteins such as the classical 
adipokines, leptin and adiponectin, as well as inflammatory cytokines such 
as interleukin 6 and tumour necrosis factor alpha.  
 
Leptin is a 16kDa hormone that has pleiotropic effects on multiple organs. It 
is primarily synthesized by white adipose tissue (Zhang, Proenca, et al. 1994) 
but is also produced by ovary (Cioffi, Van Blerkom et al. 1997), pituitary (Jin, 
Burguera, et al. 1999), placenta (Señarís, Garcia-Caballero, et al. 1997) and also 
in baboon fetal lung (Henson, Swan, et al. 2004). It has a role in the regulation 
of appetite, satiety, reproductive function, body mass and immune 
regulation (Friedman & Halaas, 1998; Chan, Matarese, et al. 2006;  Kelesidis, 
Kelesidis, et al. 2010). Circulating levels of leptin are proportional to fat mass 
(Maffei, Halaas, et al. 1995; Considine, Sinha, et al. 1996; Rönnemaa, Karonen, 
et al. 1997) and correlate inversely with insulin sensitivity independently of 
fat mass (Silha, Krsek, et al. 2003). 
 
Adiponectin is a 30kDa protein which circulates in a multimeric form in 
plasma and is secreted by adipocytes (Scherer, Williams, et al. 1995) but also 
by salivary gland epithelial cells (Katsiougiannis, Kapsogeorgou, et al. 2006), 
leucocytes (Crawford, Peake, et al. 2010) and skeletal muscle (Liu, Chewchuk, 
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et al. 2009). It has an inverse pattern of expression to leptin: it is synthesized 
in adipose tissue but is inversely correlated with fat mass, particularly in 
men (Zhang, Holt, et al. 2005); adiponectin levels correlate directly with 
insulin sensitivity (Hotta, Funahashi, et al. 2001) and treatment with 
adiponectin can reverse the insulin resistance of obesity (Yamauchi, Kamon, 
et al. 2001).  
 
There are a number of other endocrine products of adipose tissue. These are 
summarised in Table 1. Among these, inflammatory products are of 
importance in the context of obesity as their synthesis and secretion become 
dysregulated. However, their role in the physiological regulation of adipose 
tissue function is not clear.  
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Tumor necrosis factor  
(TNF)  
Stimulates lipolysis Zhang, et al. 2002 
 Increases insulin resistance via 
interference with IRS1 downstream 
signalling 
Hotamisligil, et al. 1996 
 Impairs pre-adipocyte differentiation Isakson, et al. 2009 
Monocyte chemoattractant 
protein (MCP)-1 
Promotes monocyte recruitment into 
WAT 
Kanda, et al. 2006 
Interleukin (IL)-6 Stimulates lipolysis Trujillo et al. 2004. 
IL-8 Potent chemoattractant Bruun, et al. 2001 
IL-1β Impairs insulin signalling by inhibition of 
phosphorylation of IRS1 
Lagathu, et al. 2006 




IL-10 Broad anti-inflammatory activity 
Altered ATM phenotype 
May protect against development of IR 
Couper, et all. 2008 
Fujisaka, et al. 2009 
Lumeng, et al. 2007 
IL-1Ra Antagonises IL1 Arend, et al. 2001 
Hormones   
Leptin Central regulation of appetite 
Stimulates fatty acid oxidation in liver 
and skeletal muscle 
Inhibits insulin secretion from pancreas 
Induces secretion of IL1-Ra 
Kalra, et al. 1999 
Minokoshi, et al. 2001 
 
Emilsson, et al. 1997 
Dreyer, et al. 2002  
Adiponectin Stimulates fatty acid oxidation and 
glucose utilization 
Promotes adipocyte differentiation 
Reverses obesity-associated IR 
Improves hepatic IS 
Induces secretion of IL-10 & IL1Ra 
Yamauchi, et al. 2002 
 
Fu, et al. 2005 
Yamauchi, et al. 2001 
Stefan, et al. 2003 
Wolf, et al. 2004 
Visfatin Regulates β-cell function in pancreas 
Upregulates MCP-1 in adipocytes 
Revollo, et al. 2007 
Sommer, et al. 2010 
Resistin Impairs glucose tolerance in mice 
Pro-inflammatory cytokine in humans 
Steppan, et al. 2001 




Regulates insulin sensitivity and 
adiposity in rodents 
Insulin sensitising 
Higuchi, et al. 2007 
 
Yang, et al. 2006 
Other factors   
Retinol binding protein  
(RBP)-4 
Increases adipose tissue or whole body? 
insulin resistance in animal 
studies  
Yang et al. 2005 
Plasminogen activator  
Inhibitor (PAI) -1 
Involved in regulation of adipose tissue 
development 
Morange, et al. 2000 
Angiotensinogen Increases fat mass and hypertension in 
transgenic overexpressing mice 
Massiéra, et al. 2001 
Prostaglandins Inhibit adipocyte lipolysis Fredholm, et al. 1973 
 
Table 1.1 Summary of major adipokines & their actions. (Adapted from Denison, Roberts, 
Barr & Norman, Reproduction. 2010)    
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1.2.3. Depot specific characteristics of adipose tissue 
 
There are regional differences in the characteristics of adipose depots, which 
may explain why certain adipose tissue distributions have differing effects 
on cardiovascular and metabolic risk. Visceral adipose tissue refers to intra-
abdominal adipose, including omentum, mesenteric deposits as well as retro-
peritoneal deposits such as peri-renal adipose. Depot-specific characteristics 
are both anatomical and functional; visceral adipocytes tend to be smaller 
than subcutaneous adipocytes, and there is greater stromal cell infiltration 
into visceral adipose depots, particularly in obesity (Harman-Boehm, Blüher, 
et al. 2007). Adipocyte cell size is important with respect to metabolic risk, 
though it seems this is most important in the omental depot (O’Connell, 
Lynch, et al. 2010). 
 
Omental adipose tissue is considered more metabolically active compared 
with subcutaneous adipose; there is evidence to suggest it has a greater 
secretory capacity compared with subcutaneous adipose (Hocking, Wu, et al. 
2010), as well as an enhanced lipolytic response to catecholamines, 
particularly in obesity (Hoffstedt, Arner, et al. 1997) and a differential 
response to regulation by glucocorticoids (Lee, Gong, et al. 2011). It has been 
proposed that its anatomical location, with venous drainage into the portal 
circulation allows it to act as a metabolic sensor with direct hepatic access to 
free fatty acids, which drives hepatic insulin resistance in obesity (Björntorp, 
1990; Kabir, Catalano, et al. 2004).  
 
In contrast, subcutaneous adipose, with larger adipocytes, may have more of 
a role in lipid storage, comprising approximately 80% of total body adipose. 
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Subcutaneous adipose explants secrete increased angiogenic factors 
compared with visceral adipose, which may facilitate its expansion as a 
storage depot (Hocking, Wu, et al. 2010; Gealekman, Guseva, et al. 2011). 
Subcutaneous adipose is thought to be the main contributor to circulating 
leptin concentrations; leptin mRNA is greater in subcutaneous compared 
with omental adipose tissue, with a marked gender specific effect: in men, 
leptin mRNA in subcutaneous adipose tissue is approximately twice that of 
omental adipose, but in women, there is a 5-fold increase in leptin mRNA in 
subcutaneous compared with omental adipose (Montague, Prins, et al. 1998; 
Van Harmelen, Reynsdottir, et al. 1998). 
 
Regional characteristics of adipose tissue depots show gender-specific 
patterns as well: differences in adipose tissue distribution between men and 
women have long been recognised (Krotiewski, Björntorp, et al, 1983) and 
may account for the differences in cardiovascular risk between males and 
females. Men tend toward deposition of adipose in the central or upper 
body, ‘android’ distribution, whereas women tend to distribute fat on hips, 
thighs and buttocks, a ‘gynoid’ distribution. This distinction is important in 
determining metabolic risk: there is an association between android but not 
gynoid obesity and risk of metabolic syndrome, diabetes and cardiovascular 
disease (Kissebah, Vydelingum, et al. 1982; Canoy, Boekholdt, et al, 2007). 
Molecular differences in regional adipose characteristics and response to sex 
steroids may account for these different risks: for example, in vitro, 
dehydroepiandrosterone (DHEA) preferentially stimulates lipolysis in 
omental adipose in men, but subcutaneous adipose in women (Hernándes-
Morane, Pérez-de-Heredia, et al. 2007); progesterone treatment in rats altered 
body fat distribution and adipokines expression in female but not male 
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animals (Stelmanska, Kmiec, et al. 2012). In ovariectomised mice, treatment 
with androgens leads to visceral fact accumulation (McInnes, Corbould, et al.  
2006). In post-menopausal women, adipose distribution become more central 
compared with pre-menopausal women, but this can be counteracted to a 




1.3. Alterations to adipose tissue function in obesity 
 
Obesity in its simplest definition is the presence of excess adipose tissue. 
However, it has become clear that over-expansion of the adipose depots 
leads to abnormal adipose function and systemic consequences to metabolic 
regulation.  Clinically this manifests as systemic insulin resistance, impaired 
regulation of glucose homeostasis and vascular dysfunction, contributing to 
the development of metabolic syndrome, diabetes, hypertension and 
increased cardiovascular disease risk. However, the molecular mechanisms 
which contribute to this increase in risk are not yet fully understood but 
involve a complex interaction between the secretory products of adipose 
tissue, local effects on adipose tissue and systemic effects on other organs, 





1.3.1. Adiposity and Origins of Insulin resistance 
 
Increased adipose tissue has been associated with the development of 
resistance to the action of insulin for many years and many epidemiological 
studies have shown a strong positive correlation between markers of 
adiposity including BMI (Abbasi, Brown et al. 2002; Farin, Abbasi, et al. 2006; 
Schindler, Cardenas, et al. 2006) or increased WHR (Toft, Bønna, et al. 1998) 
and measure of IR. It is likely that there is a self-propagating mechanism by 
which excess adiposity leads to local intra-adipose insulin resistance, 
originating with the lipotoxic effects of nutrient excess, with accompanying 
oxidative stress triggering adipose inflammation and exacerbating adipose 
dysfunction.  
 
During fat mass expansion, at the level of the adipocyte, there is initial 
expansion of the lipid droplet, with concomitant adipocyte hypertrophy 
(Hirsch & Batchelor, 1976). This is accompanied by changes in gene 
expression, with down regulation of genes associated with lipogenesis and 
fatty acid turnover (Roberts, Hodson, et al.  2009; McQuaid, Hodson, et al. 
2011), as well as upregulation of inflammatory cytokines such as TNFα 
(Hotamisligil, Shargill, et al.  1993). These early changes in adipocyte 
characteristics interact with the supporting stromal cells present in adipose 
tissue to lead to further self-propagating adipose tissue dysfunction. 
Consequent spillover of factors such as pro-inflammatory cytokines and 
excess fatty acids occurs not simply due to excess fat mass but to altered 
behaviour of the component cells.  Ultimately this leads to systemic diversion 
of lipid to ectopic sites which interferes with insulin function in these organs, 
thus propagating systemic insulin resistance. 
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1.3.1.1. Origins of Insulin Resistance: Inflammation  
 
Obesity has been described as a low-grade, chronic inflammatory condition. 
There is evidence for elevated circulating pro-inflammatory cytokines, 
including TNFα (Kern, Saghizadeh, et al. 1995), IL-6 (Roytblat, Rachinsky, et 
al. 2000), MCP-1 (Kim, Park, et al. 2006) and elevated acute phase proteins 
such as CRP (Visser, Bouter, et al. 1999). In 1993, work by Hotamisligil and 
colleagues showed that not only was adipose a source of TNFα, but that this 
elevated TNFα had a role in the molecular pathogenesis of obesity-associated 
insulin resistance (Hotamisligil, Shargill, et al. 1993). Subsequently, it was 
shown that not only was adipose tissue responsible for production of a 
myriad of secretory proteins, but that there was a direct correlation between 
inflammatory status and insulin resistance (Kern, Ranganathan, et al. 2001). It 
is likely that initiation of the inflammatory response in obesity lies in adipose 
tissue possibly as a response to stimulation by endoplasmic reticulum stress 
accompanying adipocyte overexpansion and lipid accumulation (Özcan, 
Cao, et al. 2004) but that this process becomes self-propagating and triggers 
chronic systemic inflammation. 
 
In 2003, Weisberg and colleagues demonstrated a correlation between 
obesity and infiltration of adipose tissue by macrophages/increased 
macrophage density and suggested that it was the increased macrophage 
population that was responsible for the elevated pro-inflammatory cytokines 
(Weisberg, McCann, et al. 2003; Xu, Barnes, et al. 2003).  However, adipocytes 
themselves are also capable of secretion of TNFα. In adipose tissue from lean 
subjects, macrophages are present, though sparse. These are thought to be 
resident, bone-marrow derived macrophages. Macrophage density is 
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significantly increased in adipose tissue from obese subjects. These are a 
specific subset of resident macrophages rather than deriving from circulating 
monocytes (Weisberg, McCann, et al. 2003), and have a specific phenotype, 
neither M1- or M2- specific. M1-like macrophages are classically activated, 
pro-inflammatory cells, whereas M2-like macrophages are alternately 
activated, pro-resolution cells. High-fat feeding in a rodent model induced a 
change in phenotypic characteristics of adipose tissue macrophages from M2 
to M1 (Lumeng, Bodzin, et al. 2007).  In humans, isolated macrophages from 
adipose tissue of obese subjects have an M2-like phenotype but have the 
capacity to produce pro-inflammatory cytokines, a more M1-like property 
(Zeyda, Farmer, et al. 2007).  
 
Mechanisms by which inflammation leads to insulin resistance are varied 
and are secondary to local effects in adipose tissue, liver and skeletal muscle. 
In adipose tissue, TNFα treatment of adipocytes leads to inhibition of insulin 
receptor signalling (Hotamisligil, Murray, et al. 1994; Liu, Spelleken, et al. 
1998). Treatment with IL6 led to long term downregulation of expression of 
GLUT-4, IRS-1 and PPARγ (Rotter, Nagaev, et al. 2003). In liver, pro-
inflammatory cytokines activate NF-κB signalling and induce insulin 
resistance (Cai, Yuan, et al. 2006); treatment with IL-6 reduces hepatic IRS1 
signalling (Klover, Zimmers, et al. 2003). Hepatic lipid infiltration in obesity 
also stimulates a local inflammatory response via oxidative stress (Peng, 
Rideout, et al. 2011). Similarly, IL-6 also reduces insulin signalling via IRS1 in 
skeletal muscle (Kim, Higashimori, et al. 2004). Interaction with other 
adipokines may also modulate the inflammatory response: visfatin is 
increased in obesity as well as other pro-inflammatory states such as arthritis 
(Berndt, Klöting, et al. 2005; Krzyzanowska, Mittermayer, et al. 2006; 
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Brentano, Schorr, et al. 2007) and may be involved in regulating insulin 
responsiveness via inflammatory mechanism including prostaglandin 
synthesis (Jacques, Holzenberger, et al. 2012). 
 
1.3.1.2. Origins of Insulin Resistance: Adipokines 
 
The endocrine products of adipose tissue also have a role in driving systemic 
metabolic dysregulation. The classic adipokines, leptin and adiponectin have 
multiple effects on normal metabolic homeostasis and appetite regulation as 
outlined in Section 1.2.2.2. In obesity, their expression and the systemic 
responses to them are altered significantly. 
 
Typically, circulating leptin levels are increased in obese individuals (Maffei, 
Halaas, et al. 1995; Havel, Kasim-Karakas, et al. 1996; Considine, Sinha, et al. 
1996). On a short-term basis, leptin enhances insulin sensitive pathways, 
including insulin-suppressed endogenous glucose production (Rosetti, 
Massilon, et al. 1997) although there may also be inhibition of some insulin-
responsive pathways (Cohen, Novick, et al. 1996). Lipoatrophic individuals 
are insulin resistant, with elevated FFA and triglyceride; leptin levels are 
typically very low and treatment with leptin can improve insulin sensitivity 
in both mice (Shimomura, Hammer, et al. 1999) and humans (Petersen, Oral, 
et al. 2002). In contrast, in diet-induced obesity there is often severe insulin 
resistance despite high levels of leptin. However, this may reflect end-organ 
insensitivity to leptin. Altered permeability of the blood-brain-barrier to 
leptin may be a factor: hypothalamic signalling in response to leptin is 
reduced in response to diet-induced obesity in a murine model when given 
peripherally, although a response is retained although attenuated when it is 
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administered directly into the cerebrospinal fluid (CSF) (El-Haschimi, 
Pierroz, et al. 2000); in humans, there is a reduced CSF:serum leptin ratio in 
obese subjects (Caro, Kolaczynski, et al. 1999).  
 
In contrast to leptin, adiponectin expression is decreased in overweight and 
obese subjects, including mice (Hu, Liang, et al. 1996) and human (Arita, 
Kihara, et al. 1999) but is also greatly reduced or absent in cases of 
lipoatrophy (Yamauchi, Kamon, et al. 2001). Treatment with adiponectin can 
reverse the insulin resistant phenotype of lipoatrophy (Yamauchi, Kamon, et 
al. 2001). Adiponectin exerts its effects on a number of tissues. In skeletal 
muscle, it upregulates expression of proteins of fatty acid transport and 
stimulates oxidative metabolism by activation of AMPK, p38 MAPK and 
PPAR (Yoon, Lee, et al. 2006) as well as stimulating glucose uptake by 
increasing GLUT4 translocation (Ceddia, Somwar, et al. 2005) and enhancing 
mitochondrial biogenesis (Qiao, Kinney, et al 2012).  In liver, adiponectin is 
insulin-sensitising (Berg, Combs, et al. 2001); plasma adiponectin levels are 
negatively correlated with insulin-suppressed endogenous glucose 
production in humans (Stefan, Stumvoll, et al. 2003); adiponectin treatment 
leads to reduced hepatocyte gluconeogenesis in a murine model (Yamauchi, 
Kamon, et al. 2002). Reduced adiponectin in obesity is therefore likely to 
contribute to obesity-associated IR by absence of its insulin-sensitising 
actions.  High-molecular weight adiponectin exists in a multimeric form of 
adiponectin, composed of 12-18 subunits; women tend to have greater high-
molecular weight adiponectin than men (Pajvani, Du, et al.  2003). In 
particular, the high-molecular weight isoform of adiponectin is thought to be 
the most relevant to its insulin-sensitising actions (Pajvani, Hawkins, et al. 
2004) and in women, the ratio of high-molecular weight:total adiponectin is 
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related to risk of diabetes independently of total adiponectin (Heidemann, 
Sun, et al.  2008). 
 
Several other adipokines have been implicated in the pathogenesis of diet-
induced insulin resistance, including omentin, apelin, resistin and RBP-4. 
Omentin is a novel adipokine which is highly expressed in visceral adipose 
and is thought to originate in the stromal vascular cells (Yang, Lee, et al. 
2006). It acts to enhance insulin signalling and increases insulin-stimulated 
glucose transport in adipocytes (Yang, Lee, et al. 2006). Expression and 
plasma levels are decreased in obese insulin resistant subjects (de Souza 
Batista, Yang, et al. 2007) but this may reflect down regulation in response to 
hyperinsulinaemia in such subjects (Tan, Adya, et al. 2008). 
 
 In contrast, apelin is increased in obese subjects (Boucher, Masri, et al. 2005). 
In a murine model, treatment with apelin increased glucose uptake and 
improved glucose tolerance in obese mice (Dray, Knauf, et al. 2008) and 
increased expression in obesity may reflect a compensatory mechanism to 
counteract developing IR. Resistin is also increased in obesity (Steppan, 
Bailey, et al. 2001; Azuma, Katsukawa, et al, 2003). Administration of anti-
resistin antibodies to mice led to an improvement in glucose tolerance and 
insulin response in a model of diet induced obesity (Steppan, Bailey, et al. 
2001). In a murine resistin knock-out model, mice had reduced hepatic 
glucose production in response to fasting, but had better glucose tolerance 
following high-fat feeding (Banerjee, Rangwala, et al. 2004). Retinol binding 
protein 4 (RBP4) is also increased in insulin resistance (Yang, Graham, et al. 
2005); overexpression of RBP4 leads to IR in a murine model (Yang, Graham, 
et al, 2005). RBP4 has been reported to be downregulated in subcutaneous 
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adipose in human obesity (Janke, Engeli, et al, 2006) but upregulated in 
omental adipose and positively correlated with fasting glucose levels (Kelly, 
Kashyap, et al,  2010) and insulin resistance (Graham, Yang, et al. 2006). RBP4 
may exert its effects on glucose homeostasis and insulin sensitivity by 
regulation of GLUT4 function (Chiefari, Paonessa, et al. 2009). 
 
1.3.1.3. Origins of Insulin Resistance: Effect of sex steroids 
 
In non-pregnant women, there is an association between levels of sex 
steroids, oestrogens and progesterone, and insulin sensitivity. Insulin 
sensitivity varies across the menstrual cycle, particularly in the luteal phase 
and with a positive association between insulin resistance and levels of 
oestrogen and progesterone (Yeung, Zhang, et al.  2010). Treatment with 17β-
estradiol improves skeletal muscle insulin sensitivity in ageing women 
(Moreno, Ordoñez, et al. 2010); however, hormone replacement therapy 
(HRT) (oestrogen only and combined with progesterone) is associated with 
insulin resistance in post-menopausal women (Ryan, Nicklas, et al. 2002). In 
women, androgen administration can induce insulin resistance, as can 
oestrogen treatment in males (Polderman, Gooren, et al. 1994). Adipose tissue 
is also a source of extragonadal oestrogen although this appears to only leads 
to a significant rise in plasma oestrogen in obese males rather than obese pre-
menopausal females (Zumoff, Strain, et al. 1981). 
 
In the context of polycystic ovarian syndrome (PCOS), there is an association 
with insulin resistance and hyperinsulinaemia (Dunaif, Segal, et al. 1989). 
While there is also an association between PCOS and obesity which could 
contribute to this association, the effect appears to be independent of obesity, 
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although overweight and obese women with PCOS tend to be more insulin 
resistant than lean women with PCOS (Dunaif, Segal, et al. 1989). The cellular 
mechanisms implicated include alteration in insulin receptor function 
through altered serine phosphorylation, (Dunaif, Segal, et al. 1992) or 
decreased GLUT4 expression (Rosenbaum, Haber, et al. 1993). Whether this is 
due to an intrinsic defect in subjects with PCOS or an effect of the hormonal 
changes of this condition is not entirely clear.  On one hand, androgen 
administration, particularly testosterone, appears to induce insulin resistance 
but treatment with anti-androgens does not always particularly improve 
insulin resistance. Similarly, the effect of PCOS on insulin sensitivity does not 
appear to correlate directly with androgen levels. It is likely that androgen 
may contribute to the insulin resistance of PCOS but other factors are also 
required.  
 
That an interaction between oestrogen, progesterone, androgen, adiposity 
and insulin resistance exists seems established. However, the direct 
molecular mechanisms are not yet fully understood and while there appears 
to be a degree of independence between each of these variables, their relative 
contributions in differing clinical contexts remains elusive, particularly in 
separating the effect of obesity on sex steroid levels and vice versa. 
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1.3.2. Consequences of Adipose Insulin Resistance 
 
In association with the development of insulin resistance in adipose tissue, 
there is spillover of both excess nutrients such as FFA as well as dysregulated 
secretion of adipokines and pro-inflammatory cytokines as outlined above. 
These factors have a number of effects on other organs to generate systemic 
insulin resistance and the pathophysiological features associated with 
obesity. 
 
In liver, excessive supply of FFA in the face of reduced adipose storage 
capacity due to insulin resistance leads to accumulation of intracellular lipid, 
although this is not always correlated with the degree of obesity per se 
(Seppälä-Lindroos, Vehkavaara, et al. 2002). There is increased VLDL 
production, due to both increased supply of FFA as well as increased de 
novo lipogenesis (Lewis, Carpenter, et al. 2002), contributing to systemic 
hyperlipidaemia and thus to the pathogenesis of atherosclerosis and elevated 
risk of cardiovascular disease (Ross & Harker, 1976). Fatty acid oxidation 
leads to the generation of reactive oxygen species (ROS) in liver and 
oxidative stress (Sanyal, Campbell-Sargent, et al. 2001) which contribute to 
hepatotoxicity and exacerbation of local inflammatory pathways.   
 
While obesity is a risk factor for hepatic steatosis, accumulation of liver fat is 
proportional to the degree of insulin resistance, independent of body mass 
index or total body fat content (Korenblat, Fabbrini, et al. 2008). Genetic 
factors may also influence hepatic fat accumulation independent of body 
weight, such as variants of patatin-like phospholipase domain-containing 
protein 3 (PNPLA3) (Romeo, Kozlitina, et al.  2008). Bariatric surgery and 
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weight loss have been shown to reduce liver fat and quickly improve hepatic 
insulin resistance (Petersen, Dufour, et al.  2005; Vitola, Deivanayagam, et al. 
2009; Lim, Hollingsworth, et al. 2011; Rossi, Fantin, et al. 2012). Hepatic lipid 
content can also be reduced by increased exercise, independent of an effect 
on body weight (Hallsworth, Fattakhova, et al.  2011). Regulation of liver fat 
is therefore not simply a function of total body fat but has a specific role in 
regulation of hepatic glucose production and insulin sensitivity. 
 
In skeletal muscle, there is similar accumulation of excess lipid in obese 
diabetic subjects (Goodpaster, Thierault, et al. 2000). This may be due to 
reduced fatty acid oxidation in extreme obesity, but other mechanisms may 
be involved at earlier stages (Hulver, Berggren, et al. 2002). Similar to the 
situation in liver, there is generation of harmful lipid species which may 
interfere with insulin signalling in myocytes (Eckardt, Taube, et al. 2011). 
This includes species such as ceramide, which can reduce insulin-stimulated 
Akt phosphorylation (Adams, Pratipanawatr, et al. 2004). Similarly, exposure 
of myocytes to excess saturated fatty acids leads to activation of PKCθ and 
impaired insulin signalling (Griffin, Marcucci, et al. 1999) as well as 
enhancing IL-6 secretion via nuclear factor-κB (Weigert, Brodbeck, et al. 
2004). However, IL-6 may also have a role in increasing glucose uptake and 
fatty acid oxidation in muscle via an adenosine monophosphate kinase 
(AMPK) pathway (Glund, Deshmukh, et al. 2007) 
 
In pancreas, there is initially a functional upregulation of beta cell activity, 
contributing to hyperinsulinaemia, (Ferrannini, Camastra, et al. 2004) which 
can be mimicked by treatment of isolated islets with free fatty acids 
(Milburn, Hirose, et al. 1995). In the long term however, the lipotoxic effect of 
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lipid accumulation in beta cells lead to reduced beta cell function, 
contributing to the pathogenesis of type II diabetes (Lee, Hirose, et al. 1994). 
This process can be ameliorated by treatment with thiazolidinediones, which 
reduced islet cell triglyceride accumulation (Shimabukuro, Zhou, et al. 1997).  
 
The multisystem effects of obesity stem from a vicious cycle of disordered 
metabolic regulation which contributes to upregulation of inflammatory 
pathways, which in turn, hinder normal metabolic regulation. The end 
outcomes of such processes are reflected in the pathologies associated with 
obesity: coronary vascular disease, diabetes, cerebrovascular disease and 





1.3.3. Variable relationship between Adiposity and Insulin Resistance  
 
It is worth noting that obesity is not exclusively associated with an adverse 
metabolic phenotype (Ferannini, Natali, et al. 1997; Bonora, Kiechl, et al. 1998; 
Karelis, St-Pierre, et al. 2004), and that up to 20% of obese patients have a 
large fat mass but normal insulin, normal insulin sensitivity high HDL 
cholesterol and low triglycerides: a metabolically healthy obese (MHO) 
phenotype. A large cohort study examining pooled data from over 1100 HEC 
studies conducted in Europe defined insulin resistance as the lowest decile of 
insulin sensitivity in the lean population, and showed that while the obese 
group as a whole were more insulin resistant, IR was less prevalent in the 
obese group than expected, occurring in only 26% of the obese group 
(Ferannini, Natali, et al. 1997). Insulin sensitivity was inversely correlated 
with BMI, but was still present in only 60% of subjects with BMI >30kg/m2.  
However, it should also be noted that the relative risk of the MHO 
phenotype is not the same as lean and metabolically healthy; MHO subjects 
have evidence of vascular abnormalities and early atherosclerotic changes 
(Karelis, St-Pierre, et al. 2004).  
 
Similarly, within the lean population there was significant variability in 
insulin sensitivity, as well as a subset of the population with an adverse 
metabolic profile, described as metabolically obese but normal weight 
(MONW). These individuals tended to have normal BMI but higher total fat 
mass, both subcutaneous and visceral, as well as an increased percentage 
body fat. Physical activity energy expenditure tended to be lower though 
similar CV fitness and low physical activity appears to play a major role in 
the development of this phenotype (Karelis, St-Pierre, et al. 2004).  
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The MHO phenotype is commonly seen in women with early onset of 
obesity (<20 years of age), and is associated with significantly reduced 
visceral fat mass (~50%), despite equivalent overall fat masses (Karelis, St-
Pierre, et al. 2004).  In a German study of 300 obese subjects with risk factors 
for insulin resistance (previous IGT or GDM), Stefan et al observed that while 
insulin resistance strongly correlated with BMI and measures of 
subcutaneous fat, visceral fat, WHR and total body fat, insulin-sensitive 
obese had significantly less intramyocellular and hepatic fat (Stefan, 
Kantartzis, et al. 2008). Visceral fat tended to be greater in obese IS subjects 
compared with obese IR subjects, but this was not statistically significant. 
These authors suggest that ectopic lipid distribution is therefore a better 
indicator of insulin resistance than visceral fat accumulation.  
 
The existence of an MHO and a MONW phenotype is of significance for 2 
reasons. Firstly, study data must be interpreted with caution, as up to a fifth 
of an obese group may have a metabolic profile differing from the remainder 
of the cohort. Secondly, the clinical management of such patients should be 
carefully considered, particularly issues such as intensive weight loss despite 




1.4. Adaptation of maternal metabolism in pregnancy 
 
The energy requirements of human pregnancy require a significant 
adaptation of maternal metabolism. Early pregnancy is characterised by 
relative lipid accretion, laying down energy stores against the upcoming 
needs of late pregnancy, when fetal growth is greatest, and the post-partum 
demands of breast-feeding ensue. This early pregnancy phase involves 
maintenance of insulin sensitivity (Catalano, Huston et al.  1999), with 
consequent lipid accretion (Franz, 1978). In contrast, late pregnancy is 
characterised by the progressive development of insulin resistance, first 
described by Burt (Burt., 1956). The mechanisms are not fully understood, 
but a role for placental hormones is likely, including human placental 
lactogen, and placenta-derived leptin. The development of insulin resistance 
in adipose tissue has the effect of releasing the lipolytic cascade from 
inhibition, promoting release of maternal free fatty acids and glycerol as 
gluconeogenic substrates, partitioning fetal energy requirements, supplied 




1.4.1. Insulin sensitivity in pregnancy 
 
Insulin sensitivity in normal pregnancy is initially maintained at pre-gravid 
levels, or slightly increased, followed by progressive development of 
systemic maternal insulin resistance (Spellacy, Goaetz, et al. 1965; Catalano, 
Tyzbir, et al,. 1991). In the third trimester, there is compensatory 
hyperinsulinaemia with enhanced first- and second-phase insulin response 
to glucose (Buchanan, Metzger, et al. 1990; Catalano, Drago, et al. 1998), as 
well as increased clearance of insulin (Catalano, Drago, et al. 1998). There is 
increased basal hepatic glucose production and a 40-60% decrease in insulin-
sensitive glucose disposal (Catalano, Huston, et al. 1999). Development of 
third trimester insulin resistance is thought to be important for normal fetal 
growth; insulin sensitivity in late pregnancy correlates inversely with both 
placental weight and birthweight (Catalano, Drago, et al, 1995). In sheep, 
there is increased insulin sensitivity and glucose uptake in association with 
placental insufficiency and intra-uterine growth restriction (Limesand, 
Rozance, et al. 2007). 
 
Assessment of insulin sensitivity in pregnancy can be made using the same 
indices as are applied to the non-pregnant population, ie. fasting measures 
such as HOMA-IR or QUICKI or dynamic assessments such as during oral 
glucose tolerance testing or the hyperinsulinaemic euglycaemic clamp 
(HEC). Different approaches are required depending on the context, whether 
as part of a research study, or as a clinically useful test applied to a 
population. In pregnancy insulin sensitivity as derived from sampling 
during 2 hour OGTT, as well as indices such as HOMA-IR and QUICKI have 
all been validated against insulin sensitivity measured during 
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hyperinsulinaemic euglycaemic clamp conditions and correlate closely 
(Kirwan, Huston-Presley, et al. 2001).  
 
During clamp studies, insulin sensitivity can be expressed as M, which is the 
glucose disposal rate, derived from mean glucose infusion rate during steady 
state conditions in mg/kg/min. In pregnancy, glucose uptake by the 
fetoplacental unit occurs by facilitated diffusion down a concentration 
gradient. Theoretically, the fetoplacental unit acts as a glucose ‘sink’ in 
pregnancy, particularly in the third trimester when fetal energy requirements 
are greatest. This could lead to potential overestimation of insulin sensitivity 
in the third trimester, with an increased contribution of the fetoplacental unit 
to apparent maternal glucose disposal. While estimates of the decrease in 
insulin sensitivity with advancing gestation have been approximately 40-60% 
(Catalano, Tyzbir, et al. 1993; Catalano, Huston, et al. 1999), the true 
decrement in insulin sensitivity could therefore be greater than this. 
Assessment of the rate of specific glucose uptake by the fetus and placenta is 
difficult to measure in vivo; in rats, there is some evidence to suggest that 
placental glucose transport is not directly sensitive to maternal insulin 
concentrations (Norris, Wang, et al. 2011), and although glucose uptake is 
sensitive to maternal hyperglycaemia, under clamped euglycaemic 
conditions, fetal uptake may therefore not make a significant contribution to 
clamp-derived M-values. With these potential limitations in mind, 
euglycaemic clamp studies remain the gold standard method of assessment 
of insulin sensitivity in both pregnant and non-pregnant populations.  
 
Skeletal muscle is a major site of insulin-stimulated glucose uptake. In 
pregnancy, this is significantly reduced by approximately 30-40% by the 
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third trimester (Friedman, Ishizuka, et al. 1999). This is associated with 
decreased IRS1 but increased IRS2 protein phosphorylation (Friedman, 
Ishizuka, et al. 1999). Protein levels of the GLUT4 transporter in skeletal 
muscle were not affected by pregnancy (Garvery, Maianu, et al. 1992).   
 
The mechanisms driving such adaptations are not clear but are likely to 
involve pregnancy-specific hormones, as well as co-opting existing maternal 
pathways regulating maternal metabolism. Two of the main pregnancy-
specific hormones include human placental lactogen (hPL) and human 
placental growth hormone (hPGH). Both these hormones are synthesized 
and secreted by placenta.  
 
hPL induces profound systemic insulin resistance when administered 
intravenously, with impaired peripheral glucose utilisation, despite 
increased plasma insulin response to glucose (Beck & Daughaday, 1967). hPL 
acts through both human growth hormone (hGH) and human prolactin 
(hPRL) receptors, which account for its somatotrophic and lactogenic 
activities. The signalling pathways employed involve phosphorylation and 
activation of the JAK-STAT pathways (Takeda, Kurachi, et al. 1997). hPL also 
acts to increase the mass of pancreatic islets and improve insulin secretion 
(Lombardo, De Angelis, et al. 2011). 
 
hPGH is secreted by syncytiotrophoblast and replaces maternal pituitary GH 
by week 20-24. hPGH is also able to induce insulin resistance, particularly in 
skeletal muscle; the mechanism is thought to be decreased PI3-kinase activity 
via upregulation of  the p85 regulatory subunit (Barbour, Shao, et al. 2002; 




Other hormones involved in the regulation of insulin resistance in pregnancy 
include adipokines, inflammatory cytokines and the sex steroids, with many 
parallels with the mechanisms employed in obesity.  
 
Adiponectin may have a role in insulin resistance of pregnancy. In non-
pregnant individuals, adiponectin usually has an insulin-sensitising action 
(Section 1.2.2). In normal weight pregnant women, both plasma levels and 
white adipose tissue mRNA levels are significantly reduced by mid-third 
trimester (Fuglsang, Skærbæk, et al. 2006; Catalano, Hoegh, et al. 2006; Nien, 
Mazaki-Tovi, et al. 2007). Compared with post-partum, adiponectin levels are 
elevated during pregnancy but gradually decline (Mazaki-Tovi, Kanety, et al. 
2007). In contrast, in overweight women, adiponectin is suppressed 
compared to lean women but does not show a further decrease in response to 
pregnancy (Nien, Mazaki-Tovi, et al. 2007). Whether decreased adiponectin 
in pregnancy is a direct response to pregnancy or a simply a function of 
increased fat mass during pregnancy is not clear although adiponectin levels 
appear to correlate closely with both fasting insulin and insulin-mediated 
glucose disposal in early pregnancy (Catalano, Hoegh, et al. 2007). In weight-
matched subjects with gestational diabetes, adiponectin is further reduced 
compared to non-diabetic subjects, including prior to onset of gestational 
diabetes (Williams, Qui, et al. 2004; Retnakaran, Hanley, et al. 2004). In 
pregnancy, placenta is a source of adiponectin (Caminos, Nogueiras, et al. 
2005; Lappas, Yee, et al. 2005; Chen, Tan, et al. 2006) so it is probable that 
there is a specific role for adiponectin rather than a secondary change in 
expression following other adaptations of maternal metabolism. This may 
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include regulation of placental response to insulin and placental amino acid 
transport (Jones, Jansson, et al. 2010).  
 
In contrast to adiponectin, circulating levels of resistin are increased in 
pregnancy, particularly in the third trimester where insulin resistance is 
maximal (Chen, Dong, et al. 2005; Nien, Mazaki-Tovi, et al. 2007b). Resistin is 
implicated in the development of insulin resistance in obesity and has both 
insulin-antagonising as well as pro-inflammatory activities (Section 1.3.1.2). 
Resistin is expressed by placenta, with greater mRNA levels in trophoblast at 
term compared with first trimester (Yura, Sagawa, et al. 2003) whereas white 
adipose tissue resistin mRNA levels did not appear to change with 
pregnancy, indicating a placenta-specific source of pregnancy-induced 
increase in resistin (Yura, Sagawa, et al. 2003). 
 
The placenta is also a source of leptin (Matsuzaki, Ogawa, et al. 1997) and 
plasma levels increase with gestation (Sattar, Greer, et al. 1998; Helland, 
Reseland, et al. 1998; Melczer, Bánhidy, et al. 2003). Increases in plasma leptin 
have been observed prior to an increase in body weight, suggesting that 
changes in circulating leptin are not simply secondary to an increase in fat 
mass (Henson & Castracane, 2006). However, longitudinal changes in leptin 
have been shown to correlate with insulin sensitivity in some studies but not 
others (Laivuori, Kaaja, et al. 2000; Kirwan, Haugel-De Mouzon, et al.  2002; 
McLachlan, O’Neal, et al.  2006) and it may be that the main role of leptin is in 
another capacity, such as regulation of fetal growth and placental function 




Placenta is also a source of the pro-inflammatory cytokines TNFα (Chen, 
Yang, et al., 1991) and IL-6 (Kameda, Matsuzaki, et al. 1990). Both these 
cytokines have been implicated in the development of insulin resistance 
associated with obesity (Section 1.3.1.1) but may also be important in 
determining the insulin resistance of normal pregnancy. In particular, TNFα 
has been inversely correlated with maternal insulin sensitivity in normal- 
and over-weight glucose tolerant pregnant women and can be used to 
predict changes in insulin sensitivity (Kirwan, Haugel-De Mouzon, et al.  
2002).  
 
Of other maternal hormones, the sex steroids oestrogen and progesterone 
also have a role in influencing maternal insulin regulation, as do maternal 
pituitary hormones, such as prolactin. Oestrogens (oestradiol, oestrone and 
17β-oestradiol) are increased in pregnancy, initially synthesised by corpus 
luteum and subsequently by placenta, and may have a role in the adaptation 
of the pancreas to the requirements of pregnancy as well as a direct effect on 
peripheral glucose utilisation via influencing skeletal muscle GLUT 4 
expression (Nadal, Alonso-Magdalena, et al. 2009; Barros, Morani, et al. 2008). 
Prolactin may also influence β-cell mass and function, including increased 
insulin secretion and may be essential for normal glucose homeostasis in 
pregnancy (Brelje, Bhagroo, et al. 2008; Huang, Snider, et al. 2009). 
  
In summary, adaptation and regulation of maternal insulin sensitivity in 
normal pregnancy is a complex process, likely originating from tissues of 
placenta/fetal origin but also co-opting maternal pituitary and ovarian 
hormones as well as adipokines. 
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1.4.2. Enhanced third trimester lipolysis 
 
1.4.2.1. Assessment of lipolysis in pregnancy 
Demonstration of enhanced stimulated lipolysis in isolated adipocytes from 
tissue of late pregnancy was first demonstrated in the late 1970s. In Wistar 
rats, while basal rates of lipolysis in isolated subcutaneous adipocytes were 
not significantly different between pregnant and non-pregnant, 
noradrenaline-stimulated lipolysis was enhanced in late pregnancy 
compared with lactation; this effect is lost at the time of parturition 
(Aitchison, Clegg, et al, 1982). In contrast, in omental adipocytes in sheep 
increased basal and isoprenaline-stimulated rates of lipolysis were observed 
towards the end of pregnancy and during lactation (Guesnet, Massoud, et al. 
1987).  In humans, basal as well as adrenaline-stimulated lipolysis is elevated 
in late compared with early pregnancy (Elliott, 1975) although Coltart and 
Williams showed inhibition of isoprenaline-induced lipolysis in whole 
subcutaneous adipose by insulin (Coltart & Williams, 1976). Others have also 
described normal basal but increased noradrenaline-induced lipolysis in 
abdominal subcutaneous adipose in early pregnancy compared with non-
pregnant women (Rebuffé-Scrive, Enk, et al. 1984). 
 
Previously, the presence of elevated circulating lipids or fatty acids had been 
accepted as evidence of active lipolysis. This may not be an accurate 
representation of the true rate of lipolysis due to re-uptake and re-
esterification of triglyceride by adipocytes, muscle and liver and 
measurement of release of glycerol is likely to be more representative. This 
can be achieved by the use of stable isotope tracers such as D2-glycerol. A 
study of lean women in the third trimester showed enhanced lipolysis along 
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with elevated endogenous glucose production (Diderholm, Stridsberg, et al., 
2005). A previous study of overweight and obese women showed that 
although basal lipolysis did not change with gestation or post-partum, that 
the ability of insulin to suppress lipolysis was significantly reduced in the 
third trimester (Sivan, Homko, et al, 1999). It is possible that this 
phenomenon is essential for normal fetal growth in late pregnancy; as in 
women with IUGR pregnancies, third trimester lipolysis is reduced 
(Diderholm, Stridsberg, et al., 2006). 
 
1.4.2.2. Mechanisms of enhanced lipolysis 
In terms of altered adipose tissue function in pregnancy, many of the 
mechanisms are common to those driving altered insulin resistance, resulting 
in freedom of the lipolytic pathway from suppression by insulin. However, 
some pregnancy-associated hormones also have direct lipolytic activity. 
Lipolysis is stimulated by hPL in adipose tissue ex vivo (Strange and Swyer, 
1974), and has a greater stimulatory effect in tissue from pregnant than non-
pregnant women (Williams and Coltart, 1978). However, the situation in vivo 
is less clear, as hPL can both stimulate lipolysis, an anti-insulin action, but 
also promotes insulin secretion in response to glucose by pancreatic beta-
cells (Lombardo, De Angelis, et al. 2011).  
 
Studies by Kirwan et al showed a strong correlation between circulating 
maternal TNFα and insulin resistance, a novel finding demonstrating that it 
is not only the classical regulators of lipid metabolism which play a role in 
the metabolic  adaptations of pregnancy (Kirwan, Haugel-De Mouzon, et al. 
2002).  Altered adrenoceptor function in the third trimester may also have a 
role in regulation of lipolysis at this stage, with a modified balance between 
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alpha and beta-adrenoceptors, although this was described in a non-primate 
mammalian model (Bousquet-Mélou, Muñoz, et al. 1999). 
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1.5. Consequences of maternal obesity in pregnancy  
1.5.1. Impact of maternal obesity on the mother 
1.5.1.1. Fat distribution in pregnancy  
 
Weight gain in pregnancy is highly variable; in lean women, average weight 
gain is approximately 10-12kg, secondary to gains in several compartments: 
approximately 3-4kg from fetus, 0.5kg from placenta, ~0.8kg amniotic fluid, 
~3kg adipose tissue, 1.2kg blood, ~1.0 kg uterus and ~1.5kg extracellular 
extravascular fluid (Hytten & Chamberlain, 1991). Weight gain is 
predominantly subcutaneous, largely in trunk and thigh (Sohlström, 
Wahlund, et al. 1993; Sohlström and Forsum, E. 1995; Stevens-Simon, 
Thureen, et al. 2001). In obese women, gestational weight gain tends to be less 
than that of lean women (Soltani & Fraser, 2000; Ehrenberg, Huston-Presley, 
et al, 2003). However, obese women tend to accumulate more central weight 
gain compared to lean women (Soltani & Fraser, 2000). In 2009, the Institute 
of Medicine issued recommendations on gestational weight gain for women 
of differing pre-pregnancy BMI: 11.5 – 16 kg for women with BMI 18.5 – 24.9 
kg/m2, with smaller recommended weight gain in higher BMI groups, eg 5 – 
9kg in patients with BMI > 30kg/m2. In women gaining more than the 
recommended amount of weight, there was an associated increase in adverse 





1.5.1.2. Maternal insulin & glucose regulation 
 
In normal pregnancy there is progressive development of insulin resistance 
with compensatory hyperinsulinaemia (Spellacy & Goetz. 1963). In women 
who do not develop this compensatory hyperinsulinaemia, gestational 
diabetes can develop. Beta cell function is impaired, with reduced insulin 
response to glucose compared to women without GDM (Homko, Sivan et al., 
2001). Obesity is a risk factor for the development of GDM (Chu, Callaghan, 
et al. 2007) and likely reflects a reduced ability to mount a compensatory 
beta-cell response to pregnancy-induced insulin resistance (Qvigstad, 
Voldner, et al. 2010). The importance of glycaemic control in pregnancy was 
highlighted by the HAPO study, which has shown that maternal glucose 
levels are strongly correlated with pregnancy outcome including 
birthweight, even where maternal glucose levels fall below diagnostic criteria 
for gestational diabetes (Metzger, Lowe, et al. 2008). 
 
1.5.1.3. Maternal vascular endothelial function 
 
An association between obesity and increased incidence of hypertensive 
disorders in pregnancy has long been recognised (Fisher, & Frey, 1958). This 
includes increased incidence of pre-gravid chronic hypertension (Seely & 
Ecker, 2011) as well as development of pregnancy induced hypertension and 
pre-eclampsia (Eskenazi, Fenster et al., 1991; Bianco, Smilen et al. 1998; 
Duckitt & Harrington, 2005; Jensen, Ovesen, et al. 2005). The risk of pre-
eclampsia in a patient with BMI >35kg/m2 is approximately double that of a 




Potential mechanisms by which obesity leads to an increase in hypertensive 
disorders in pregnancy include a detrimental effect on endothelial function, 
inflammation, dyslipidaemia and oxidative stress. Markers of endothelial 
dysfunction and inflammation are altered in pre-eclampsia, including nitric 
oxide (Choi, Im et al. 2002), sFlt-1 (Maynard, Min, et al, 2003), interleukin 6 
(Greer, Lyall, et al. 1994) and VEGF (Lyall, Greer, et al. 1997). Obesity also 
predisposes to a pro-inflammatory environment with increased oxidative 
stress and dyslipidaemia and thus may contribute to a cycle of pathogenic 
changes that exacerbate development of conditions such as pre-eclampsia. In 
obese pregnant women, there is persistence of a pro-inflammatory 
environment compared with lean women as well as vascular dysfunction 
with altered endothelial-dependent and –independent relaxation (Ramsay, 
Ferrell, et al. 2002). It may be that each of these pathways feeds into a 
common mechanism lowering the threshold for the development of 




1.5.1.4. Effects on parturition 
Obese women are more likely to require induction of labour for prolonged 
pregnancy as well as instrumental and operative delivery (Sebire, Jolly, et al. 
2001; Arrowsmith, Wray et al. 2011). They are also at increased risk of post-
partum haemorrhage, particularly atonic haemorrhage (Sebire, Jolly, et al. 
2001; Blomberg, M. 2011). These outcomes can be linked by ineffectiveness of 
myometrial contractility. The effect of obesity on the myometrium is not 
clear. There is some evidence for reduced inherent contractility of isolated 
myometrium from obese subjects (Zhang, Bricker, et al. 2007) although other 
studies have not shown any relationship between BMI and spontaneous 
contractility (Higgins, Martin, et al. 2009). 
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1.5.2. Impact of maternal obesity on the fetus 
Maternal obesity has a number of influences on the fetus. At the very early 
stages in pregnancy, there is an increased risk of miscarriage (Lashen, Fear et 
al., 2004) and congenital anomaly (Rasmussen, Chu, et al. 2008; Stothard, 
Tennant, et al, 2009; Mills, Troendle, et al. 2010). Later on in pregnancy, there 
is an association with increased birthweight (Garn and Pesick, 1982), with 
associated morbidity secondary to delivery complications such as shoulder 
dystocia. There is a reduction in the number of low birthweight offspring, 
although some studies have reported a paradoxical increase in very low birth 
weight offspring, possibly secondary to placental dysfunction (McDonald, 
Han, et al. 2010). However, this may be confounded by the increased 
incidence of preterm deliveries (Madan, Chen, et al. 2010). The incidence of 
preterm birth is again confounded by an increased rate of induced preterm 
delivery for maternal indications; there is an overall reduction in 
spontaneous preterm labour (Hendler, Goldenberg et al. 2004). 
The effect of obesity on fetal nutrient supply and birthweight is contentious. 
In healthy pregnancy, transport of nutrients to the fetus relies on transfer 
from maternal to fetal circulation across the placenta. In the case of some 
nutrients such as glucose, this occurs by diffusion along a concentration 
gradient from mother to fetus, facilitated by relative maternal 
hyperglycaemia (Chinard, Danesino et al, 1956). In the context maternal 
diabetes, excess supply of glucose to the fetus with a compensatory fetal 
hyperinsulinaemia is thought to account for fetal macrosomia in such 
pregnancies (Skyler, O’Sullivan, et al. 1980). Amino acid transport on the 
other hand relies on active transport via specific transport proteins against a 
concentration gradient (Cleal & Lewis, 2008). In obese mice, there is 
upregulation of placental nutrient transport, with increased expression of 
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glucose transporter (GLUT) 1 and sodium-coupled amino acid transporter 
(SNAT) 2 as well as increased offspring birthweight (Jones, Woollett, et al. 
2008). In sheep, maternal obesity also increases expression of some placental 
fatty acid transporters, as well as circulating fetal triglyceride and 
birthweight (Zhu, Ma, et al. 2010). In humans, there is some evidence for 
alteration of placental fatty acid transport in the context of maternal obesity, 
but this was not reflected in fetal hypertriglyceridaemia, elevated free fatty 
acids or greater birthweight (Dubé, Gravel, et al. 2012). 
Of increasing importance is the impact of the maternal metabolic 
environment on long term offspring health. At birth, there is already 
evidence of altered fetal metabolism including altered adipokine levels and 
insulin resistance (Catalano, Presley, et al. 2009). Similarly, while birthweight 
is elevated, this is manifested in increased adiposity of the neonate, with 
elevated adiposity of offspring of obese mothers (Sewell, Huston-Presley, et 
al. 2006). 
Later on in life, higher birthweight has been associated with increased risk of 
childhood and adolescent obesity, as well as adult obesity (Curhan, Willet, et 
al,. 1996; Whitaker, 2004).  The relationships between birthweight and 
maternal metabolism and later life health are complex and it is difficult to 
dissect out the effects of genetics, in utero influences and later environmental 
effects. Low birthweight is also associated with later life central obesity 
(Loos, Beunen, et al. 2001; Kuh, Hardy, et al., 2002), hypertension, diabetes 
and cardiovascular disease (Curhan, Willet, et al., 1996), although this 
appears to be most strongly associated where there is co-existing obesity 
(Frankel, Elwood, et al.  1996). 
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In animal studies, maternal nutritional status has been shown to influence 
offspring body composition and metabolic characteristics although specific 
effects have been variable, reflecting the animal model used as well as the 
exact composition of diet and timing of exposure to the experimental diet. 
Maternal high fat feeding (45% fat) in Wistar rats has been observed to lead 
to reduced offspring birth weight but adult obesity (Howie, Sloboda et al., 
2008; Nivoit, Morens, et al., 2009). Other rodent models have described 
alterations in offspring insulin levels, leptin levels, fat mass and blood 
pressure (Khan, Dekou, et al. 2004; Samuelsson, Matthews, et al. 2008). 
Maternal diet in pregnancy can influence later response to diet: offspring of 
Sprague-Dawley rats fed an obesogenic diet (75% carbohydrate) pre-
conception had no difference in pup birth weight but postnatally, offspring 
weaned to high fat diet had a greater increase in body weight if they were 
offspring of obese compared to lean dams (Shankar, Harrell, et al. 2008). In 
smaller non-human primate models of maternal diet-induced obesity, there 
were similar trends towards increased adiposity of offspring of obese 
baboons (Farley, Tejero, et al. 2009) and obese macaques (McCurdy, Bishop, 
et al. 2009).  
Mechanisms by which the maternal environment programmes fetal 
metabolism include effects on central regulation of appetite and feeding 
behaviours with altered expression of thalamic neurotransmitters (Chang, 
Gaysinskaya, et al., 2008; Kirk, Samuelsson, et al., 2009; Sullivan, Grayson, et 
al. 2010), as well as interaction between prenatal stress and glucocorticoid 
exposure (Drake & Walker, 2004). Peripherally, effects on adipocyte structure 
and function have been reported; in a murine model of diet induced obesity, 
there was evidence of adipocyte hypertrophy and altered expression of 
adrenoceptors, 11β-HSD-1 and PPARγ2 at 3 months in offspring of high fat 
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fed compared with lean dams (Samuelsson, Matthews, et al. 2008). Similarly, 
in an ovine model, maternal overnutrition stimulates PPARγ, LPL, 
adiponectin and leptin mRNA expression in perirenal fat of offspring, 
predisposing to lipogenesis (Muhlhausler, Duffield, et al. 2007).  
It also becoming increasingly apparent that maternal obesity has an impact at 
the periconceptual stage; obesity has been shown to have an effect on oocyte 
quality. Normally maturing oocyte contain lipid droplets and there is some 
evidence in murine models that excess lipid accumulation in oocytes occurs 
in animals on a high fat fed diet, similar to ectopic lipid accumulation 
observed at other sites such as liver or skeletal muscle in obesity (Wu, 
Dunning, et al. 2010). Lipid accumulation is then associated with excess 
endometrial reticulum stress, generation of reactive oxygen species and 
mitochondrial dysfunction as well as impaired ability to maintain a 
pregnancy (Wu, Dunning, et al. 2010; Igosheva, Abramov, et al. 2010). This 
may contribute to reduced fertility observed in obese women, but also to 
periconceptual programming of embryos via suboptimal maternal 
mitochondrial function. 
Not only are there direct effects of maternal obesity on offspring metabolism, 
but these effects also appear to persist to subsequent generations, potentially 
through epigenetic mechanisms (Drake and Walker, 2004; Waterland, 
Travisano, et al. 2008; Davis, McGonagle, et al. 2008; Aagaard-Tillery, Grive, 
et al. 2008; Li, Huang, et al. 2012).  
It is therefore clear that the maternal environment is not only crucial for the 
normal development of offspring metabolic regulation but that there are 




This thesis addresses aspects of maternal metabolism in apparently healthy 
obese pregnant women. While there is an abundance of epidemiological data 
describing the increased risk of adverse outcomes for mother and offspring 
in the context of obesity in pregnancy, there is less known about the 
underlying mechanisms to account for these outcomes. The complex 
endocrine regulatory activities of adipose tissue are only beginning to be 
described in the relatively recent literature, as are the cellular perturbations 
observed in obesity in non-pregnant individuals.  
The long-term effects of obesity contribute to a vicious cycle of obesity and 
further ill health in subsequent generations. At present, there are few 
effective therapies and no specific pharmacological targets. The interactions 
between the normal physiological adaptations of pregnancy and those 
associated with pre-gravid obesity, outwith the context of co-morbidities 




1.7. Hypothesis and Aims 
This project was designed with the aims of initially describing features of 
intermediary metabolism in healthy obese pregnant women and how these 
diverge from those of normal weight women, particularly with respect to 
characteristics of adipose tissue.   
We hypothesised that: 
1. Increased severity of obesity is associated with exaggerated insulin 
resistance secondary to interaction between pre-existing obesity and the 
metabolic adaptations of pregnancy compared with less obese and lean 
women. 
2. That this exaggerated insulin resistance is associated with adaptation of 
adipose tissue function in terms of expression of adipokines and 
inflammatory cytokines. Specifically, that expression of adipokines and 
inflammatory cytokines is altered in pregnant compared with non-
pregnant women, and further exaggerated in obese compared with lean 
pregnant women. 
3. That there is enhanced adipose tissue lipolysis compared with lean 
pregnant controls. 
4. That this state of insulin resistance and enhanced lipolysis is associated 




Chapter 2    General Methods 
 
2.1. Patient Recruitment 
2.1.1. Ethical approvals 
 
Ethical approval for this study was obtained from the Lothian Research 
Ethics Committee. Three ethical approvals relate to this thesis: 
1. LREC 07/S1103/25. ‘The effect of maternal weight on the fetomaternal 
unit in pregnancy’. Chief investigator, Dr Fiona Denison. 
2. LREC 09/S1103/6. ‘Altered Metabolic Processes in Obese Pregnant 
Women’ (AMPOP study). Chief investigator, Professor Jane Norman; 
principle investigator, Dr Sarah Barr. 
3. LREC 08/S1101/39. ‘Hormones in Pregnancy’. Chief investigator, Dr 
Rebecca Reynolds. 
Also applicable is the following approval: 
1. West of Scotland REC4, 09/S0704/3, ‘Edinburgh Reproductive Tissue 
BioBank’ (ERTBB). Chief investigator, Dr Simon Riley. 
 
2.1.2. Recruitment process/Metabolic Clinic 
For studies in tissues obtained from term pregnancies (Chapter 3), tissue 
(blood, subcutaneous adipose, omental adipose and placenta) was obtained 
from healthy women undergoing elective caesarean section at the Royal 
Infirmary of Edinburgh and who had consented to storage and use of tissues 





For longitudinal studies in pregnancy, obese women were recruited from the 
Metabolic Antenatal Clinic at the Royal Infirmary of Edinburgh. This is a 
pan-Lothian high risk antenatal clinic for women with a booking BMI greater 
than 40kg/m2. Normal weight (BMI 20-25 kg/m2) ‘control’ women were 
recruited from routine antenatal clinics in Edinburgh.  
Non-pregnant participants were recruited as volunteers responding to 
advertisements. 
2.1.3. Oral Glucose Tolerance Testing 
When women undertook oral glucose tolerance testing, the following 
standard method was used. Following an overnight fast, participants 
attended the Royal Infirmary of Edinburgh at 8am. Fasting venous blood 
samples were obtained from a peripheral vein. Glucose (75g) was 
administered as oral Lucozade Energy Original (410ml of 70kCal/100ml 
formulation) (GlaxoSmithKline). A second venous sample was obtained 2 
hours after glucose administration. Gestational diabetes was diagnosed on 
the basis of either fasting glucose > 5.5 mmol/L or 2 hour glucose > 8.9 




2.2. Tissue collection 
 
2.2.1. Blood sampling 
 
Whole blood was collected from a peripheral vein into the appropriate 
container (Sarstedt Monovette ®, UK) and transported on ice. Plasma or 
serum was separated within 30 minutes of collection by centrifugation at 
12000rpm for 10minutes at 4oC. Blood fractions were stored at -80oC until 
analysis. 
 
Blood collected for plasma was anti-coagulated with either sodium EDTA or 
lithium heparin. Blood collected for serum was collected into either a plain 
container or one containing a separation polyacrylic ester gel. For glucose 
determination, samples were collected into tubes containing fluoride 
(1mg/ml blood) and EDTA. 
 
2.2.2. Third trimester adipose tissue biopsy 
 
2.2.2.1. Site of biopsies 
Adipose tissue biopsies were obtained from women undergoing elective 
caesarean section. Subcutaneous adipose tissue was excised by diathermy or 
sharp dissection from the abdominal adipose depot at the site of skin incision 
in the lower abdomen. Visceral adipose tissue was obtained from the 





2.2.2.2. Tissue handling 
Any damaged tissue (identified macroscopically) was quickly excised from 
the sample. Tissue was divided into aliquots and placed immediately on dry 
ice and then stored at -80oC for later use.  
 
2.2.3. Percutaneous adipose tissue biopsy  
 
Subcutaneous adipose tissue was biopsied as part of the AMPOP study 
protocol (see Chapter 4). With the patient supine, an area of skin lateral to the 
umbilicus was cleaned with sterile solution (chlorhexidine) and draped. An 
area 3cm in diameter was infiltrated with 1% lidocaine without adrenaline. 
Using a 12G needle inserted laterally into the subcutaneous tissue, adipose 
tissue was aspirated into a sterile 50ml syringe under suction. Approximately 
10ml sterile isotonic saline (supplier) was drawn up into the syringe, then 
tissue was rinsed over sterile wire mesh to remove excess blood. Visible 
blood clots were removed with sterile forceps. Aspirated tissue was placed in 
a sterile 2ml eppendorf and placed immediately on dry ice. Tissue was stored 
at -80oC until use. Up to three aspirations were carried out to obtain sufficient 
tissue.  
 
In pregnant women, abdominal examination was carried out to determine 
fundal height prior to proceeding with the biopsy. When biopsies were 





2.3.  Materials 
 
2.3.1. Blood collection 
   S-Monovette® blood 
collection system 
(Lithium Heparin, 
EDTA, fluoride and 
serum gel) 
Sarstedt Ltd., Leicester, UK 
   
2.3.2. RNA extraction & cDNA synthesis  
 RNeasy Lipid minikit Qiagen, Crawley, 
UK 
Cat. No. 74804 
 RNase-free DNAse I Qiagen, Crawley, 
UK 
Cat. No. 79254 
 QIAzol Lysis Reagent Qiagen, Crawley, 
UK 
Cat. No. 79306 
 Chloroform (>99%, 
PCR reagent) 
Sigma, Dorset, UK C7559-5VL 
 Ethanol [for molecular 
biology] 
Sigma, Dorset, UK E7023-4X4L 
 High capacity cDNA 
synthesis kit 
Applied Biosystems 4368816 
 RNAse inhibitor Applied Biosystems AM2682 
   
2.3.3. Real time RT-PCR (Taqman®) Gene expression assays & solutions 
 Cyclophilin A Applied Biosystems Hs99999904_m1 




 ME1  Applied Biosystems Hs00159110_m1 
 RBP4  Applied Biosystems Hs00924047_m1 
 DGAT2 Applied Biosystems Hs00261438_m1 
 HSD17b2 Applied Biosystems Hs00157993_m1 
 PPARalpha Applied Biosystems Hs00947537_m1 
 SCD1 Applied Biosystems Hs01682761_m1 
 11β-HSD1  Applied Biosystems Hs00194153_m1 
 LPL  Applied Biosystems Hs00173425_m1 
 HSL  Applied Biosystems Hs00193510_m1 
 ATGL  Applied Biosystems Hs00982042_m1 
 Leptin  Applied Biosystems Hs00174877_m1 
 Adiponectin Applied Biosystems Hs00605917_m1 
 IL6 primers/probes Applied Biosystems Hs00985639_m1 
 TNFα Applied Biosystems Hs00174128_m1 
 MCP1 Applied Biosystems Hs00234140_m1 
 CD68 Applied Biosystems Hs00154355_m1 
 18S  Applied Biosystems 4319413E 
 TaqMan® Universal 
PR Mastermix  
Applied Biosystems 4364338 
 MicroAmp® reaction 
plates (96- and 384-
well) 
Applied Biosystems 4366932/4326270 
 MicroAmp® optical 
Adhesive Film 
Applied Biosystems 4360954 




2.3.4. ELISA    
 IL6 High Sensitivity 
ELISA  
R&D systems, UK HS600B  
 TNFα High Sensitivity 
ELISA  
R&D systems, UK HSTA00D 
 MCP1 ELISA  RayBio, UK ELH-MCP1-001 
 Leptin Quantikine 
ELISA 
R&D systems, UK DLP00 
 Adiponectin 
Quantikine ELISA 







 Leptin ELISA RayBio, UK ELH-Leptin-001 
 Adiponectin ELISA RayBio, UK ELH-ADIPONECTIN-
001 
 Insulin ELISA Mercodia, Sweden 10-1113-01 




2.3.5. Tracer & Hyperinsulinaemic Euglycaemic Clamp  
 Accu-Chek Blood 
Glucose Monitor 
Roche Diagnostics Ltd., Burgess Hill, UK 
 6,6-d2-glucose Cambridge 




 1,1,2,3,3-d5-glycerol Cambridge 




 Actrapid Insulin Novo Nordisk, Crawley, UK 
 Glucose 20% Baxter, Berkshire, 
UK 
FKB0213B 
   
2.3.6  Gas Chromatography –Mass spectrometry 
 HPLC grade Water Fisher Scientific (Loughborough, UK) 
 HPLC grade 
acetonitrile 
VWR (Lutterworth, UK) 
 Heptane Rathburn (Walkerburn, UK) 
 Pyridine Sigma, Dorset, UK  
 Acetic anhydride Sigma, Dorset, UK  
 Glucose Sigma, Dorset, UK  
 Glycerol Sigma, Dorset, UK  
 Methane, research 
grade 




2.4. Molecular Biology 
 
2.4.1. RNA extraction 
 
RNA extraction was carried out from whole frozen adipose tissue using 
Qiagen RNeasy Lipid Mini kit as follows. 
1. Tissue (100mg) was disrupted in 1ml Qiazol reagent using a tissue 
lyser and steel beads (TissueLyser, Qiagen, UK) for 3 x 3 minutes at 
25Hz.  
2. Tissue homogenate was then transferred to new tubes and incubated 
at room temperature for 15 minutes. 
3. Chloroform (200μL) was added to each tube, shaken vigorously and 
incubated at room temperature for 2-3 minutes. 
4. Samples were centrifuged at 12 000 x g for 15 minutes at 4oC and 
separated into layers. 
5. The uppermost aqueous layer was transferred to clean tubes, taking 
care not to transfer solvent or protein material. 
6. Ethanol (70%) was added (approximately 600μL, equivalent to the 
volume of aqueous layer obtained), vortexed and the mix applied to 
the RNeasy spin column in 2 x 700 μL batches. Following 
centrifugation at 8000 x g at room temperature, RNA was separated 
by affinity to the membrane and eluate discarded. 
7. On column DNaseI digestion was carried out (Qiagen); DNAseI was 
applied to the membranes for 15 minutes at room temperature to 
specifically degrade genomic DNA; columns were then washed by 




8. Columns were subsequently washed with buffer RPE and RNA was 
eluted from the column using 50μL RNAse free water, followed by a 
second elution with eluate to increase the final concentration of RNA.  
 
 
RNA concentration was then evaluated spectrophotometrically by 
Nanodrop. RNA purity was assessed using A260/280 ratio, ratios between 
1.8-2.0 were satisfactory. RNA contamination with protein and solvent was 
assessed using A260/230 ratio, ratios between 2.0 and 2.2 were satisfactory. 





2.4.2. cDNA synthesis 
 
RNA (200-500ng) was reverse transcribed in 20μL reaction volume using 
cDNA synthesis kit (High capacity cDNA reverse transcription kit, Applied 
Biosystems, UK). Random primers were used (ABI, UK). Reverse 
transcriptase negative and template negative controls were also synthesized 
with each cDNA prep. 
 
cDNA was synthesised using a GS1 thermal cycler(GStormTM), with a cycle 
of: 25°C for 10 minutes, 37°C for 120 minutes and 85°C for 5 minutes. cDNA 
was stored at -20oC until use. 
 
cDNA synthesis reaction volumes are shown in Table 2.1. 
 
Table  2.1. cDNA synthesis mixes and controls. 
 1x reaction volume RT negative Template negative 
500ng RNA Make up to 10μL with 
DEPC water 
Make up to 10μL 
with DEPC water 
- 
Random primers 2 2 2 
dNTP 2 2 2 
Reverse 
transcriptase 
1 - 1 
DEPC water 5 6 15 




2.4.3. Real time reverse-transcriptase PCR 
 
2.4.3.1. Method 
Relative messenger RNA expression was determined using quantitative real 
time PCR (qRT-PCR) (TaqMan®, Applied Biosystems) using pre-designed 
gene expression assays (Applied Biosystems, UK). Reactions were set up in 
96- or 384-well MicroAmp® fast optical reaction plates containing 24μL 
Master Mix and 1μL cDNA (for 96-well plates; for 384 well plates, a 12μL 
reaction volume was used in the same proportions). Plates were sealed with 
an optical adhesive cover. Standard curves were generated using serial 2-fold 
dilutions of pooled cDNA and included in each assay; concentrations of 
unknowns are therefore expressed relative to all samples in the experiment. 
Reverse transcriptase negative (to exclude contamination by genomic DNA), 
template negative (to exclude contamination in the cDNA synthesis process) 
and water (to exclude contamination of the reagents) controls were included 
in each experiment; all samples were run in triplicate. The gene of interest 
and housekeeping genes were run in separate singleplex reactions from the 
same cDNA prep. The probe for the gene of interest was labelled with the 
reporter dye FAM; housekeeping genes were labelled with the reporter dye 
VIC; both probes used the quencher dye TAMRA at the 3’ end. The PCR 
reaction was run on the ABI Prism® 7500 Sequence Detection system 
(Applied Biosystems) with the following conditions: 50oC for 2 minutes, 95oC 
for 10 minutes, followed by 40 x cycles of 95oC for 15 seconds then 60oC for 
60 seconds, 72oC for 10 minutes. Data was analysed using the programme 
SDS Version 2.1 (Applied Biosystems). Baseline was set manually 3-4 cycles 
prior to the earliest amplification. The threshold was set manually in the 




2.4.3.2. Data analysis 
Relative quantification of transcript levels was determined using a standard 
curve method. Mean Ct (cycle threshold) of each standard was plotted 
against log10 dilution factor and linear regression was used to fit a standard 
curve to the data. Acceptable standard curves had a slope between -3.1 and -
3.5, with r2 >0.97. Unknown samples were diluted 1:20 or 1:40 for use. Mean 
Cts of unknowns were interpolated from the standard curve, deriving a log10 
relative dilution value (A) for that sample; this value was then exponentiated 
to the power of 10 to give the final relative concentration of RNA:  
 relative concentration = 10A x sample dilution factor 
 
Finally relative transcript levels were normalised against expression of a 
housekeeping gene for subsequent analysis. 
 
2.4.3.3. Housekeeping Gene Choice 
 
18S (eukaryotic ribosomal RNA) (Hs99999901_s1) and cyclophilin A 
(Hs99999904_m1) were used as housekeeping genes.  
 
18S was initially chosen for these experiments as it is commonly used in the 
literature, both in adipose tissue and in other tissues. It is highly abundant in 
most cell types, representing approximately 80% of total cellular RNA and 
codes for the small subunit of eukaryotic ribosomes. However, when 
undiluted and/or in high abundance 18S leads to template inhibition of the 
TaqMan reaction and unreliability of the standard curve at high 
concentrations. The 18S standard curve is not linear at high concentrations. A 




range from 1:32 to 1:1024 was used for the remainder of the experiments. As 
most of the patient samples were used initially diluted 1:20, the majority did 
not fall within the standard curve of 18S. Additionally, many of the target 
genes were expressed at a much lower frequency, and some, such as adipose 
triglyceride lipase and glucocorticoid receptor, become undetectable above 
1:256 dilution. Diluting the samples to 1:40 appeared to allow sufficient 
dilution for 18S, without diluting out the target genes. 
 
18S was suitable as a housekeeping gene as there was no correlation between 
18S expression and BMI and it is therefore stable across the range of samples 
where target genes might be expected to vary. Ideally, more than one 
housekeeping gene should be employed (Gabrielsson, Olofsson, et al, 2005). 
Cyclophilin A was used in later experiments; it has been used in adipose 
tissue by others in this department (Wake, Stimson et al., 2007), and is a 
satisfactory choice for a second housekeeping gene in adipose tissue. One 
potential limitation of this as a housekeeping gene is that it may be 
upregulated in response to some inflammatory stimuli in a murine model 
(Nigro, Satoh, et al. 2010) and is reported as possibly affected by 
hyperglycaemia in vitro in one study (Ramachandran, Venugopal, et al.  
2012). Both of these conditions may be associated with obesity. As none of 
the population studied in this thesis were diabetic and samples were 
obtained fasting, then hyperglycaemia is not likely to be a major 
consideration in this population. There is no reported direct association 
between obesity and levels of cyclophilin A. It is of greater practical use 
compared to 18S as transcript levels of cyclophilin A were in a similar range 
of abundance as the genes of interest, there were no issues with template 




2.5. Enzyme-linked Immunosorbent Assay (ELISA) 
 
Commercially available ELISA kits were used, according to manufacturers’ 
instructions. Briefly, the basis for the ELISA assay is selective binding of the 
protein of interest in a sample to a specific monoclonal antibody which is 
anchored to the surface of a 96-well plate. Sample was applied to the pre-
coated plate and incubated (2hours – overnight). The sample is then removed 
and the plate washed (typically, phosphate buffered saline with Tween 
detergent (PBS-T), commercially supplied wash buffer with each kit was 
used). This removes unbound protein, leaving the protein of interest bound 
to the plate. A secondary detection antibody is then applied. This is usually a 
second antibody specific for the protein of interest which has been 
biotinylated; the plate is washed again to remove unbound detection 
antibody. The protein of interest is now sandwiched between the coated 
primary antibody and the secondary detection antibody. The detection 
antibody is quantified by addition of a solution of horseradish peroxidase 
conjugated to streptavidin; streptavidin binds biotin tightly and specifically. 
Unbound streptavidin is washed off and a detection solution applied. The 
detection solution contains a molecule which releases a coloured dye in 
response to peroxidase activity, for example 3,3’,5,5’-tetramethylbenzidine 
(TMB), which forms  3,3',5,5'-tetramethylbenzidine diimine which has a blue 
colour. This particular reaction is stopped by addition of sulphuric acid, 
leading to a colour change to yellow. Light absorption at 450nm is measured 
by spectrophotometry; absorption is proportional to the concentration of 
yellow species present, which is directly proportional to the concentration of 




Details of intra-assay and inter-assay co-efficients of variation for each assay 




2.6. AMPOP study: Gas Chromatography Mass Spectrometry 
(GCMS): Protocol 
 
Gas Chromatography Mass Spectrometry (GCMS) is a technique to separate 
and quantify chemical species. Chromatography is initially employed to 
separate compounds of differing molecular mass in a mixture on the basis of 
their specific elution times as they pass along a column. Samples are 
dissolved in a volatile liquid which is injected into a column coated with thin 
layer of liquid (stationary phase); the samples are vaporised and carried 
through the column by an inert gas such as helium (mobile phase). 
Interactions between the different species and the stationary phase slow 
down movement of the compounds in the mixture through the column so 
that they are eluted at different times depending on their mass.  
 
Species emerging from the column are then detected by mass spectrometry. 
This technique uses ionisation of each molecule as it leaves the column; ions 
then pass into the analyser, which measures the mass:charge ratio (m/z) and 
intensity. This data are displayed as a peak, with retention time on the x-axis; 
peak area is proportional to the quantity of that ion present. Specific 
compounds can be identified by their characteristic spectra.  
 
For the quantification of many stable isotopomers in biological samples, 
samples must first be derivatised to stabilise them for analysis as the 
isotopomers alone are not suitable for direct analysis by GC-MS. Plasma 
samples were prepared for GCMS analysis by 96-well protein precipitation, 





The sample preparation protocol is as follows: 
 
i. Prepare standard solutions.  
a. Glucose (5mg/mL), glycerol (0.025 mg/mL), d2-glucose (0.1mg/mL) 
and d-glycerol (0.025mg/ml) in HPLC water. Once made up, can be 
stored for 3-4 weeks only. Store in fridge. 
b. Internal standard mix. 13C6 Glucose (5 mg/mL) and butanetriol 
(0.25mg/mL) in HPLC water.  
 
ii. Prepare reagents. 
a. Acetic anhydride (5%) in heptane. Freshly prepared on day of assay. 
b. Pyridine: acetic anhydride (1:1, v/v). Freshly prepared on day of assay. 
 
iii. Set up collection plate (Strata Impact Protein Precipitation 2ml plates, 
Phenomenex, UK). In each run, 8 x enrichment samples, 9 x standard 
samples and 1 x blank sample are included. 
 
iv. Preparation of enrichment standard samples. 
a. Use glass tubes. 
b. Prepare as per table below: 
Standard 0% 0.25% 0.5% 1% 2% 4% 8% Tracer only 
D2 glucose (μL) 0 1.25 2.5 5 10 20 40 40 
Glucose (μL) 500 498.75 497.5 495 490 480 460 0 
D5 glycerol (μL)  0 1.25 2.5 5 10 20 40 40 
Glycerol (μL) 500 498.75 497.5 495 490 480 460 0 
HPLC water (μL) 0 0 0 0 0 0 0 120 





a. Add 1ml acetonitrile to each cartridge well. 
b. Prepare standards directly into the relevant cartridge well as per the 
following tables: 
Quantities Required: 
 Blank 0 1 2 3 4 5 6 7 8 9 
Amount Glucose (μg) Blank 0 10 20 50 100 150 200 300 400 500 
Amount Glycerol (μg) Blank 0 0.005 0.01 0.25 0.5 0.75 1.0 1.5 2.0 2.5 
Amount D2 Glucose 
(μg) 
Blank 0 0.2 0.4 1.0 2.0 3.0 4.0 6.0 8.0 10.0 
Amount D5 Glycerol 
(μg) 
Blank 0 0.005 0.01 0.25 0.5 0.75 1.0 1.5 2.0 2.5 
 
Volumes of Stock Solutions Required (μL): 
 Blank 0 1 2 3 4 5 6 7 8 9 
























D2 glucose 0.1mg/ml +  























HPLC water (μl) 200 200 196 192 180 160 140 120 80 40 0 
Final Volume in cartridge 
(μL) 




c. Add 200 μL of unknown plasma sample to separate wells. 
d. To wells containing unknown samples and standard samples, add 25 
μL Internal Standard mix (13C6 Glucose and butanetriol as above). 
e. Add 200μL of enrichment standards as prepared above to separate 
wells. No internal standard mix is required for these wells. 
f. Wells are thus prepared as follows 
 Standards  Standard + Internal Standard mix x 9  
 Enrichment Enrichment standard alone x 8  
 Blank  200μL HPLC grade water  
 Unknowns Plasma sample + Internal Standard mix  
g. Incubate at room temperature for 20 minutes. 
h. Apply vacuum (0.3 bar, in IST VacMaster®-96, Biotage, Uppsala, 
Sweden); extracts are collected (96-well Masterblock®, Greiner Bio 
One, Frickenhausen, Germany). Extracts are then transferred to 
labelled tubes. 
i. Eluates are dried down under nitrogen at 37oC (SPE DryTM 96 Dual, 
Biotage, Uppsala, Sweden). Samples can be frozen at this point for 
later analysis.  
 
vi. Derivatisation 
a. Add 200μL pyridine:acetic anhydride (1:1, v/v as above) to the dried 
extracts.  
b. Incubate at room temperature for 15 minutes.  
c. Dry down under nitrogen at 37oC as above. 





vii. Transfer reconstituted samples to GCMS vials (200μL conical glass 
inserts, National Scientific, USA) and seal (11mm silver crimp cap, 
Agilent, UK). 
 
The GC-MS system consisted of a Finnigan GC8000TOP GC, an AS800 
autosampler and a single quadrupole Voyager mass spectrometer operated 
via Xcalibur (Version 1.2). The analytical column was an HP-Innowax 
column (30m x 0.32mm x 0.25μm; Agilent, Berkshire, UK). The sample was 
injected using splitless injection in a 1μL volume. Injection temperature was 
260oC. The column over temperature was 60oC at injection, programmed to 
reach 150oC at a rate of 30oC per minute then further programmed to reach 
260oC at a rate of 10oC per minute with a final hold time of 3 minutes. Source 
temperature was 175oC. Helium gas was used as the mobile phase at a rate of 
2.5mL per min. 
 
Mass spectra were acquired using negative chemical ionisation with methane 
(BOC, Glasgow, UK) as the reagent gas. Selective ion monitoring was used 
with a total run-time of 18 minutes. Glycerol, d5-glycerol and butanetriol 
were monitored from 0 – 10 minutes; glucose, d2-glucose and 13C6-glucose 
were monitored from 10-18 minutes. The following ions were monitored: 
derivatised glucose (m/z 287), d2-glucose (m/z 289), glycerol (m/z 217), d5-
glycerol (m/z 222) and internal standards 13C6 glucose (m/z 293) and 
butanetriol (m/z 231). Glucose, d2-glucose and 13C6-glucose were detected as 





2.7. AMPOP study: Magnetic Resonance Imaging Techniques 
 
Magnetic Resonance Imaging (MRI) is a technique which uses the properties 
of atomic nuclei within magnetic field to generate images. It has advantages 
over other imaging modalities such as X-ray, computed tomography and 
ultrasound in that it produces higher resolution images of soft tissues and 
does not require the use of ionising radiation. This last feature makes it 
particularly useful for studies in pregnant women. The ability to resolve soft 
tissues of different types makes this technique useful for identification of 
adipose tissue and it was used in the studies reported in this thesis to 
quantify intra-abdominal adipose. 
 
Further detail regarding the specific chemical composition of regions of 
interest can be gained from the use of complementary techniques such as 
magnetic resonance spectroscopy (MRS). This technique makes use of the 
properties of specific isotopes within different chemical species. In this study, 
we used 1H-MRS, but other magnetic isotopes can also be used, such as 13C, 
31P and 19F.  The behaviour of each 1H is influenced by the chemical structure 
of the molecule which it is part of; this allows characteristic spectra to be 
generated which correspond to specific metabolites of interest; in this study, 
triglyceride and water. Not only does this technique allow identification of 
specific metabolites, but also their quantification; thus we are able to quantify 
intra-organ lipid content by this method. 
 
In this study, we used a 3 Tesla (3T) magnet. This has a stronger magnetic 
field than most MRI systems which are used for routine clinical purposes 
(commonly 1.5T systems). With respect to patient safety for scanning at 3T, 




occurs during MR imaging; the effect of this is minimised by keeping the 
scanning room air conditioned, minimising scan time and keeping scan 
subjects loosely clothed while being scanned. In pregnant patients, the effect 
of excess heat on fetal development in the first trimester is not known, and 
imaging of pregnant patients at 3T is not currently recommended. In the 
third trimester, the effect of heating on the fetus was not thought to be a 
significant problem provided that steps were taken to minimise heat 
accumulation. Theoretical estimates of heat accumulation in fetal tissues 
secondary to radiofrequency exposure suggest that temperature rises would 
be lower than expected to cause teratogenesis, however, these estimates rely 
on models derived from sheep studies and therefore there is uncertainty 
regarding associated risk (Gowland and De Wilde, 2008). Mathematical 
modelling of the heat exchange in a human pregnant model suggests that as 
long as acceptable maternal exposure limits are adhered to, fetal exposure 
would also remain within those acceptable limits (Hand, Li, et al.  2010). 
Secondly, the MR system is noisy and aural protection was provided for 
subjects within the scanner. The impact of excess noise on fetal hearing is 
thought to be minimal; no patients reported any specific fetal responses to 
noise during scan sessions. There are few studies of long term follow up of 
infants exposed to MRI antenatally; those which have been carried out have 
not shown any detrimental effects on neurological development or hearing 
but small sample size makes it difficult to definitively prove absence of harm 





2.7.1. Patient recruitment 
Patients were recruited from the Metabolic Antenatal Clinic and control 
cohort as described above. Pregnant women were imaged at approximately 
36 weeks gestation, (for demographic details, see Chapter 5). All had healthy 
singleton pregnancies, with a normal OGTT at 28 weeks and no contra-
indications to MR scanning.  
 
2.7.2. Study Protocol 
 
Patients were imaged at the Clinical Research Imaging Centre at the Royal 
Infirmary of Edinburgh on a Siemens Magnetom Verio 3T Whole Body MRI 
scanner (Siemens Medical, Erlangen, Germany). Patients were positioned in 
the scanner in a left lateral position to prevent aorto-caval compression. MRI 
data was obtained using a combination of body matrix and spine matrix coil 
elements.  The body matrix coil was positioned over the maternal liver and 
thigh. Aural protection was provided by use of ear plugs and headphones. 
Contact was maintained with the scanning staff at all times through the use 
of an intercom. Heart rate and SpO2 were continuously monitored during the 
scan process; blood pressure was recorded prior to commencing scanning 
and every 10 minutes thereafter. 
 
MRI and MRS was acquired a combination of body matrix and spine matrix 
elements. 2D multi-slice FLASH images were acquired axially central to the 
right lobe of the maternal liver with water and lipid signals in and out of 
phase, using echo times of 2.46, 4.92, and 8.61ms. MRS was also acquired in 





2.7.3. Assessment of Intra-abdominal Adipose 
 
To define subcutaneous and intra-abdominal fat, a 3D T1-weighted VIBE 
sequence was acquired axially through the liver with in and out phase 
images, and lipid signals defined using a combination of the in and out of 
phase images with a semi-automated thresholding technique employed 
using the commercial software SliceOmatic™ (TomoVision, Quebec, 
Canada).  
 
Adipose tissue appears bright on T1-weighted images. Regions of interest 
with signal intensity above an investigator-defined threshold were coloured 
to delineate intra-abdominal adipose (red) and subcutaneous adipose (green) 
and paraspinal adipose (blue) (Figure 2.1). The volume of the coloured areas 
can be calculated and expressed as a percentage of the total abdominal 
volume. Intra-abdominal adipose is defined as all adipose within the 
abdominal cavity, and does not distinguish between intra- and retro-
peritoneal deposits. Subcutaneous adipose is defined as all adipose inferior 
to skin but superior to abdominal cavity. Where breast tissue is in the field of 
view, this was excluded from analysis. Intra-observer variability was 
assessed by the same observer defining the same image on 10 separate 
occasions inter-observer variability was assessed by comparison of data of 2 
independent observers of the same subject (see Chapter 5.3.3). 
 
For the studies in this thesis, there are several factors influencing our 
approach. This is discussed in further detail in Chapter Five. In brief: firstly, 
patients are positioned in a left-lateral tilt rather than supine. Secondly, at 36 




abdominal volume. Both of these contribute to a significant distortion of the 
normal female intra-abdominal anatomy, with both compression and 
elevation of organs in a variable distribution. This leads to issues with 
defining a region of interest. Firstly, the routine landmarks used for the non-
pregnant population, while fixed, lie in the same region as the uterus. This 
limits their usefulness, as the majority of the field of view at this level will be 
composed of uterus and uterine contents rather than intra-abdominal organs, 
ie adipose. Additionally, acquisition of MR data is affected by motion 
artefact; contributions from fetal movement and amniotic fluid thus limit the 
usefulness of data in this region. We therefore endeavoured to identify a 
fixed landmark cranial to this. Images were reviewed by 2 investigators 
(Sarah Barr and Calum Gray) and by a consultant obstetric radiologist (Jane 
Walker). The left renal pelvis was chosen as a suitable landmark (a) as it was 
clearly identifiable in all patients, (b) since it is a retro-peritoneal organ, it is 
less affected by the presence of a gravid uterus and (c) it is sufficiently cranial 
to uterine fundus that acceptable data quality is maintained. The left renal 
pelvis is usually located at the position of the first lumbar vertebra.  
 
Following identification of a fixed anatomical landmark, a multi-slice 
approach was used. It was felt that a single-slice approach would be 
sufficiently non-representative to outweigh the validity of any data and that 
a multi-slice approach which included the uterus would be sufficiently 
affected by artefact that the additional data would not be reliable. Therefore a 
region composed of 18-20 x 3mm consecutive slices cranial to left renal pelvis 
were analysed using SliceOmatic™ as described as this avoided involving a 





Figure 2.1 Representative SliceOmatic™ images 
 
 
Figure 2.1 Representative abdominal slices from an obese (left) and a lean (right) subject. 





2.7.4. Assessment of Intra-organ Lipid Content 
 
2.7.4.1. 1H-MR Spectroscopy 
 
1H proton MRS PRESS single voxel spectra were obtained in the right lobe of 
the liver and right quadriceps muscle remote from any large vessels using an 
echo time of 30 ms and a voxel size of 2cm3(liver) and 3cm3 (muscle). Spectra 
were obtained with and without water suppression, and lipid concentration 
was calculated from the water-suppressed acquisition using the spectroscopy 
analysis tool jMRUI.  
 
2.7.4.2. In- and out-of-phase imaging 
 
Intrahepatic lipid signal contribution was also calculated through subtraction 
of in and out of phase images (2.46ms and 8.61ms), and T2* decay during this 
time corrected using the two in-phase images (2.46ms and 4.92ms) according 
to an established protocol. This was carried out in addition to attempting to 
acquire 1H-MRS data as there were difficulties in obtaining satisfactory 
spectra from all subjects. Due to the poor quality of hepatic spectra obtained, 
hepatic fat fraction data was derived using this method alone.  
 
These calculations (from 1H-MRS spectra and in- and out-of phase imaging) 
were performed by Dr Calum Gray; statistical analysis of the calculated lipid 







 Chapter Three 
Adipose tissue function & metabolic adaptation in lean and 
obese pregnancy 
 
3.1. Introduction  
 
Pregnancy is associated with significant adaptation of maternal metabolism. 
In normal pregnancy, resistance to the action of insulin develops with 
increasing gestation, and is maximal in the third trimester (Catalano, Huston, 
et al. 1999). This development of insulin resistance (IR) is associated with 
changes in the function of adipose tissue, with increasing rates of lipolysis as 
this pathway is freed from inhibition by insulin. Enhanced lipolysis in the 
third trimester is important for normal fetal growth; reduced rates of 
lipolysis have been associated with fetal growth restriction and low birth 
weight (Diderholm, Stridsberg et al.  2005; Diderholm, Stridsberg et al.  2006).  
 
Obesity is also associated with significant changes in lipid metabolism, and 
features increased systemic and intra-adipose inflammation, as well as 
alterations in circulating adipokines such as leptin and adiponectin. These 
systems drive local and systemic insulin resistance in obese subjects (Xu, 
Barnes et al. 2006; Antuna-Puente, Feve et al. 2008).  
 
 Whilst the drivers of maternal metabolic adaptation in pregnancy are not 
fully understood, there is modulation of normal metabolic regulatory 
systems by placental products, including those exclusive to the placenta such 
as placental lactogen, as well as those which are synthesized by both the 




membranes are a source of both leptin (Masuzaki, Ogawa, et al. 1997) and 
adiponectin (Caminos, Nogueiras et al. 2005), both of which are also 
synthesized by maternal adipose tissue. Inflammatory pathways may also be 
involved, directly or indirectly: the placenta is a significant source of several 
cytokines (Denison, Kelly, et al. 1998).  
 
The aim of this study was to characterise the longitudinal changes in 
circulating metabolic and inflammatory markers in obese pregnant women at 
three different time points during pregnancy, and to evaluate the possible 
contribution of adipose tissue to circulating levels of these factors in the third 
trimester.  
 
Where obesity and pregnancy co-exist, we hypothesised that: 
1. Obese pregnant women have exaggerated insulin resistance in the 
third trimester compared with lean pregnant women 
2. This is accompanied by exaggerated circulating adipokines and 
inflammatory markers. 
3. Increased adipose tissue expression of adipokines and inflammatory 
markers in obese patients accounts for any observed increase in 
circulating levels of these factors. 
 
To address these hypotheses, two parallel studies were undertaken. Firstly, 
we undertook a case-control study of obese and lean pregnant women. We 
recruited healthy pregnant women with a booking BMI > 40kg/m2 and 
weight-matched controls with BMI between 20 and 25 kg/m2. Women were 
seen at 3 time points during pregnancy, at 16, 28 and 36 weeks gestation. 




obtained.  Delivery outcome and birth weight were recorded. All women had 
a normal OGTT at 28 weeks gestation (Section 2.1.3). Circulating adipokines, 
pro-inflammatory cytokine, glucose, insulin and NEFA were measured. 
Indices of insulin sensitivity were calculated. 
 
Secondly, we carried out a cohort study of adipose tissue from pregnant 
women at term. Paired subcutaneous and omental adipose tissue biopsies 
were obtained from healthy, non-diabetic women undergoing an elective 
caesarean section delivery at term (> 37 completed weeks gestation). 
Transcript levels of adipokines, pro-inflammatory cytokines and genes 
involved in the regulation of lipid synthesis and storage were measured 







3.2.1. Specimen collection 
 
All biological samples were collected following informed consent from the 
donor. Ethical approval was obtained from the Lothian Research Ethics 
Committee (see Chapter 2.1.1). 
 
3.2.1.1. Longitudinal samples 
 
Fasting plasma and serum samples were collected as described in Section 
2.2.1 from healthy women with singleton pregnancies enrolled in the 
Metabolic Antenatal Clinic and the accompanying control cohort. Women 
were excluded if they: had any pregnancy complications, such as gestational 
diabetes pre-eclampsia or obstetric cholestasis; had any endocrine 
comorbidities such as hypothyroidism or pre-existing diabetes; were on any 
regular medications with metabolic activities such as glucocorticoids, 
including oral and inhaled, or anti-inflammatory medications; if there were 
any concerns regarding abnormal fetal growth; if they delivered pre-term 
(prior to 37 completed weeks gestation).  Participants attended 3 times 
during pregnancy, at 16, 28 and 36 weeks gestation. At each visit 
measurements were made of waist, hip, upper thigh and upper arm 
circumference; skinfold thicknesses at biceps, triceps and subscapular 
skinfolds were measured using Harpenden callipers and body composition 
(fat mass and fat free mass) estimated using bioelectrical impedance (TBF-
300A Body Composition Analyser, Tanita, IL, USA). While every attempt 




samples, the number of subjects included varies slightly for some measures 
and assays; this was due to a small number of patients who either did not 
attend for one of the visits or in whom the blood samples were unsuitable for 
inclusion in analysis. Baseline characteristics are shown for the whole cohort 
in Table 3.1. No patients gave a history of polycystic ovarian syndrome 
(PCOS). However, a history of menstrual irregularity was present in a 
slightly greater proportion of obese compared to lean subjects (10/26 vs 7/24). 
This was not statistically significant (p = 0.59, Fisher’s exact test). The 
prevalence of PCOS is an important consideration as this is a population of 
women with known increased risk of insulin resistance.  
 
3.2.1.2. Term tissue samples 
 
Paired subcutaneous and omental adipose biopsies were obtained as 
described in Section 2.2.2 from healthy women with singleton pregnancies of 
a range of booking BMI who were undergoing elective caesarean section 
delivery at term (37-42 completed weeks gestation). Tissue samples were 
immediately frozen at -80oC until use. Tissue samples were collected as part 
of a larger tissue collection protocol involving collection of a number of 






3.2.2. Plasma and serum analyses 
A number of variables were analysed. These were specifically chosen either 
as markers of metabolic indices or inflammation for the larger source cohort 
of women attending the Metabolic Antenatal Clinic and the lean control 
cohort, or to answer specific questions only in the smaller nested cohort 
presented in this chapter. While the possibility of correlation by chances 
exists due to the number of variables being analysed, it was hoped that this 
would be minimised as each variable was selected to answer a specific 
question. 
In the source cohort, C-reactive protein was measured as a non-specific 
marker of inflammation as a means of assessing the inflammatory 
environment in a larger population where specific cytokines were not being 
measured. Serum insulin, glucose and non-esterified fatty acids (NEFA) were 
also measured in the larger MAC cohort, as was alanine transferase (ALT), as 
an index of potential hepatic dysfunction within the population. 
The specific assays performed in the nested cohort in this Chapter are 
detailed as follows. 
 
3.2.2.1. ELISA assays 
All ELISAs were carried out according to the general protocol specified in 
Chapter 2.5. Plasma samples using EDTA as anti-coagulant were used.  All 
ELISAs were carried out according to the manufacturers instructions; kit 
manufacturer details are listed in Chapter 2.3.4. Pro-inflammatory cytokines 
interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and 




associated with obesity and insulin resistance in both pregnant and non-
pregnant populations.  
Leptin and adiponectin were chosen as these are two key adipokines with 
associations with obesity and in the case of adiponectin, with the 
development of the insulin resistance of pregnancy. High molecular weight 
adiponectin was also analysed as there is some evidence to suggest that the 
relative proportion of high molecular weight to total adiponectin is more 
important in terms of its insulin sensitising activity (Fisher, Trujillo, et al. 
2005).  
 
3.2.2.1.1.  Interleukin 6 ELISA 
IL-6 was measured using high-sensitivity Quantikine® Colorimetric 
Sandwich ELISAs from R&D systems. The assay range was 10 to 0.156pg/mL; 
limit of detection was 0.04pg/mL; mean intra-assay CV was 6.5%, mean inter-
assay was CV 10%. 
 
3.2.2.1.2.  TNFα ELISA 
TNFα was measured using high-sensitivity Quantikine® Colorimetric 
Sandwich ELISAs from R&D systems. The assay range was 32 to 0.5 pg/mL; 
limit of detection was 0.1pg/mL; mean intra-assay CV 10.7%; mean inter-
assay CV 22.5%. 
 
3.2.2.1.3.  Monocyte Chemoattractant Protein 1 ELISA 
MCP-1 was measured using a Human MCP-1 ELISA kit from RayBio®. The 
assay range was 1000 – 31.2pg/mL; limit of detection was 2pg/mL; mean 




3.2.2.1.4.  Leptin ELISA 
Leptin was measured using standard Quantikine® Colorimetric Sandwich 
ELISAs from R&D systems. All samples were diluted 1:100 prior to assay. 
The assay range was 1000 to 15.6pg/mL; limit of detection was 7.8pg/mL; 
mean intra-assay CV 11.2%; mean inter-assay CV 13.4%.   
 
3.2.2.1.5. Total Adiponectin ELISA 
In the circulation, adiponectin occurs in several forms. Upon secretion it self 
associates into trimers; the trimers can also associate to form hexamers and 
dodecamers. It is thought that the different species of adiponectin activate 
different signalling pathways and the high-molecular weight forms may 
have a role in vascular dysfunction in obesity (Kobayashi, Ouchi et al. 2004). 
Total adiponectin was measured using standard Quantikine® Colorimetric 
Sandwich ELISAs from R&D systems. This does not distinguish between the 
trimeric, hexameric or dodecameric forms of adiponectin.  Samples from lean 
patients were diluted 1:400 prior to assay; samples from obese patients were 
diluted 1:100; control samples were diluted 1:200. The assay range was 250 to 
3.9ng/mL; limit of detection was 0.25ng/mL; mean intra-assay CV was 9.4%; 
mean inter-assay CV 4.5%.  
 
3.2.2.1.6.  High Molecular Weight Adiponectin ELISA 
High-molecular weight adiponectin was measured using a Human High 
Molecular Weight Adiponectin ELISA kit from Millipore. This ELISA 
requires pre-treatment of plasma samples with a specific protease enzyme to 
remove the hexameric and trimeric forms of adiponectin. This was carried 
out by incubating 20µL of plasma with 170µL of supplied digestion buffer 




1:10 with dilution buffer prior to use, and are thus assayed at 1:200 dilution. 
The assay range was from 200 to 1.56ng/mL; the limit of detection was 
0.5ng/mL; mean intra-assay CV was 3.4%. 
 
3.2.2.2. Plasma glucose, C-reactive protein and liver function analyses 
 
Plasma glucose, C-reactive protein and liver function assays were carried out 
by the Biochemistry Laboratory of the Royal Infirmary of Edinburgh using 
an Abbott CD1600 Bioanalyser. Plasma glucose was measured using a 
hexokinase assay using plasma samples with fluoride oxalate.  
 
3.2.2.3. Serum insulin and serum Non-esterified Fatty Acids 
 
Fasting serum insulin was assayed in duplicate by using a commercially 
available ELISA kit (Mercodia, Uppsala, Sweden). The mean intra-assay CV 






3.2.3. Calculations  
 
Homeostasis model assessment of insulin resistance (HOMA-IR) was 
calculated as follows for each patient: 
HOMA-IR  =  (Fasting Glucose x fasting Insulin) / 22.5 
Where glucose is in mmol/L and insulin is in mU/L 
 
Quantitative Insulin Sensitivity Check Index (QUICKI) was also calculated as 
follows for each patient: 
QUICKI  = 1 / (log10 Fasting Glucose) + (log10 Fasting Insulin) 
Where glucose is in mg/dL and insulin is in mU/L 
 
3.2.4. Gene expression assays 
 
3.2.4.1.  RNA extraction 
RNA extraction was carried out as described in Chapter 2.4.1. 
 
3.2.4.2.  cDNA synthesis 
Complimentary DNA (cDNA) synthesis was carried out as described in 
Chapter 2.4.2. 
 
3.2.4.3.  Real time RT-PCR  
Real time RT-PCR (Taqman®) was carried out as described in Chapter 2.4.3. 
Transcript levels of genes of interest were normalised to transcript levels of 
18S or Cyclophilin A. A standard curve was generated for each gene using 





3.2.5. Statistical Analyses 
 
All statistical analyses were carried out using GraphPad Prism® software. 
Data are presented as mean ± SEM unless specifically stated. Demographic 
data were compared using Students’ t-test. ELISA data were analysed using 
2-way ANOVA with repeated measures where appropriate. Between-group 
comparisons were carried out with Bonferroni post-hoc testing. Real time 
RT-PCR data are expressed in arbitrary units; Rank-Spearman correlation 
was used as data were not normally distributed. Proportional data was 
analysed using Fisher’s exact test. Significance was set at p < 0.05.  
Transcript data was correlated with booking BMI rather than current 
adiposity. It is possible that adipose tissue characteristics may be influenced 
by recent depot expansion of the magnitude seen in pregnancy and while a 
more current measure of weight would have been ideal, both as a measure of 
current and also to provided information regarding weight gain in 
pregnancy, it was not possible to obtain this on the day of tissue collection 
due to a number of practical issues of access to the patient in a very busy 
clinical area. Additionally, routine weighing of pregnant women in the third 
trimester is not current practice and it is not possible to abstract this data 
retrospectively from the clinical record. A small number of patients recruited 
had also been attending the Metabolic Antenatal Clinic and had measures of 
weight and body composition made at 36 weeks gestation but as this 
represented only 5 subjects out of a cohort of a cohort of 45, it was of limited 
value. A pragmatic decision to use booking BMI only was made by the 
research team collecting a number of tissue types from patients attending for 





Statistically significant differences between lean and obese women were 
found for most parameters measured, indicating adequate power in a cohort 
of this size. While statistically significant differences were detected between 
lean and obese subjects with respect to IL6 and MCP-1, there were no 
significant differences in plasma TNFα concentrations, although there was a 
trend towards greater TNFα in obese women. A sample size of 137 subjects 
in each group would have been required to give 80% power to show that 
such a difference was significant at the 5% significance level. A cohort of this 







3.3.1. Weight gain and anthropometric measurements in pregnancy 
 
Table 3.1 summarizes the demographic characteristics of the longitudinal 
cohort. There was no significant difference in age, parity, mode of delivery or 
birth weight between lean and obese women. However, obese women had 
significantly higher systolic and diastolic blood pressure at 16 weeks (121 ± 
2.1 vs 106 ± 1.6mmHg and 68 ± 0.6 vs 63 ± 1.0mmHg respectively, both 
p<0.001). 
 
The patient characteristics of the term tissue cohort are shown in Table 3.2 
 
In the longitudinal study, changes in total body weight and fat mass are 
shown in Table 3.3. Lean women gained more weight than obese women 
between 16 and 36 weeks (10.2 ± 0.8 vs 7.5 ± 1.0kg, p = 0.05). This represents a 
significantly higher percentage change in body weight from 16 to 36 weeks 
(16.7 ± 1.4 vs 6.4 ± 0.9%, p <0.0001).  
 
Estimates of fat mass were made using bioelectrical impedance. Lean women 
gained more absolute fat mass than obese women, also representing a 
significantly higher percentage gain from 16 to 36 weeks (5.5 ± 2.8 vs 2.8 ± 0.8 
kg, p = 0.02;  29.8 ± 3.6 vs 5.0 ± 1.6%, p <0.0001, respectively).  
 
Skinfold thicknesses at biceps, triceps and subscapular skinfolds are shown 





Mean skinfold thickness increased slightly at each site between 16 and 36 
weeks in lean women (biceps, 13.9 ± 1.0 vs 17.8 ± 2.2mm; triceps, 15.3 ± 0.8 vs 
18.3 ± 1.8mm; subscapular, 14.3 ± 1.4 vs 17.0 ± 2.1mm) although this did not 
reach statistical significance at any site. In obese women, mean biceps 
skinfold decreased between 16 and 36 weeks (34.8 ± 2.8 vs 29.5 ± 2.7 mm, not 
significant); mean triceps skinfold also decreased between 16 and 36 weeks 
(40.3 ± 3.5 vs 31.3 ± 3.8 mm, p < 0.05) and mean subscapular skinfold 





Table 3.1 Demographic Characteristics of the Longitudinal Cohort 
Table 3.1 Demographic characteristics of the longitudinal cohort. Data are presented as 
mean ± SEM unless otherwise stated. Lean and obese are compared using Students’ t-test; 
proportional data regarding mode of delivery was analysed by Fisher’s exact test.. 
 
 
Table 3.2 Demographic Characteristics of Term Tissue Cohort 
 
n = 45 Mean ± SEM Range 
Age (years) 32.9 ± 0.7 23 - 43 
Parity (median) 1+ n/a 
0+ (n) 
 
n = 8  
1+ (n) n = 26  
2+ or above (n) n = 11  
Booking BMI  (kg/m2) 29.9 ± 1.1 20.7 – 48.8 
Gestation at delivery (median) 39+1 37+1 – 41+4 
Birthweight (g) 3578.5 ± 64.9 2770 - 4470 
Table 3.2 Demographic characteristics of term cohort. 
Data are presented as mean ± SEM, (range) unless otherwise specified. 
  Lean (n=24) Obese (n=26) p 
Age (years) 33.6 ± 0.9 32.3 ± 1.0 0.3 
Mean Parity 1+0 1+0  
Baseline Gestation (weeks + days) 15+6 16+2 0.55 
Baseline BMI (kg/m2) 22.7 ± 0.3 43.1 ± 0.5 <0.0001 
Baseline Fat Mass (kg) 18.1 ± 0.9 57.7 ± 1.7 <0.0001 
Baseline SBP (mmHg) 106 ± 1.6 121 ± 2.1 <0.0001 
Baseline DBP (mmHg) 63 ± 1.0 68 ± 0.6 <0.0001 
Gestation at Visit 2 28+4 28+2 0.23 
Gestation at Visit 3 36+3 36+2 0.73 
Gestation at delivery (weeks + days) 40+5 40+3 0.6 
Birth weight (g) 3567 ± 120 3615 ± 113 0.8 
Mode of delivery (n)    
SVD 13 11 0.55 
Instrumental delivery 5 5  









Table 3.3 Weight gain and fat mass accretion in pregnancy 
  
    
    
    
    
    
    
    
    
    
    
Table 3.3 weight gain and fat mass accretion 
a Lean compared to obese 
b p  <0.01    16 weeks compared with 36 weeks 
c p  <0.05     16 weeks compared with 36 weeks 
d p < 0.01   16 weeks compared with 36 weeks (n = 17) 
e not significant 16 weeks compared with 36 weeks (n = 17) 
 
* Fat mass estimates were available at all 3 time points for n = 17 in each group; analysed 
using 2-way ANOVA with repeated measures. 
  Lean (n=24) Obese (n=26) pa 
Weight (kg)    
16 weeks 61.4 ± 1.1 116.5 ± 2.6 <0.001 
28 weeks 68.2 ± 1.4 121.1 ± 2.8 <0.001 
36 weeks 71.6 ± 1.5b 124.1 ± 2.9c <0.001 
Mean weight gain (kg) 16 – 36 weeks 10.2 ± 0.8 7.5 ± 1.0 0.05 
Weight gain (%) 16 – 36 weeks 16.7 ± 1.4 6.4 ± 0.9 <0.0001 
Fat Mass (kg)*    
16 weeks 18.1 ± 0.9 56.1 ± 1.7 <0.001 
28 weeks 26.0 ± 2.1 58.1 ± 1.9 <0.001 
36 weeks 23.5 ± 1.6d 58.7 ± 2.1e <0.001 
Mean gain in fat mass (kg) 16-36 weeks 5.5 ± 2.8 2.8 ± 0.8 0.02 



























































































Figure 3.1 Longitudinal changes in skinfold thickness measurements.  
 
A. Biceps skinfold; n = 19 (lean); n = 17 (obese); overall effect of BMI p < 0.0001 
B. Triceps skinfold; n = 18 (lean); n = 17 (obese); overall effect of BMI p <0.0001 
C. Subscapular skinfold; n = 13 (lean); n=9 (obese) overall effect of BMI p < 0.0001  
 







3.3.2. Longitudinal changes in fasting glucose, fasting insulin and indices 
of insulin sensitivity 
 
Longitudinal changes in fasting glucose and insulin are shown in Table 3.4. 
All patients had a normal oral glucose tolerance test at 28 weeks gestation. 
There was no significant overall effect of BMI or gestation on fasting glucose. 
However, fasting plasma glucose was significantly greater at 36 weeks in 
obese compared with lean women (p < 0.05).  
 
Fasting insulin was significantly greater in obese compared with lean women 
at all gestations (p < 0.0001). Both BMI and gestation had a highly statistically 
significant overall effect (p < 0.0001) on insulin. In lean and obese women, 
there was a significant increase in fasting insulin between 16 and 36 weeks (p 
< 0.01 and p < 0.001 respectively). 
 
HOMA-IR and QUICKI scores were calculated (see Section 3.2.3) and are 
shown in Figure 3.2. HOMA-IR scores reflect insulin resistance; a higher 
score implies greater insulin resistance. QUICKI scores reflect insulin 
sensitivity; a higher score implies greater insulin sensitivity. HOMA-IR and 
QUICKI are derived from the same data, namely fasting glucose and fasting 
insulin and therefore express the same information but with an emphasis on 
either insulin resistance or sensitivity, respectively. Insulin resistance 
according to HOMA-IR scores was significantly greater in obese compared 
with lean women at all three gestations (Figure 3.2 A) (p < 0.001). There was a 
positive overall correlation of gestation with HOMA-IR (p < 0.0001); this was 






Table 3.4 Longitudinal changes in fasting glucose and insulin 
 
 Lean (n = 24) Obese (n = 26) p 
Fasting glucose (mmol/L)    
16 weeks 4.2 ± 0.06 4.4 ± 0.05 ns 
28 weeks 4.3 ± 0.09 4.4 ± 0.05 ns 
36 weeks 4.1 ± 0.08 4.4 ± 0.1 < 0.05 
Fasting insulin (mU/L)    
16 weeks 4.4 ± 0.6 14.7 ± 1.3 < 0.0001 
28 weeks 6.7 ± 0.5 16.2 ± 1.5 < 0.0001 
36 weeks 6.9 ± 0.6 17.9 ± 1.4 < 0.0001 
 
Table 3.4 Longitudinal changes in fasting glucose and insulin.  
 



















































Figure 3.2 Longitudinal changes in indices of insulin sensitivity 
 
A. HOMA-IR scores in lean and obese women at 16, 28 and 36 weeks. 
B. QUICKI scores in lean and obese women at 16, 28 and 36 weeks. 
 
Data are presented as mean ± SEM. n = 24 (lean); n = 26 (obese). 
* p <0.05 *** p <0.001 Data were analysed by 2-way ANOVA with repeated measures with 







3.3.3. Longitudinal changes in leptin  
 
Plasma leptin was greater in obese compared with lean women at all three 
gestations (Figure 3.3A) (at 16 weeks, 54.0±8.9 vs 17.3±2.4 ng/mL; at 28 weeks, 
65.1±7.6 vs 25.9±4.6 ng/mL; at 36 weeks, 72.7±8.5 vs 24.7±4.5 ng/mL, all 
p<0.001). There was a significant increase in plasma leptin in obese patients 
between 16 and 36 weeks (54.0 ± 8.9 vs 72.7 ± 8.5 ng/ml, p< 0.05); but no such 
increase with gestation in lean women.  
 
Transcript levels of leptin were not significantly correlated with BMI in either 
subcutaneous or omental adipose tissue at term (Figure 3.3 B&C).  
 
3.3.4. Longitudinal changes in adiponectin 
 
Total plasma adiponectin was significantly greater in lean compared with 
obese women at 16 weeks (Figure 3.4A) (9.4 ± 1.0 vs 5.8 ± 0.60 µg/mL, p < 
0.001); however, at 28 and 36 weeks there was no significant difference 
between lean and obese women (6.1 ± 0.51 vs 5.5 ± 0.51 µg/mL at 28 weeks; 
6.3 ± 0.70 vs 5.1 ± 0.41 µg/mL at 36 weeks). There was a significant reduction 
in total plasma adiponectin from 16 to 28 weeks in lean women (9.4 ± 1.0 vs 
6.1 ± 0.51 µg/mL , p < 0.001); however, there was no such reduction in obese 
women. 
 
At term, there was no significant correlation between transcript levels of 






High molecular weight adiponectin was measured in the same samples as 
total adiponectin and the ratio of the two calculated (Figure 3.5). Similar to 
the case with total adiponectin, there was a significant decrease in high 
molecular weight adiponectin in lean women between 16 and 28 weeks, but 
no further decrease (5.1 ± 0.5, 2.3 ± 0.3 and 2.4 ± 0.4 µg/mL at 16, 28 and 36 
weeks respectively, p < 0.001 between 16 and 28 weeks). Obese women had 
slightly lower high-molecular weight adiponectin at 16 weeks compared 
with lean women, though this is not statistically significant, and no change 
with gestation (4.0 ± 0.8, 3.25 ± 0.5 and 3.7 ± 0.5 µg/mL at 16, 28 and 36 weeks 
respectively).  Lean women had a significantly lower ratio of high molecular 
weight to total plasma adiponectin at all gestations (0.38 ± 0.01 vs 0.63 ± 0.02; 



















































































Figure 3.3 Longitudinal changes in circulating leptin and third trimester adipose leptin mRNA 
 
A. Fasting plasma leptin. Data are presented as mean ± SEM (ng/mL). n = 14 (lean); n = 12 
(obese).  * P <0.05 ** p < 0.001 Data were analysed by 2-way ANOVA with repeated 
measures with Bonferroni post-hoc testing. 
 
B & C. Transcript levels of leptin in paired subcutaneous (B) and omental (C) adipose tissue 
at term obtained during elective caesarean section delivery. 
Transcript levels are expressed in arbitrary units (AU), relative to transcript levels of 18S; 







Figure 3.4 Longitudinal changes in adiponectin & third trimester adipose 
adiponectin mRNA 
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***  p <0.001
 
Figure 3.4 Longitudinal changes in circulating adiponectin and third trimester adipose 
adiponectin mRNA 
 
A. Fasting total plasma adiponectin. Data are presented as mean ± SEM (µg/ml), n=18 per 
group.  Data were analysed by 2-way ANOVA with repeated measures with Bonferroni post-
hoc testing. 
 
B & C. Transcript levels of adiponectin in paired subcutaneous (B) and omental (C) adipose 
tissue biopsies at term; transcript levels are expressed in arbitrary units (AU), relative to 


























































































 Figure 3.5 Longitudinal changes in circulating total and high molecular weight adiponectin 
 
A. Fasting total plasma adiponectin.  
Data are presented as mean ± SEM (µg/ml), n=18 per group.  
 
B. High Molecular weight adiponectin. 
Data are presented as mean ± SEM (µg/mL). n=6 per group. ***p<0.001 
 
C. Ratio of high molecular weight:total plasma adiponectin.  
Data are presented as mean ± SEM; n=6 per group. *** p<0.001 
 








3.3.5. Longitudinal changes in inflammatory markers in pregnancy 
 
Plasma IL-6 increased with gestation in lean women (Figure 3.6 A) (0.84 ± 
0.07, 1.5 ± 0.2 and 1.7 ± 0.2 pg/mL at 16, 28 and 36 weeks respectively, p < 0.01 
between 16 and 36 weeks). Plasma IL-6 also increased in obese women with 
gestation (1.8 ± 0.1, 2.1 ± 0.2 and 3.3 ± 0.4 pg/mL at 16, 28 and 36 weeks 
respectively, p < 0.001 between 16 and 36 weeks). Plasma IL6 was 
significantly greater in obese compared with lean women at 16 and at 36 
weeks (p < 0.01 and p < 0.001. respectively).   
 
At term, transcript levels of IL-6 were significantly positively correlated with 
booking BMI in subcutaneous adipose tissue (Rs 0.43, p 0.003, Figure 3.6 B) 
but not in omental adipose (Rs 0.16, p = 0.3, Figure 3.6 C). 
 
Plasma MCP-1 increased with gestation in lean women (Figure 3.7 A) (17.6 ± 
2.5, 48.0 ± 4.7 and 60.3 ± 5.0 pg/mL at 16, 28 and 36 weeks respectively; p < 
0.01 between 16 and 28 weeks). Plasma MCP-1 also increased with gestation 
in obese women (21.2 ± 2.9, 56.9 ± 5.5 and 81.8 ± 8.5 at 16, 28 and 36 weeks 
respectively; p < 0.001 between 16 and 28 and 28 and 36 weeks). Obese 
women had significantly greater plasma MCP-1 than lean women at 36 
weeks only (p < 0.05).  
 
At term, transcript levels of MCP-1 were significantly positively correlated 
with booking BMI in subcutaneous adpose tissue (Rs 0.33, p = 0.03, Figure 3.7 





Plasma TNFα did not change with gestation in lean or obese women, and 
was not significantly different between lean or obese women at any gestation 
(Figure 3.8 A). At term, transcript levels of TNFα were not correlated with 
booking BMI in either subcutaneous or omental adipose tissue (Figure 3.8 B 
& C).  
 
Serum CRP was significantly greater in obese compared with lean women at 
all three gestations (p < 0.0001), but there was no significant effect of 




Figure 3.6 Longitudinal changes in Interleukin-6 in pregnancy & third 











































































Figure 3.6 Longitudinal changes in circulating interleukin-6 and third trimester adipose 
interleukin-6 mRNA 
 
A. Plasma IL-6 measured by ELISA. Data are presented as mean ± SEM (pg/mL); n=19 
(lean), n=20 (obese). * p<0.05 **p<0.01 ***p<0.001 Data were analysed by 2-way ANOVA 
with repeated measures with Bonferroni post-hoc testing. 
 
B &C. Transcript levels of IL-6 in subcutaneous (B) and omental (C) paired adipose tissue 
biopsies obtained at elective caesarean section at term. Data are expressed in arbitrary units 








Figure 3.7 Longitudinal changes in MCP-1 in pregnancy & third trimester 












































































Figure 3.7 Longitudinal changes in circulating MCP-1 and third trimester adipose MCP-1 
mRNA 
 
A. Plasma MCP-1 measured by ELISA in lean and obese pregnant women. Data are 
presented as mean ± SEM (pg/mL). n = 16 per group. * p<0.05  *** p<0.001 Data were 
analysed by 2-way ANOVA with repeated measures with Bonferroni post-hoc testing. 
 
B &C. Transcript levels of MCP-1 in subcutaneous (B) and omental (C) paired adipose tissue 
biopsies obtained at elective caesarean section at term. Data are expressed in arbitrary units 








Figure 3.8 Longitudinal changes in TNFα in pregnancy & third trimester 






































































Figure 3.8 Longitudinal changes in circulating TNFα and third trimester adipose TNFα 
mRNA 
 
A. Plasma TNFα measured by ELISA. Data are presented as mean ± SEM (pg/mL). n=19 
(lean), n=20 (obese). Data were analysed by 2-way ANOVA with repeated measures with 
Bonferroni post-hoc testing. 
 
B & C. Transcript levels of TNFα in subcutaneous (B) and omental (C) paired adipose tissue 
biopsies obtained at elective caesarean section at term. Data are expressed in arbitrary units 


































Figure 3.9 Longitudinal changes in CRP in pregnancy 
 
Data are presented as mean ± SEM (mg/L). n = 20 (lean); n = 23 (obese). 
* p < 0.05  ** p < 0.01  *** p < 0.001 
 





3.3.6. Longitudinal changes in Non-esterified Fatty Acids (NEFA) and 
ALT in pregnancy 
 
Fasting serum NEFAs were greater in obese compared with lean women at 
all three gestations (Figure 3.10) (at 16 weeks, 0.29 ± 0.02 vs 0.53 ± 0.03, p < 
0.001; at 28 weeks, 0.27 ± 0.02 vs 0.45 ± 0.02, p < 0.001; at 36 weeks, 0.36 ± 0.03 
vs 0.49 ± 0.03 mmol/L, p < 0.01). There was a significant interaction between 
BMI and gestation (p = 0.02). In lean women, there was a significant increase 
in NEFA from 28 to 36 weeks (p < 0.01); in obese women, there was a small 
decrease in NEFA from 16 to 28 weeks ( p < 0.05).  
 
Serum ALT was measured at 16, 28 and 36 weeks (Figure 3.11). Obese 
women had significantly greater serum ALT at 16 weeks compared with lean 
women (23 ± 3.2 vs 15.8 ± 1.1  IU/L, p < 0.05); There was a significant 
reduction in serum ALT between 16 and 28 weeks in obese women (23.0 ± 
3.2, 18.5 ± 1.8 and 17.4 ± 1.6 IU/L at 16, 28 and 36 weeks, respectively, p < 
0.01). There was no effect of gestation in lean women (15.8 ± 1.1, 16.4 ± 1.4 
and 15.4 ± 0.9 IU/L at 16, 28 and 36 weeks, respectively).  
 
3.3.7. Fatty acid metabolism in adipose tissue at term 
 
Transcript levels of genes coding for enzymes involved in fatty acid synthesis 
were quantified in subcutaneous and omental adipose tissue at term (Table 
3.5). There was a statistically significant negative correlation between 
transcript levels of fatty acid synthase (FASN) and BMI in both subcutaneous 
(Rs -0.33, p = 0.03) and omental (Rs -0.32, p = 0.03) adipose tissue at term 
(Figure 3.12).   





























Figure 3.10 Longitudinal changes in NEFA in pregnancy 
 
Data are presented as mean ± SEM (mmol/L). n = 24 (lean); n = 25 (obese). 
* p < 0.05  ** p < 0.01  *** p < 0.001 
 
Data were analysed by 2-way ANOVA with repeated measures with Bonferroni post-hoc 
testing. 
 























Figure 3.11 Longitudinal changes in alanine transferase in pregnancy. 
 
Data are presented as mean ± SEM (IU/L). n = 23 (lean); n = 24 (obese). 
* p < 0.05 ** p < 0.01  *** p < 0.001 
 






Figure 3.12 Transcripts of Fatty Acid Synthase (FAS) in adipose tissue at 
term 
 



















































Figure 3.12 Transcript levels of FAS in adipose tissue at term. 
 
A & B. Transcript levels of FAS in in subcutaneous (A) and omental (B) paired adipose tissue 
biopsies obtained at elective caesarean section at term.  
 
Data are expressed in arbitrary units (AU) relative to transcript levels of cyclophilin A; n=45. 




Table 3.5 Transcript levels of genes regulating lipid storage, synthesis and 




Transcript levels as determined by qRT-PCR were correlated with booking BMI using Rank 
Spearman correlation. 
Gene Role Subcutaneous Omental 
  
Rs p Rs p 
FAS Fatty acid synthase (Figure 3.12) -0.33 0.03 -0.32 0.03 
RBP4 Levels positively correlate with fat 
mass and inversely correlate with 
insulin sensitivity (Yang, Graham et al,  
2005; Kotnik, Fischer-Posovszky et al. 
2011) 
-0.10 0.5 0.04 0.8 
PPAR alpha Nuclear receptor; involved in 
regulation of fatty acid oxidation (Van 
Raalte, Li et al. 2004) 
0.12 0.4 0.02 0.9 
DGAT2 Catalyses rate-limiting step in 
triglyceride synthesis (Yen, Stone et al.  
2008) 
-0.07 0.6 -0.10 0.5 
ME1 Generates NADPH for fatty acid 
synthesis (Wise & Ball, 1964)  
-0.01 0.9 -0.16 0.3 
SCD1  Required for unsaturated fatty acid 
synthesis; involved in response to 
leptin (Paton & Ntambi, 2009) 
0.10 0.5 -0.04 0.8 
11β-HSD1 Enzyme catalysing the interconversion 
of cortisol to cortisone; involved in 
regulating the local availability of 
active steroid in adipose tissue (Seckl, 
Morton et al. 2004)  
0.03 0.8 -0.02 0.9 
GR Nuclear receptor for glucocorticoids 
(Macfarlane, Forbes et al. 2008) 
-0.04 0.8 -0.08 0.6 
LPL Involved in the hydrolysis of  
circulating lipoproteins (Wang & Eckel, 
2009)  
-0.19 0.2 -0.17 0.3 
HSL Rate limiting step in lipolytic cascade; 
catalyses hydrolysis of triglyceride to 
diglyceride (Kraemer & Shen, 2002) 
0.15 0.3 -0.17 0.3 
ATGL Novel triglyceride lipase (Zechner, 
Kienesberger, et al. 2008)  
0.27 0.07 0.10 0.5 
CD 68 LDL receptor; Monocyte cell line 
marker; upregulated in obesity and 
insulin resistance (Di Gregorio, Yao-
Borengasser et al. 2005) 







In this chapter we have shown in response to pregnancy, there were 
significant changes to maternal metabolic characteristics. In lean women, 
adipose tissue underwent a large expansion with similar changes in 
adipokine profile as observed in non-pregnant individuals with excess 
adipose accumulation. By the third trimester, lean women had evidence of 
excess inflammation, hyperlipidaemia and insulin resistance. In keeping with 
our hypotheses, obese pregnant women had evidence of exaggerated insulin 
resistance, inflammation and altered adipokine profile. However, there were 
some features of obese pregnancies which were not in keeping with the 
hypothesis that altered adipose tissue function alone is sufficient to account 
for these differences.  
 
3.4.1. Weight gain in pregnancy 
 
Weight gain is a feature of normal pregnancy due to growth of the fetus, 
placenta and uterus, as well as expansion of fluid volumes including 
amniotic fluid and circulating blood volume. Weight gain in pregnancy is 
highly variable, with estimates of 6-18kg reported for normal weight women 
(Taggart, Holliday et al. 1967; Nutrition During Pregnancy, Institute of 
Medicine, 1990; Dawes & Grudzinskas, 1991, Bergmann, Flagg et al.  1997, 
Kopp-Hoolihan, van Loan et al. 1999, Soltani and Fraser, 2000; Eriksson, Löf 
et al.  2010). Relative contributions from different tissues are estimated at 
approximately 26% from fetus, 4% from placenta, 6% from amniotic fluid, 8% 




extracellular water, with the remainder as fat mass (Hytten & Chamberlain, 
1991). 
 
It has also been recognised that pre- or early pregnancy BMI is associated 
with differences in gestational weight gain (Bergmann, Flagg et al. 1997; 
Cedergren, 2006). In our cohort of women, subjects with a booking BMI 
>40kg/m2 gained significantly less weight than normal weight women.  There 
is also known to be a significant increase in maternal fat stores, particularly 
in the second trimester (Pipe, Smith et al. 1979, Kopp-Hoolihan, van Loan et 
al. 1999, Soltani & Fraser, 2000), with utilization of maternal fat in later 
pregnancy when fetal energy requirements increase. On average, women 
gain 2-5kg of fat mass (Hytten & Chamberlain, 1991, Kopp-Hoolihan, van 
Loan et al.  1999, Ehrenberg, Huston-Presley et al. 2004). Similar to overall 
weight gain, we have shown that morbidly obese women gain less total fat 
mass than normal weight women. In normal weight women, this gain in fat 
mass represents a significant expansion of their pre-pregnancy depots, with 
an average 29% increase in fat mass from 16 to 36 weeks, compared with an 
average 5% increase in overall fat stores over the same time in morbidly 
obese women. The difference between mean total weight gain and mean gain 
in fat mass was approximately 4-5kg for both lean and obese pregnant 
women (Table 3.3, p107); the additional weight gain in lean women is largely 
represented by additional fat mass.  
 
Ehrenberg et al have previously shown that women who have a higher pre-
gravid fat mass have a similar gain in fat mass compared to lean women 
(Ehrenberg, Huston-Presley et al. 2004). In a comparison of obese women 




diabetes, Okereke et al observed a mean gain in fat mass of approximately 3-
4kg in both groups (Okereke, Huston-Presley et al. 2004). Soltani and Fraser 
observed a smaller increase in fat mass in obese compared with lean women 
(3.7 vs 4.9 kg), though this was not significant.  In our cohort, obese patients 
gained significantly less fat mass than lean women (2.8 vs 5.5 kg). 
Discrepancies between studies may in part be due to differences in 
methodology between studies (estimation of fat mass using water 
displacement (Catalano, Wong et al. 1995; Ehrenberg, Huston-Presley et al. 
2004; Okereke, Huston-Presley et al. 2004;) versus estimation from 
anthropometric measurements (Soltani & Fraser, 2000); versus bioelectrical 
impedance measurements (this study)). Assessment of body composition 
during pregnancy is difficult to carry out. The gold standard method of 
assessment of body composition, DEXA, is unsuitable during pregnancy due 
to use of ionising radiation, and therefore it is also difficult to assess the 
validity of the available methods during pregnancy.   
 
Our morbidly obese patients also attended a high-risk antenatal clinic and 
there received serial measurements of weight at each visit, as well as advice 
regarding weight gain during pregnancy and dietetic input. It is possible that 
this intervention contributed to a smaller weight gain than might have been 
expected. However, it may also be a reflection of the greater initial fat mass 
of the obese patients in our cohort and genuine physiological inability to 
store excess calories in adipose tissue. Triglyceride storage in adipose tissue 
is insulin sensitive, and is therefore subject to suppression in insulin 




3.4.2.   Body fat distribution 
 
Previous studies have suggested that in pregnancy, fat mass is accumulated 
in the subcutaneous depot (Taggart, Holliday et al. 1967; Soltani & Fraser, 
2000); although other studies which have included an evaluation of the 
visceral fat depot have indicated that visceral fat accumulation is also 
important (Kinoshita & Itoh, 2006). The greater overall skinfold thicknesses 
observed in our obese cohort supports a significantly greater subcutaneous 
adipose depot in these women compared with lean; however, it is not 
possible to assess visceral fat accumulation without the use of imaging 
studies.  
 
Regional distribution of body fat is important due to regional variations in 
adipose tissue metabolism. In particular, the distinction between upper and 
lower body obesity is important: increased upper body or central fat 
distribution has a stronger correlation with increased risk of metabolic 
complications of obesity than lower body fat distribution (Jensen, 2008). In 
pregnancy, fat distribution tends to favour central body sites: increase in 
skinfold thicknesses are greatest in suprailiac and upper thigh sites 
compared either upper arm or lower thigh (Ehrenberg, Huston-Presley et al. 
2003). However, lean women predominantly gained subcutaneous tissue in 
peripheral sites ie upper arm whereas obese women gained more central 
adipose tissue (suprailiac and subscapular) (Ehrenberg, Huston-Presley et al. 
2003). 
 
Upper body distribution of fat in obese subjects in pregnancy is associated 




response than in lean women or obese women with a predominantly lower 
body adipose distribution (Landon, Osei et al. 1994). Upper body sites only 
were assessed in our cohort of patients; while obese women had significantly 
greater upper body fat distribution compared with lean women, the only 
difference was that in obese women triceps skinfold thickness was 
significantly reduced. This may reflect preferential deposition of adipose 





3.4.3.    Indices of insulin sensitivity 
 
Insulin sensitivity was assessed using two methods in this study, HOMA-IR 
and QUICKI. Both these techniques make use of fasting insulin and fasting 
glucose levels and reflect fasting insulin sensitivity. QUICKI scores indicate 
insulin sensitivity, the greater the score, the higher the IS. Conversely, 
HOMA-IR scores reflect insulin resistance, the greater the score the greater 
the IR. The hyperinsulinaemic euglycaemic clamp (HEC) is the gold standard 
method of assessing insulin sensitivity. Insulin sensitivity assessed using this 
method in lean women increases slightly in early pregnancy, and then 
reduces by approximately 40% (Catalano, Huston et al. 1999). We have 
shown that throughout pregnancy, insulin sensitivity is lower in obese 
compared with lean women using both HOMA-IR and QUICKI assessments 
(Figure 3.6). Both these indices correlate well against the HEC technique 
(Muniyappa, Lee et al.  2007). The advantage of these indices is that they can 
easily be derived from a single fasting sample and are useful in population 
studies as well as for repeated measures. However, they do not provide 
information on the dynamic response to insulin which can be derived from 
clamp data.  
 
In this cohort, insulin resistance, regardless of which fasting index is used, is 
a consistent feature of late pregnancy and in severely obese pregnant 
women, this is significantly exaggerated compared with lean women. The 
timing of onset of severe IR in obese women, and the extent to which it is 
more severe than in lean women is less clear. Furthermore, it is also evident 
that these differences occur in women with a normal 28 weeks glucose 




illustrating the wide range of insulin resistance that can be tolerated in the 




3.4.4. Determinants of insulin resistance 
 
3.4.4.1. Leptin in obese pregnancies 
 
During pregnancy, serum leptin levels increase compared with non-pregnant 
women (Hardie, Trayhurn et al.  1997; Highman, Friedman et al. 1998; 
Hendler, Blackwell et al. 2005; McLachlan, O’Neal et al. 2006) and correlate 
with levels of estradiol and hCG, particularly in the first trimester, as well as 
with insulin sensitivity (McLachlan, O’Neal et al. 2006). Leptin concentrations 
continue to increase with gestation, with a lower rate of increase or a decline 
in the third trimester (Henson & Castracane, 2006); similarly, Sattar et al 
observed a significant increase in plasma leptin in pregnant compared with 
non-pregnant women, with an increase in plasma leptin until approximately 
30 weeks gestation, followed by a decline (Sattar, Greer et al. 1998). In lean 
women, these changes in circulating leptin levels correlate with changes in 
fat mass, with an increase to approximately 30 weeks followed by a decline 
in maternal fat mass, but with an overall greater fat mass persisting at 36 
weeks compared with non-pregnant women (Eriksson, Löf et al. 2010).  
 
We observed a similar pattern in plasma leptin in lean women, with an 
increase between 16 and 28 weeks in parallel with peak fat mass, followed by 
plateauing of circulating leptin at 36 weeks. However, in obese women, we 
observed a different pattern of circulating leptin: plasma leptin increased 
with gestation but continued to increase in the third trimester, despite very 
little change in fat mass. However, this represents a similar increment in 
plasma leptin in both groups (approximately 35% in obese women vs 40% in 




greater fat mass than lean women, which could account for overall greater 
levels of leptin; however, obese women gain less fat mass during pregnancy 
than lean women, suggesting that increment in plasma leptin is not simply a 
function of increment in fat mass.  
 
Misra and Trudeau also observed an increase in serum leptin with gestation 
in a cohort of normal weight and overweight/obese (BMI > 26.0kg/m2) 
women, but found a smaller rate of increase for obese compared with lean 
women, and a significant reduction in serum leptin per kg body weight in 
obese but not lean women (Misra and Trudeau, 2011). In contrast, in our 
cohort, plasma leptin/kg body weight increased more with gestation in obese 
compared to lean women (0.28 ± 0.04 vs 0.33 ± 0.06 ng/ml/kg between 16 and 
36 weeks in lean women, n = 14; 0.47 ± 0.08 vs 0.60 ± 0.07 ng/ml/kg between 
16 and 36 weeks in obese women, n = 12; p < 0.05). However, when this was 
calculated using kg fat mass rather than total body weight, there was a small 
but not significant increase in obese women, and there were no significant 
differences between lean and obese women at any gestation, supporting the 
hypothesis that tissues other than adipose have a significant contribution to 
gestational increases in maternal leptinaemia in human pregnancy.  
 
The relevance of such calculations is somewhat limited: while they may 
reflect a genuine upregulation of leptin production by tissues other than 
adipose in obese pregnant women, the values generated are influenced firstly 
by potential errors in estimation of fat mass in pregnancy and secondly by a 
larger volume of distribution in obese women, which renders estimation of 
leptin production inaccurate, as the same mass of leptin will correspond to a 




therefore important to directly measure leptin secretion from tissues to more 
comprehensively assess the true rate of secretion.  
 
In human pregnancy, placenta is a major source of leptin (Masuzaki, Ogawa 
et al. 1997), in contrast to other species such mouse, where placental leptin is 
not synthesized (Malik, Carter et al. 2005) and adipose tissue is the major 
source. Placental leptin transcript levels were significantly lower in term 
placenta compared with first trimester (Henson & Castracane, 2000), 
mirroring the pattern of circulating maternal leptin. Placental leptin is largely 
released into the maternal circulation (Linneman, Malek et al. 2000), and may 
have a direct role in orchestrating maternal metabolic responses to 
pregnancy. It may also be important in regulation of energy substrate supply 
to the fetus despite very little direct secretion to the fetal side of the placenta. 
Placental amino acid transport is influenced by maternal leptin 
concentrations: leptin influences system A amino acid uptake via a STAT3- 
dependent pathway (von Versen-Hoynck, Rajakumar et al. 2009), and is 
influenced by obesity: maternal hyperleptinaemia is associated with reduced 
placental system A amino acid transport, and reduced leptin-stimulated 
amino acid uptake by placenta in obese compared with lean women (Farley, 
Tejero et al. 2010).  
 
The functional role of hyperleptinaemia in pregnancy is thought to be as part 
of the regulation of maternal appetite; in non-pregnant individuals, leptin 
has a central action to suppress appetite. In pregnancy, the development of 
central leptin resistance could account for the presence of maternal 
hyperphagia in the face of increasing maternal fat stores. In mice, leptin 




successful parturition but did influence maternal appetite and weight gain, 
(Mounzih, Qiu et al. 1998). In rats, direct intracerebroventricular (icv) 
infusion of leptin in pregnant animals fails to suppress maternal appetite, 
unlike in non-pregnant animals (Ladyman and Grattan, 2004), consistent 
with hypothalamic leptin resistance. There are increased levels of leptin-
binding protein in pregnant rats, limiting the availability of leptin to the 
brain (Seeber, Smith et al. 2002). Downregulation of leptin receptor in the 
ventromedial hypothalamic (VMH) nucleus has also been observed in 
pregnant rats, along with reduced STAT3 phosphorylation in response to 
leptin in the same region (Ladyman & Grattan, 2004). In non-pregnant 
animals, leptin also acts on both pro-opiomelanocortin (POMC) neurone and 
neuropeptide-Y (NPY) neurones in the arcuate nucleus of the hypothalamus 
to regulate anorectic and orexigenic stimuli respectively. In pregnant rats, 
levels of POMC mRNA decline and NPY increase in the arcuate nucleus with 
advancing gestation, despite concomitant increases in circulating leptin, 
though leptin-stimulated STAT3 phosphorylation in this region is not 
affected by pregnancy (Ladyman, Tups et al. 2009). Thus, despite elevated 
peripheral leptin levels secondary to increased fat stores or placental 
secretion, pregnancy is a state of functional central leptin resistance, with 








3.4.4.2. Adiponectin in obese pregnancies 
 
Obesity is associated with reduced expression and secretion of adiponectin 
from adipose tissue (Arita, Kihari et al. 1999). Adiponectin has a role in 
insulin sensitisation and can reverse the insulin resistance associated with 
obesity in mice (Yamauchi, Kamon et al. 2001). In normal weight pregnant 
women, circulating total adiponectin levels are maintained in the first 
trimester but then decline to lowest levels in the third trimester (Cseh, 
Baranyi et al. 2004; Fuglsang, Skjaerbaek et al. 2005; Catalano, Hoegh et al. 
2006; Eriksson, Löf, et al. 2010; Paradisi, Ianniello, et al. 2010). Our findings 
support this, with reduced plasma total adiponectin in lean women from 28 
weeks.  In obese pregnant women, we found lower plasma total adiponectin 
at all three time points compared with lean women, but this was only 
significant at 16 weeks; this concurs with the findings of Nien et al. who 
found a similar convergence between lean and overweight women (Nien, 
Mazaki-Tovi, et al. 2007). Adiponectin levels in pregnancy correlate with 
insulin sensitivity (Cseh, Baranyi et al. 2004; Catalano, Hoegh et al. 2006) as 
they do in non-pregnant individuals (Weyer, Funahashi et al. 2001), but 
appear to also have a role in some pathological conditions, with further 
reduction in subjects with gestational diabetes (Horosz, Bomba-Opon et al. 
2011), and paradoxical elevation in pre-eclampsia (Ramsay, Jamieson et al. 
2003).  
 
Adiponectin exists in plasma in a trimeric, hexameric and multimeric (high 
molecular weight) form. It is thought that the high-molecular weight form is 
most specifically related to its insulin-sensitising activity (Fisher, Trujillo, et 




reduction in lean women between early and late gestation in high molecular 
weight as well as total adiponectin (Catalano, Hoegh et al. 2006); however, 
we have shown that no such decrease occurs in morbidly obese women, and 
that HMWA levels are slightly higher throughout pregnancy in obese 
compared with lean women, though this is not statistically significant (Figure 
3.9). Instead, the ratio between total and HMW adiponectin is consistently 
elevated throughout pregnancy in obese compared with lean women (Figure 
3.9). Whether this is observed in this cohort of women as an effect of 
pregnancy or obesity is not certain although elevated HMW:total adiponectin 
levels are associated with a reduced risk of development of type II diabetes 
in women (Heidemann, Sun et al. 2008) and may represent an adaptation to 
counteract development of insulin resistance.  
 
Adiponectin may also have a role in modulating placental function. Placenta 
is a source of adiponectin in pregnancy (Caminos, Nogueiras, et al. 2005); it is 
localised to syncytiotrophoblast (Chen, Tan, et al. 2005), and trophoblast 
insulin-stimulated amino acid transport is negatively regulated by 
adiponectin in a STAT3-dependent manner (Jones, Jansson et al. 2010). Thus 
an additional benefit of elevated adiponectin in obese pregnant women 
might be to limit placental amino acid transport which could otherwise 




3.4.4.3. Inflammatory mechanisms 
 
Several studies have indicated that obesity in pregnancy is associated with 
worsening of maternal inflammatory status (Ramsay, Ferrell, et al. 2002; 
Roberts, Riley et al. 2011); our findings support this, with evidence of 
enhanced circulating levels of C-reactive protein, IL-6 and MCP-1. While 
there was no significant relationship between gestation and non-specific 
markers of inflammation such as CRP or specific cytokines such as TNFα, 
both MCP-1 and IL-6 were significantly increased in lean and obese subjects 
with increasing gestation, indicating a potential pregnancy specific effect. IL-
6 and MCP-1 have been implicated in the development of insulin resistance 
in non-pregnant obese subjects, contributing to intra-adipose IR (Kern, 
Ranganathan et al. 2001; Bastard, Maachi, et al. 2002) and hepatic IR (Senn, 
Klover, et al. 2002; Klover, Zimmers, et al. 2003; Cai, Yuan, et al. 2006).  
 
Increases in TNFα and IL-6 in normal pregnancy have previously been 
reported (Makhseed, Raghupathy et al.  2000; Curry, Vogel et al.  2008) and 
increased levels of TNFα have been associated with insulin resistance in 
pregnancy (Kirwan, Haugel-de-Mouzon, et al. 2002). In our cohort, there was 
an increase in TNFα in lean women between 16 and 28 weeks with a decline 
in the third trimester; in obese women, TNFα was modestly increased 
throughout pregnancy compared to lean women. Excess inflammatory 
markers in obese subjects in the third trimester may contribute to enhanced 
IR observed in obese patients at this gestation. 
 
Features of intra-adipose inflammation include infiltration of macrophages 




a type 1 pro-inflammatory response (Lumeng, Bodzin, et al. 2007), as well as 
increased synthesis and secretion of pro-inflammatory cytokines eg. TNFα 
and IL-6 by both adipocytes and stromal vascular cells (Hotamisiligil, Arner, 
et al. 1995; Kern, Saghizadeh et al.  1995). It is likely that this system plays a 
role in both the response to increasing adiposity and as a contributor to the 
development of subsequent insulin resistance. Adipose tissue macrophages 
are observed in obese adipose tissue in crown-like structures surrounding 
apoptotic adipocytes (Cinti, Mitchell et al. 2005); increased MCP-1 synthesis 
is important for macrophage infiltration and activation (Kanda, Tateya, et al. 
2006; Kim, Park et al. 2006). Several cytokines have direct action on insulin 
signalling in adipocytes: TNFα downregulates expression of the insulin 
receptor and IRS1; IL-6 reduces the expression of IRS-1 in 3T3-L1 cells, and 
reduces insulin stimulated glucose transport (Rotter, Nagaev, et al. 2003).  
 
The role of the adipose tissue macrophage in the development of insulin 
resistance of normal pregnancy has not yet been clearly described. In normal 
mice, pregnancy induces infiltration of macrophages in adipose tissue in late 
pregnancy, with associated upregulation of CD68, MCP1, TNFa and PAI1 in 
subcutaneous adipose tissue (Zhang, Sugiyama et al. 2011). This may 
therefore indicate that macrophage infiltration is a normal response to 
episodes of adipose tissue expansion, with a role in the normal development 
of IR in pregnancy. While we observed an upregulation of IL-6 and MCP-1 in 
the subcutaneous adipose tissue of obese subjects, there was no relationship 
between BMI and transcript levels of CD68, a surrogate marker of mature 
macrophages. This may be a reflection of a number of factors. Firstly, 
transcript level of CD68 may not be the best indicator of the presence or 




BMI recorded at the booking visit in early pregnancy. Lean women undergo 
a significant increase in weight in pregnancy, and early pregnancy BMI will 
not be reflective of weight gain during pregnancy. Thus there may be a 
correlation between adipose CD68 transcript levels and third trimester BMI 
which was not apparent when comparing CD68mRNA and booking BMI.  
 
The uteroplacental unit is a major source of pro-inflammatory cytokines 
(Denison, Kelly, et al. 1998; Lappas, Permezel et al. 2004), and is a potential 
significant contributor to gestational increases in circulating cytokines. In this 
study, in lean women, IL-6 and MCP-1 levels increase from 16 to 28 weeks, 
followed by a smaller, not statistically significant, rise to 36 weeks. However, 
in obese women, there is a further significant increase in IL-6 and MCP-1 
between 28 and 36 weeks, leading to an enhanced pro-inflammatory 
environment in obese women at the end of the third trimester. This supports 
the findings of several previous studies at term which have demonstrated 
enhanced circulating pro-inflammatory cytokines (Ramsay, Ferrell, et al. 
Roberts, Riley et al. 2011). It may also suggest that the increase seen in early 
pregnancy is part of a normal response to pregnancy, but that further 
subsequent increases are the additional contribution of obesity. Notably, 
placental expression of pro-inflammatory cytokines is increased in obese 
compared with lean placentae in sheep and humans (Zhu, Du, et al. 2010; 
Roberts, Riley et al. 2011), along with increased macrophage density 
(Challier, Basu, et al. 2008). 
 
The role of inflammation in normal pregnancy is complex. While increases in 
pro-inflammatory cytokines with advancing gestation have previously been 




be important. Indirect evidence for activation of anti-inflammatory pathways 
comes from improvement in several pro-inflammatory conditions during 
pregnancy, such as rheumatoid arthritis (Nelson, Hughes, et al. 1993; Hazes, 
Coulie, et al. 2011). However, not all inflammatory conditions are improved 
by pregnancy and it is clear that inflammatory processes still occur in 
pregnancy, such as acute pancreatitis, pelvic inflammatory disease and 
sepsis. In particular, pregnancy is associated with an increased susceptibility 
to sepsis and excess mortality from infections such as influenza (Neuzil, 
Reed, et al. 1998). 
 
Immune suppression in pregnancy was postulated as a mechanism to 
explain lack of rejection of placental tissue expressing paternal antigen or 
rejection of the fetus by the maternal immune system; however, it is more 
likely that there is a complex phased interaction between the maternal 
immune system and trophoblast designed to facilitate implantation, support 
of a successful pregnancy and ultimately contribute to initiation of the 
inflammatory event of parturition (Mor, Cardenas, et al. 2012). Therefore, 
while there is immune modulation in pregnancy, it cannot be wholly viewed 
as an anti-inflammatory environment.  
 
In pregnancy, there is a balance between pro-inflammatory and pro-
resolution mechanisms, particularly in the context of initiation of parturition 
(Jabbour, Sales, et al 2009). These are thought to become disordered in some 
cases of preterm labour, particularly those triggered by infection, with 
upregulation of pro-inflammatory pathways in preterm labour (Romero, 
Gotsch, et al. 2007). In contrast, the pro-resolution cytokine interleukin-10 (IL-




the timed inflammatory process of labour (Hanna, Hanna, et al.  2000; 
Thaxton & Sharma, 2010).  
 
A complex orchestration of cytokines helps to regulate the balance between 
sub-populations of T-helper cells necessary for pregnancy, where a shift 
towards a Th2 response is thought to favour a successful pregnancy 
(Ernerudh, Berg, et al. 2011); the observation that there is an increase in 
‘inflammation’ or an increase in what are considered pro-inflammatory 
cytokines in this population of patients is therefore only one aspect of the 
cytokine profile of normal pregnancy. Excess inflammation observed in 
obese patients may contribute to an altered immunological environment, 
which in early pregnancy may account for reduced fertility and by later in 




3.4.5. Consequences of enhanced insulin resistance in obese pregnant 
women 
 
One of the main functions of adipose tissue is storage of energy in the form 
of triglyceride. Uptake of circulating fatty acids into adipocytes occurs via 
fatty acid transport proteins (FATPs); translocation of these proteins to the 
cell membrane can be regulated by insulin (Wu, Ortegon, et al. 2006). Glucose 
uptake into adipocytes occurs via GLUT4, also in an insulin-dependent 
manner. Insulin acts to suppress the opposing pathway of lipolysis via 
inhibition of hormone-sensitive lipase. In insulin-resistant states therefore, 
uptake of fatty acids is reduced, and release of fatty acids and glycerol 
enhanced.  
 
In pregnancy, elevated circulating free fatty acids in late pregnancy has long 
been recognised (Warth, Arky, et al. 1975). Enhanced lipolysis in the third 
trimester has also been described (Diderholm, Stridsberg, et al. 2005), and 
correlated with birth weight (Diderholm, Stridsberg, et al. 2006). The increase 
in plasma NEFA that we have observed in our lean cohort at 36 weeks is 
consistent with these previous observations. Similarly, enhanced insulin 
resistance in obese subjects is consistent with elevated NEFA throughout 
pregnancy (Figure 3.10). The relative decrease in NEFA observed between 16 
and 28 weeks in obese subjects may reflect increased uptake and utilisation 
of NEFA in response to the energy requirements of late pregnancy, despite 
maintenance of an insulin-resistant maternal environment.  
 
Under physiological conditions in fasted individuals, reduced insulin 




drives uptake by liver during fasting as a substrate for gluconeogenesis.  In 
the context of insulin resistance, intra-adipose uptake of NEFA is reduced, 
leading to spillover into ectopic sites such as liver or skeletal muscle without 
utilisation via beta-oxidation. In non-pregnant, obese individuals, plasma 
NEFA levels correlate with the degree of hepatic steatosis, with greater 
steatosis in suvbjetcs with higher NEFA (Holt, Wild, et al. 2006). In obese 
pregnant women, pre-existing insulin resistance and saturation of adipose 
tissue storage capacity may contribute to enhanced hepatic steatosis.  
While not specific for fatty liver, mild elevation of liver aminotransferases 
such as ALT can be an indicator of hepatocellular damage and is a feature of 
hepatic steatosis. We have observed mild elevation of ALT in obese pregnant 
women, with significant elevation compared with lean women in early 
pregnancy (Figure 3.11), followed by a subsequent reduction with increasing 
gestation. This unexpected finding may reflect improvement of hepatic 
steatosis in obese women in pregnancy, despite severe insulin resistance in 
maternal tissues and elevated plasma NEFA. This may be a consequence of 
preferential diversion of circulating fatty acids to the fetus in late pregnancy.  
These data are partly in keeping with the study by Meyer et al. who found 
that obese women began pregnancy with greater plasma triglyceride levels 
compared with lean women but reached a similar maximum level in the 
third trimester; however, they did not find a similar pattern of change in 
plasma NEFA, which may be a reflection of less severe obesity in their cohort 




3.4.6. Adipose tissue lipid storage  
 
In obesity, adipose tissue lipid accumulation is increased, which may be 
secondary to re-esterification of dietary triglyceride in adipose tissue as well 
as de novo lipogenesis. One of the key steps of de novo lipogenesis is 
regulated by fatty acid synthase (FASN). This process is not normally 
considered to contribute significantly to overall lipogenesis, but has 
previously been observed to be upregulated in obesity and insulin resistance 
(Berndt, Kovacs et al. 2007) and thus thought to contribute to lipid 
accumulation in obesity, particularly in the visceral compartment. In 
contrast, we have observed a negative correlation between BMI and 
transcript levels of FASN in subcutaneous and omental adipose tissue in the 
third trimester (Figure 3.12). In the third trimester, maternal adipose stores 
are consumed to supply the energy requirement of the fetus: de novo 
lipogenesis in adipose tissue would not be desirable in this context. 
Transcript levels of other genes involved in the lipogenic pathways were not 
correlated with BMI in this cohort. This points to a possible pregnancy 
specific mechanism facilitating diversion of lipid from adipose tissue to the 
fetus, despite the opposing stimulus secondary to obesity. However, there is 
also conflicting evidence that adipose de novo lipogenesis is reduced in the 
context of obesity, and more specifically, where there is reduced insulin 
sensitivity (Diraison, Dusserre, et al. 2002; Ranganathan, Unal et al.  2006). 
Therefore, lower levels of FASN in correlation with higher BMI may be a 









We have shown that obese pregnant women have significant perturbation of 
lipid and carbohydrate metabolism, with evidence of enhanced insulin 
resistance throughout pregnancy, consequent elevation of plasma NEFA, and 
diversion from the pregnancy-related changes in adipokines and 
inflammatory profile seen in lean pregnant women. However, despite the 
dual metabolic insult of obesity and pregnancy, the divergence between the 
two groups was not as pronounced as initially hypothesised, and many 
indices appeared to converge rather than diverge eg. plasma adiponectin 
profile.  
 
The contribution of adipose tissue to this pattern is likely to be less 
significant than initially hypothesised. While obese pregnant women have a 
much greater adipose tissue mass compared with lean women, pregnancy-
related expansion of this fat mass appears to be significantly curtailed. At 
term, the transcript profile of adipose tissue is broadly similar between lean 
and obese women, and the characteristic responses observed in non-
pregnant obese subjects are noticeably absent eg, lack of upregulation of 
leptin. This points to discrete mechanisms driving the metabolic changes of 
pregnancy and obesity, despite many similarities in the physiological 
consequences of these conditions.  In obesity, overexpansion of adipose 
tissue appears to generate a local inflammatory response and local 
dysfunction of insulin regulation in this site, which then spills over 
systemically to influence hepatic and skeletal muscle insulin regulation, 
culminating in a vicious cycle of systemic metabolic dysregulation. In 




metabolism appear to co-opt some of these mechanisms, particularly those 
involving inflammatory cytokines, and adipokines. Dissection of these 
mechanisms remains difficult and their interactions even more so, though 
placenta is implicated partly because of the relatively rapid resolution of 
normal maternal metabolism following delivery and because of discordance 
in temporal changes in adipokines and inflammatory markers between lean 
and obese women which are not explicable by changes in fat mass alone. 
 
Our analysis of HOMA and QUICKI in this chapter showed that obese 
pregnant women have a poorer metabolic profiles (in terms of greater insulin 
resistance/ decreased insulin sensitivity) compared with lean pregnant 
women in the third trimester. We wanted to define whether this was related 
to hepatic or peripheral insulin resistance, and to confirm that these 
differences persist when examined using the gold standard hyperglycaemic 
euglycaemic clamp. Thus we recruited a cohort of obese and a comparator 
cohort of lean women to undergo HEC studies at various time points during 





Chapter 4  
Whole body insulin sensitivity and lipolysis: 




Obesity and pregnancy both lead to profound changes in the regulation of 
metabolism. In the previous chapter, we have shown that obese pregnant 
women had evidence of deranged metabolism and excess inflammation 
throughout pregnancy compared with lean pregnant women. However, 
there were also some features which are not as divergent from the lean 
phenotype as initially hypothesised, such as the transcript characteristics of 
adipose tissue at term. It was not possible to dissect which of these features 
were secondary to the effects of pregnancy and which were secondary to 
obesity ie. were the lean women becoming more ‘obese’ in their phenotype, 
or was there a ‘normalisation’ effect of pregnancy in obese women? In this 
chapter, a longitudinal case-control study was designed which included a 
non-pregnant control group to examine some aspects of intermediary 
metabolism and the response of adipose tissue with the aim of separating the 
relative contributions of obesity and pregnancy. 
 
Central to the metabolic response to both obesity and pregnancy is 
modification of insulin sensitivity in liver, adipose tissue and skeletal muscle. 
Insulin sensitivity can be assessed by a number of means (see Chapter 1), but 
the gold standard method of assessment of whole body insulin sensitivity is 
the hyperinsulinaemic euglycaemic clamp (HEC). This technique involves a 




concentrations with a concomitant infusion of glucose to maintain 
euglycaemia at approximately 4.7 mmol/L. Insulin-stimulated glucose 
uptake under steady state conditions is used as a measure of IS and is 
calculated from the amount of glucose required to maintain euglycaemia in 
such conditions. The use of stable isotope tracers in the context of a HEC 
allows further detail of regulation of insulin sensitive pathways to be 
defined, including endogenous glucose production and rate of lipid 
breakdown.  
 
Insulin sensitivity (IS) is often reduced in obese subjects, which contributes to 
the pathogenesis of Type II diabetes mellitus, (De Fronzo and Ferrannini, 
1991). Where there is reduced IS, metabolic pathways normally opposed by 
insulin are freed from inhibition. Consequently, lipolysis is enhanced, 
leading to elevated release of free fatty acids (FFAs) and glycerol, 
particularly from visceral adipose tissue (Nielsen, Guo et al, 2004). In turn, 
this leads to increased circulating fats and a lipotoxic effect on a number of 
organs, notably liver (Boden, Cheung et al, 2002) and skeletal muscle (Liu, 
Jahn et al., 2011) which further exaggerates insulin resistance at these sites.  
 
In pregnancy, IS decreases in lean women by approximately 60% between 
early and late gestation (Catalano, Tyzbir et al., 1991). This fall in IS is 
associated with enhanced lipolysis in the third trimester (Diderholm, 
Stridsberg et al., 2005). This change with gestation has been proposed as an 
evolutionary mechanism to promote energy storage initially while pregnant 
women are insulin sensitive, followed subsequently by diversion of maternal 
dietary fuels from storage in maternal depots to be used for offspring growth 




underlying this are not fully understood, but are likely to involve post-
receptor defects in insulin-sensitive tissues such as downregulated IRS-1 in 
skeletal muscle (Barbour, McCurdy et al., 2007). The factors underlying 
decreased IS are not clearly established, although a complex interaction 
between placental and maternal hormones seems likely. 
 
The adverse consequences of enhanced lipolysis and excess free fatty acid 
release outwith pregnancy include elevated plasma lipids, endothelial 
damage, atherogenesis and consequent cardiovascular disease. In pregnancy, 
a degree of enhanced lipolysis is not only desirable, it is essential for normal 
growth: reduced third trimester lipolysis is associated with growth 
restriction (Diderholm, Stridsberg, et al., 2006).  The major pregnancy-related 
morbidities in obese women include gestational diabetes, pre-eclampsia and 
increased birthweight of offspring. Obesity-related metabolic changes may 
contribute to the pathogenesis of these conditions as a result of enhanced 
insulin resistance, FFA-associated endothelial damage and increased nutrient 
supply to the fetus. However, with respect to lipolysis, the specific changes 
in insulin sensitivity of severely obese non-diabetic pregnant subjects has not 





The aims of this study were firstly, to characterise whole-body insulin 
sensitivity and rate of lipolysis in severely obese non-diabetic pregnant 
women and secondly, to identify potential drivers of these metabolic 
adaptations.  
 
We hypothesised that:  
 Severe obesity in pregnancy is associated with exaggerated insulin 
resistance in the third trimester as assessed by use of the 
hyperinsulinaemic euglycaemic clamp. 
 Worse IR is associated with reduced endogenous hepatic glucose 
production and enhanced lipolysis. 
 Changes in insulin sensitivity are associated with changes in transcript 
level of genes regulating inflammation, lipolysis and lipogenesis in 
subcutaneous adipose tissue at an earlier gestation, with a convergent 





4.2.1. Study Title and Ethical Approvals 
 
Origins and Consequences of Altered Metabolic Processes in Obese Pregnant 
Women (AMPOP).  
Chief Investigator Professor Jane Norman 
Principal Investigator Dr Sarah Barr 
 
Ethical approval was sought from Lothian Research and Ethics Committee in 
January 2009. Approval was gained in April 2009 (LREC number 09/S1103/6, 
9 April 2009). This study was co-sponsored by NHS Lothian R&D (R&D 
number R/RM/2009/04, April 2009).  Five substantial amendments were 
approved (1, September 2009; 2, November 2009; 3, January 2010; 4, June 
2010; 5, September 2010). The study was carried out at the Wellcome Trust 







Women were recruited in 4 groups: 
Obese pregnant  OP 
Obese non-pregnant ONP 
Lean pregnant   LP 
Lean non-pregnant   LNP 
 
Obesity was defined as BMI > 35kg/m2 to ensure an adequate population of 
women with severe obesity from which to recruit. While obese pregnant 
patients were drawn from a population with booking BMI > 40kg/m2, non-
pregnant obese patients remained adequately matched for BMI (Table 4.1). 
Lean participants were defined as having BMI 20.0 – 24.9 kg/m2. Pregnant 
participants were asked to undergo two clamp procedures, at approximately 
19 weeks gestation (‘early’ pregnancy, E) and at approximately 36 weeks 
gestation (‘late’ pregnancy, L).  All non-pregnant participants underwent a 
single clamp procedure. Prior to all clamp procedures, a needle biopsy of 
abdominal subcutaneous adipose tissue was obtained.  
 
Pregnant participants were recruited from routine antenatal clinics in 
Lothian and from the Metabolic Antenatal Clinic previously described. Non-
pregnant volunteers were recruited following response to advertisement, 
women who had previously attended the Metabolic Antenatal clinic and had 
given permission to be contacted about further studies, and from the 





Seventy four eligible pregnant women were given study information 
between July 2009 and March 2011; of these, 19 women attended for 
screening (12 obese and 7 lean).  
 
Advertisements were placed for non-pregnant participants in February 2010, 
March 2010, February 2011 and March 2011; 65 eligible respondents were 
given study information. A further 35 women who had previously attended 
the Metabolic Antenatal clinic and had given permission to be contacted 
about further studies were also sent study information.  Sixteen potential 




4.2.3. Inclusion criteria, exclusion criteria and pre-clamp screening 
 
Participants were eligible for inclusion if they were aged 18-45 years, healthy 
and of Caucasian ethnic origin. Exclusion criteria included hypertension, 
diabetes, active endocrine disorders (including thyroid hormone 
replacement), polycystic ovarian syndrome, previous history of gestational 
diabetes, use of anti-inflammatory or glucocorticoid medications (including 
inhaled or topical). These criteria were chosen to exclude women with 
conditions or features known to have an independent effect on insulin 
sensitivity. Where possible, non-pregnant participants had regular menstrual 
cycles; clamps were carried out in the follicular phase of the cycle, 
determined by the date of the last menstrual period. Oral contraceptive 
medication was not considered an exclusion; clamps were carried out in the 
pill-free week where applicable. Three patients were using continuous 
progesterone preparations as contraception. Specific exclusion criteria for 
pregnant women included multiple pregnancy, gestational diabetes, pre-
eclampsia, large-for-gestational age or small-for-gestational age fetus. 
 
All non-pregnant subjects underwent a 75g oral glucose tolerance test prior 
to participation. WHO guidelines were used to exclude current diabetes: 
fasting plasma glucose <7.0mmol/L, and 2-hour plasma glucose <11.1 
mmol/L. All pregnant subjects had a fasting plasma glucose sample prior to 
participation and a 75g oral glucose tolerance test at 28 weeks gestation. 
SIGN criteria were used to exclude GDM: fasting plasma glucose 
<5.5mmol/L, and 2-hour plasma glucose < 9.0mmol/L. Where additional risk 
factors for GDM were present, eg. obesity or previous macrosomia, then an 




prior to participation. All subjects also had fasting plasma (EDTA and 
lithium heparin anticoagulants) and serum samples obtained for analysis of 
cytokines, FFAs and adipokines. The samples were collected, chilled, 
separated and stored as described in Chapter 2 (sample handling). 
 
The height and weight of each participant was recorded as well as waist, hip, 
mid-upper arm and mid-thigh circumferences. Biceps, triceps and 
subscapular skinfold thicknesses were measured using Harpenden callipers 
and used to assess body fat distribution. Fat mass was estimated by bio-
electrical impedance. Pregnant patients had anthropometry carried out at 






For materials, including drugs and tracer details, see Chapter 2. 
Baseline fasting lipid profiles (including total cholesterol, high-density 
lipoprotein cholesterol, low-density lipoprotein cholesterol and triglyceride), 
plasma glucose, liver function tests, and urea and electrolytes (sodium, 
potassium, chloride, bicarbonate and creatinine) were measured at the 
biochemistry laboratory of the Royal Infirmary of Edinburgh.  
 
The following tasks were carried out by the candidate: all subject 
recruitment; glucose tolerance testing; adipose tissue biopsies; all clamp 
studies; plasma cytokine and adipokine quantification by ELISA; RNA 
extraction, cDNA synthesis and real time RT-PCR (see Chapter 2 for details 
of protocols).  
 
Stable isotope enrichment was measured using gas-chromatography mass 
spectrometry by Sanjay Kothiya in the Wellcome Trust Mass Spectrometry 
Core Facility as detailed below (and see Chapter 2 for protocol). Serum 
insulin and NEFA were analysed by Graham Harold (senior technician) as 





4.2.5. Adipose Tissue Biopsy 
Participants attended at 0730h following an overnight fast. A subcutaneous 
adipose tissue biopsy was carried out under aseptic conditions. Patients were 
positioned supine, abdominal skin exposed, skin cleaned with chlorhexidine 
and draped. 1% lignocaine without adrenaline was used to anaesthetise an 
area of skin and subcutaneous tissue approximately 5cm2 lateral to 
umbilicus. Using a 12G needle and 50mL syringe, adipose tissue was 
aspirated under suction. Adipose tissue was then quickly rinsed with sterile 
saline to remove obvious blood contamination, transferred to a 2mL round-
bottom eppendorf, labelled and placed immediately on dry ice. Two to three 
aspirations were carried out to ensure sufficient material for analysis was 
obtained. Pressure was applied to the site to prevent bruising for 5 minutes 
following aspiration; the site was then cleaned and covered with a dressing. 
For biopsies in pregnant women, abdominal examination was carried out 
prior to the procedure to identify the uterine fundus. At 36 weeks, women 
were positioned in a left lateral position to prevent aorto-caval compression.  
 
RNA extraction, cDNA synthesis and real time RT-PCR was carried out as 
described in Chapter 2. Briefly, tissue in 1mL qiazol lysis solution was 
homogenised using steel beads with a TissueLyser for 2 x 3 minutes at 25Hz. 
RNA was purified from the homogenate following chloroform and ethanol 
extraction using columns and resuspended in RNAse-free H2O (Qiagen Lipid 
MiniKit). On-column DNAse digestion was carried out. RNA was quantified 
spectrophotometrically and stored at -80oC until use. RNA (500ng) was 
reverse transcribed using a commercial cDNA synthesis kit (Applied 
Biosystems). All PCR primers and probes were obtained from Applied 




targets, see Chapter 2). Quantitative real time RT-PCR was carried out using 
Taqman® reagents and the 7900HT Fast Real-Time PCR system. A standard 
curve was generated for each gene using serial dilutions of pooled cDNA 
from all samples. All samples were assayed at either 1:10 or 1:20 dilutions, 
according to the relative abundance of the gene of interest. Transcript levels 




4.2.6. Hyperinsulinaemic Euglycaemic Clamp 
4.2.6.1. Participant preparation 
 
Clamp procedures were carried out following adipose biopsy. A 17G cannula 
was inserted into a peripheral arm vein for administration of insulin, 
dextrose and tracer solutions via a multichannel adaptor. Baseline plasma 
and serum samples were obtained for determination of baseline tracer 
enrichment, fasting plasma glucose and fasting lipid profile respectively. A 
second 17G cannula was inserted into a distal vein in the contralateral arm 
for blood sampling. This arm was wrapped in a heated blanket for the 
duration of the study. A slow IV infusion of 0.9% saline was infused through 
this cannula to maintain cannula patency.  
 
4.2.6.2. Drug preparation & dosage calculation  
Actrapid insulin was prepared in 0.9% saline at a concentration of 0.3U/mL. 
Insulin was infused at 20mU/m2/min (low dose) and 40mU/m2/min (high 
dose), according to the body surface area (BSA) in m2 of the subject. BSA was 
calculated using the Mosteller formula: 
 
The rate of infusion in mL/min of stock insulin solution was calculated as 
follows: 
 
Stock solutions of stable isotope tracers were prepared by Dr Alistair Millar, 
Radiopharmacist, Royal Infirmary of Edinburgh, using water as diluent. 




40mg/mL; 6,6-2H2-glucose was provided in vials of 5.0mL at a concentration 
of 350mg/mL.  
 
Both tracers were prepared on the day of study for use in a single infusion 
volume of 300mL of 0.9% saline and infused at a rate of 50ml/hour.  
The molar weight of d5-glycerol is 97g/mol; molar weight of d2-glucose is 
182g/mol. 
 
D5-glycerol was prepared at a concentration of 0.132μmol/kg/ml to achieve a 
delivery rate of 6.6 μmol/kg/hour; d2-glucose was prepared at a 
concentration of 0.44μmol/kg/ml to achieve a delivery rate 22 μmol/kg/hour. 
Infusion was prepared as follows in a final volume of 300ml: 
D5-glycerol: 0.123μmol/kg/ml = 12.8μg/kg/ml = 3.84mg/kg in 300ml; 





4.2.6.3. Clamp Protocol 
 
A bolus dose of d5-glycerol (1.6 μmol/kg = 155.2 μg/kg) and d2-glucose (25 
μmol/kg = 4.5 mg/kg) was administered at time 0 mins, followed by 
continuous infusion of prepared tracers (as above) for 5.5 hours. At 60, 70, 80 
and 90 minutes, plasma samples were obtained. All plasma samples were 
collected using lithium heparin anticoagulant. Samples were collected on ice, 
separated by centrifugation and plasma stored at -80oC as described in 
Chapter 2. 
 
At 90 minutes, insulin infusion at 20mU/m2/min was commenced for 120 
minutes with concomitant variable infusion of 20% glucose. A loading 
regime for insulin infusion was used as follows: 
 90-95 minutes  (from start) 2 x low dose infusion rate 
 95-100 minutes   1.5 x low dose infusion rate 
 100 minutes onward 1 x low dose infusion rate 
Blood samples were obtained every 5 minutes by first withdrawing 
approximately 5 mL blood from the vein as well as saline present in the 
adaptor, discarding this sample, then withdrawing approximately 0.3mL 
blood for sampling; whole blood glucose concentrations were measured 
using an AccuChek blood glucose monitor. The sampling cannula was 
flushed with 2mL 0.9% saline after each withdrawal. The rate of infusion of 
20% glucose was titrated to maintain whole blood glucose concentrations 
between 4.5mmol/L and 5.5 mmol/L. Additional plasma samples were 




anticoagulant for assessment of plasma glucose. These analyses were carried 
out in the laboratory of the Royal Infirmary of Edinburgh. 
At 180, 190, 200 and 210 minutes, plasma samples were obtained. At 180 
minutes, insulin infusion rate was increased to 40mU/m2/min. At 300, 310, 
320 and 330 minutes, plasma samples were obtained. 
The volume of dextrose infused was noted at 180, 210, 300 and 330 minutes. 
These values were used to calculate the mean volume of dextrose required to 
maintain euglycaemia in steady state conditions in and thus the rate of 
glucose infusion at steady state in mg/kg/min (Glucose Infusion Rate, GIR).  
A summary of the protocol is shown (Figure 4.1): 
 





4.2.7. Gas-Chromatography Mass Spectrometry  
 
The GCMS protocol is detailed in Chapter 2. Briefly, 200μL plasma samples 
with 25μL internal standard mix (13C6-Glucose and butanetriol) were 
deproteinised using 1mL acetonitrile and dried under nitrogen following 
vacuum filtration. Samples were then derivatised using pyridine and acetic 
anhydride (1:1 ratio) to form glucose pentacetate and glycerol triacetate, 
dried down under nitrogen at 37oC and reconstituted in 5% acetic anhydride.  
1μL of the reconstituted solution was injected into the GCMS system as 
detailed in Chapter 2. 
 
The peak abundance of ions for derivatised glucose (m/z 287), d2-glucose 
(m/z 289), glycerol (m/z 217), d5-glycerol (m/z 222) and internal standards 13C6-
glucose (m/z 293) and butanetriol (m/z 231) were measured. Tracer/tracee 
ratios were calculated from the ratio of the peak areas and calibrated against 
standard curves of known concentration and isotopic enrichment.  Sample 
measurements were corrected for background enrichment (mass+5 glucose 





4.2.8. Calculations  
Mean glucose disposal (M) under steady state conditions was calculated in 
mg/kg/min according to the volume of glucose infused over the last 30 
minutes of each stage of the clamp study. This is the same as glucose infusion 
rate, (GIR) (Section 4.2.6). This is expressed per mg total body weight as it is 
a measure of whole body glucose disposal. Total body weight was used to 
express glucose disposal to account for whole body utilisation of glucose. 
Although expression of glucose utilisation per kg fat-free mass is also used in 
the literature and is likely to include the contribution by the uteroplacental 
unit, a whole body measure of glucose utilisation will also include insulin-
stimulated glucose uptake by adipose tissue, which in obese subjects, 
contributes significantly to total body weight. An index of insulin sensitivity 
was also derived (M/I) which was calculated by dividing M by the mean 
insulin concentration (mU/L) during that part of the clamp.  
 
Rate of appearance (Ra) and rate of disappearance (Rd) glucose and glycerol 
were calculated as follows: 
Firstly, tracer: tracee ratio (T/Tr) was calculated for each time point using the 
peak areas on the mass spectrum corresponding to each isotope. Tracee 
refers to unlabelled glucose or glycerol and tracer refers to labelled glucose 
or glycerol.  
Ra glucose was calculated as follows: 
Tracer  =  T/Tr = Ra d2glucose 
Tracee    Ra glucose 
 
Therefore: 
Ra Glucose = Ra d2Glucose 
   T/Tr 




The rate of appearance of labelled glucose and glycerol are known as this 
corresponds to the rate of tracer infusion: 
Ra d2glucose  4mg/kg/hour  = 0.067mg/kg/min 
Ra d5glycerol  0.64mg/kg/hour =  0.01mg/kg/min 
 
Ra glycerol is calculated in the same way, using the tracer:tracee ratios 
derived from the sample spectra. Rate of lipolysis can be calculated on the 
assumption that breakdown of triglyceride is the only source of unlabelled 
glycerol ie. Ra glycerol = rate of lipolysis.  
 
Both Ra glucose and Ra glycerol are then corrected for and expressed per kg 
fat-free mass using fat-free mass estimates derived from bioimpedance 
assessments. Ra (glucose or glycerol) is equal to Rd (glucose or glycerol) 
when in isotopic steady state; Rd values represent substrate uptake by 
tissues. Expressing Rd per kg fat-free mass has the advantage of expressing 
substrate uptake according to the mass of tissue which utilises it, which is 
predominantly skeletal muscle. However, the disadvantage is that estimates 
of fat-free mass in pregnancy are potentially inaccurate due to the 
contribution of fetoplacental tissues (1.1.2.1, page 9) and does not take into 
account insulin-stimulated glucose uptake by adipose tissue, which 
contributes significantly to total body mass, particularly in obese subjects.  
 
The natural abundance of other isotopic species in both the d2-glucose and 
the variable glucose infusion require further corrections to be made to the 





Firstly, the true Ra d2-glucose is composed of both d2-glucose present in the 
continuous infusion of tracer as well as background d2-glucose present in the 
variable glucose infusion. A correction of 92.5% was applied to the rate of 
infusion of tracer which reflects the true abundance of pure d2-glucose in the 
continuous infusion. The remainder of the glucose present in the continuous 
infusion is made up of other glucose species arising due to the natural 
abundance of other isotopes such as 13C. This leads to the formation of 
glucose molecules with additional mass, depending on how many of the 6 
carbon molecules in glucose are replaced by heavier isotopes. Including all 
theoretical isotopologues, this means that only 92.5% of the mass of a 
preparation of d2-glucose is truly of this mass, which is important for 
quantification using GC-MS.  
 
This isotopic distribution also applies to the variable glucose infusion, 
meaning that 1.1% of the variable GIR is composed of d2-glucose which is 
then added to the known rate of stable isotope infusion to obtain the true 
infusion rate of d2-glucose. 
 
Therefore: 
True Ra d2-glucose = 92.5% rate of infusion of d2-glucose + 1.1% variable GIR 
= (0.925 x 0.067) + (0.011 x GIR)  
= 0.062 + (0.011 x GIR). 
 
Secondly, steady state values for calculated Ra glucose were used to 
determine the rate of endogenous glucose production (EGP). Ra glucose is 
composed of both EGP as well as unlabelled glucose infused with the 




unlabelled glucose present, which is also 92.5%, with the remainder being 
composed of other mass isomers, including d2-glucose and 13C substitutions.  
EGP is then calculated by subtracting the rate of corrected variable GIR from 
calculated Ra glucose: 
EGP = Ra glucose - (0.925 x GIR) 
 
No exogenous unlabelled glycerol was infused and the abundance of other 
isotopic species within the tracer infusion is sufficiently low as to be 




4.2.9. Statistical analyses 
 
Data are expressed as mean ± SEM unless otherwise stated. Specific between-
group comparisons of descriptive characteristics of the cohort were made 
using unpaired Student’s t-test unless otherwise stated.  
Data from the hyperinsulinaemic euglycaemic clamps, and measurements of 
plasma and adipose tissue variables were analysed using 2-way analysis of 
variance. Bonferroni post-hoc testing was used to detect between-group 
differences using GraphPad Prism software. Significance was set at p < 0.05. 
All statistical analyses were carried out by the investigator (SB). 
 
Baseline values for weight were used other than tracer and insulin dosage at 
visit 1 and GC-MS calculations. Mean weight change between baseline and 
visit 1 for all subjects was 0.6 ± 0.1 kg.  
 
Data are presented for all participants with satisfactory screening who went 
on to attend Visit 1 (16 weeks gestation). Pregnant subjects who were 
diagnosed with gestational diabetes at 28 weeks were excluded from 
participating in Visit 2 (36 weeks gestation: n = 1, lean group; n = 3, obese 
group). Their data from Visit 1 was included in analysis as they had had 
normal glucose tolerance testing prior to entering the study and were not 
diabetic at the time of Visit 1. Two otherwise eligible pregnant women were 
unable to attend for Visit 2, one lean and one obese. Final cohort numbers are 
as follows: Lean non-pregnant, n = 7; Obese non-pregnant, n = 7; Lean 
pregnant Visit 1, n = 6; Lean pregnant Visit 2, n = 4; Obese pregnant Visit 1, n 




We were unable to perform an a priori power calculation prospectively due to 
insufficient available data in obese women – we have done a post hoc power 
calculation was performed as follows. 
 
We had anticipated that the difference between the M value in the obese and 
the lean might be maintained by the end of pregnancy, in other words that 
the M value in the obese would be 50% that in the lean. Our study had 80% 
power to show these differences at the 5% significance level, if they truly 
existed. In practice, we showed that the mean (SD) M value at term was 3.97 
(1.118) in the lean and 2.84 (1.488) in the obese group; in other words, that the 
value in the obese was 71% that in the lean. A sample size of 22 in each group 
would have been required to give 80% power show that these differences 
were statistically significant at the 0.05 significance level. 
 
We also showed a trend to a greater insulin stimulated lipolysis in the 36 
week pregnant group. These differences were not statistically significant – a 
sample size of 8 in each group would have been needed to identify that the 
values we observed in the obese group were significantly greater than the 






4.3.1. Patient Baseline Characteristics 
 
Demographic characteristic of participants are shown in Table 4.1.  Details 
are given for all patients who had satisfactory screening and went on to 
attend their first clamp study, regardless of later exclusion/withdrawal.  
 
There were statistically significant between-group differences in participant 
ages. Lean pregnant women were older than lean non-pregnant participants 
and obese pregnant women; obese pregnant women were younger than 
obese non-pregnant women. The groups were otherwise well matched in 
height, weight, and for pregnant participants, gestation at delivery and 
birthweight. 
 
The proportion of nulliparous women was greater in the lean non-pregnant 
group compared to lean pregnant (7/7 versus 1/6, Fisher’s exact-test, p = 
0.005); the proportion of nulliparous women in the lean non-pregnant group 
was also significantly greater compared to the obese non-pregnant group (7/7 
versus 2/7, Fisher’s exact-test, p = 0.02). 
 
There were no significant differences in gestation at each visit between lean 





Table 4.1 Demographic Characteristics of Study Cohort 












Age (years) 35 ± 0.7 27 ± 1.2 0.0003 26 ± 0.7c 34 ± 2.0d 0.002 
Height (m) 1.67 ± 0.02 1.66 ± 0.02 ns 1.63 ± 0.02 1.63 ± 0.02 ns 
Weight (kg) 63.7 ± 1.9 118.0 ± 3.1 <0.0001 63.0 ± 3.1 109.8 ± 3.9 <0.0001 




1/6 4/9 ns 7/7e 2/7f 0.02 
SBP (mmHg) 122.3 ± 7.2 119.3 ± 2.9 ns 122.1 ± 2.3 120.4 ± 4.5 ns 
DBP (mmHg) 74.2 ± 3.4 77.3 ± 1.5 ns 72.9 ± 1.7 74.4 ± 3.7 ns 
Mean gestation  



















- - - 
















- - - 
Mean gestation at 
delivery (weeks + 
days) 







ns - - - 
 
Data are expressed as mean ± SEM. ns = not significant. Blood pressure and weight given 
were measured at visit 1. 
 
Details are given for all patients who had satisfactory screening and went on to attend first 
clamp study, regardless of later exclusion/withdrawal. 
 
Comparisons were made between the following groups using unpaired Student’s t-test to 
compare age, height, weight, BMI, SBP, DBP, gestations and birthweight; Fisher’s exact test 
was used to compare parity and mode of delivery 
 
a Lean pregnant versus obese pregnant 
b Lean non-pregnant versus obese non-pregnant 
c p < 0.0001 lean pregnant versus lean non-pregnant 
d p = 0.007 obese pregnant versus obese non-pregnant 
e p = 0.005 lean pregnant versus lean non-pregnant 




4.3.2. Body composition 
 
Changes in total body weight and estimated total body fat mass between 
baseline visit and study visit 2 are shown in Table 4.2. Fat mass was 
estimated using bioelectrical impedance (Tanita body composition analyser, 
see Chapter 2 for details). Limitations of the use of bioelectrical impedance 
for estimation of fat mass in pregnancy are discussed in Chapter 3. 
 
Obese women were heavier than lean women as expected, both in the 
pregnant and non-pregnant groups. There was an increase in weight from 
baseline to visit 2 in both lean and obese pregnant women but this was not 
statistically significantly different between the two groups. However, when 
weight gain was expressed as a percentage change from baseline, lean 
women had a greater percentage increase in weight compared with obese 
women. 
 
Similarly, obese women had greater fat mass than lean women, whether 
pregnant or non-pregnant. There were no significant differences between 
baseline estimates of fat mass in pregnant compared with non-pregnant 
women, both lean and obese. While there was an increase in mean fat mass 
from baseline to visit 2 in kilograms for lean pregnant women, obese women 
did not appear to similarly expand their fat mass with increasing gestation. 
Again, while there was no significant difference in change in fat mass in kg 
between lean and obese pregnant women, when this was expressed as 
percentage change from baseline, lean women had a greater expansion of fat 




Table 4.2 Longitudinal Changes in Body Composition 
 Pregnant Non-pregnant 
Weight (kg) Lean Obese pa Lean Obese pb 
Baseline 
63.7 ± 1.9 
(n = 6) 
118.0 ± 3.1 
(n = 9) 
<0.0001 63.0 ± 3.1 
(n = 7) 
109.8 ± 3.9 
(n = 7) 
< 0.0001 
Visit 2 
71.9 ± 3.1 
(n = 4) 
124.9 ± 4.3 
(n = 5) 
< 0.0001 
   
pc 0.02 0.04     
∆ Weight (kg) 8.2 ± 1.8 5.2 ± 1.7 ns    
∆ Weight (%)  13.0 ± 2.9 4.5 ± 1.6 0.03    
Fat Mass (kg)       
Baseline 20.7 ± 1.4 58.1 ± 2.5 < 0.0001 16.5 ± 2.5 54.7 ± 3.4 < 0.0001 
Visit 2 25.7 ± 1.2 61.1 ± 3.3 0.02    
pd 0.04 ns     
Mean ∆ Fat Mass 
(kg) 
5.4 ± 1.6 1.3 ± 2.6 ns    




1.6 ± 2.4 0.004    
 
Data are expressed as mean ± SEM; ns = not significant. 
 
Details are given for all patients who had satisfactory screening and went on to attend first 
clamp study, regardless of later exclusion/withdrawal. 
 
a Lean pregnant versus obese pregnant, unpaired Students’ t-test. 
b Lean non-pregnant versus obese non-pregnant, unpaired Students’ t-test. 
c Weight, baseline versus visit 2, paired t-test. 





4.3.3. Clamped glucose and isotopic enrichments 
 
Plasma glucose was clamped at 4.6mmol/L (figure 4.2A). Mean plasma 
insulin concentrations of 24.2 ± 0.9 mU/mL were achieved for low dose HEC 
and 42.6 ± 1.2 mU/mL for high dose HEC (Figure 4.2B). Achieved plasma 
insulin was slightly greater in obese compared to lean subjects (Figure 4.3) 
which may reflect reduced insulin clearance in obese subjects. There was an 
overall effect of BMI when all lean subjects were compared with all obese 
subjects (p < 0.001, 2-way ANOVA) but no between group differences were 
identified at any specific time points on post-hoc testing. When obese and 
lean were compared at different time points (ie., non-pregnant, 19 weeks 
gestation or 36 weeks gestation), there was an effect of BMI at 19 weeks only. 
Expression of insulin sensitivity as M/I (p162) takes these differences into 
account by correcting for achieved plasma insulin. 
 
Isotopic enrichment at steady state was achieved for all groups (Figure 4.4). 
Mean CV for isotopic enrichment at steady state was 5.0 ± 0.3% (glucose) and 




Figure 4.2 Clamped plasma glucose and insulin 










4 . 6 m m ol/ L





















) A c h ie v e d  p la s m a  in s u lin







M e a n p la sm a  ins u lin
2 4 .1   0 .9  m U/ m L
M e a n p la sm a  ins u lin
4 2 .6   1 .2  m U/ m L




















Figure 4.2. (A) Mean plasma glucose throughout the clamp procedure for all subjects. (B) 
Mean plasma insulin throughout the clamp procedure for all subjects. Data are expressed as 




Figure 4.3 Achieved plasma insulin in lean compared with obese subjects 
 
Figure 4.3. Achieved plasma insulin throughout the clamp procedure for all subjects. Data 
are expressed as mean ± SEM. Overall effect of BMI, p < 0.001; no specific between group 






























































Figure 4.4. d2-Glucose enrichment in lean (A) and obese (B) subjects and d5-glycerol 
enrichment in lean (C) and obese (D) subjects. Data are presented as mean ± SEM. 
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4.3.4. Whole body glucose disposal 
Whole body glucose disposal (WGD) was calculated in mg glucose/kg total 
body weight/minute at steady state during high-dose clamp conditions and 
is an indirect measure of whole body insulin sensitivity (IS), where a greater 
glucose disposal rate implies greater insulin sensitivity. Insulin sensitivity 
can also be expressed as M/I, in mg/kg/min/mU/L, an expression of glucose 
disposal per unit plasma insulin; this also corrects for slight differences in 
achieved plasma insulin in different groups.  
 
WGD is shown in Figure 4.5 and M/I is shown in Figure 4.6. Obese non-
pregnant women had significantly lower IS as measured by WGD compared 
with lean non-pregnant women as expected. Expressed as M/I, obese non-
pregnant women also had lower insulin sensitivity though this was not 
statistically significant in this cohort. 
  
In lean pregnant women, IS by both indices was maintained or slightly 
increased at 19 weeks gestation compared with non-pregnant, followed by a 
significant decrease of approximately 50% by 36 weeks.  
 
In contrast, in obese women, while there was no significant difference in IS at 
19 weeks compared with non-pregnant, there was no corresponding 
decrement in IS between 19 and 36 weeks. 
 
At 19 weeks gestation, obese women had lower IS compared with lean 
pregnant women of the same gestation; by 36 weeks gestation, there was no 



















































Figure 4.5.(A) Whole body glucose disposal and (B) M/I ratios in lean and obese women  
 
Data are expressed as mean ± SEM.  
Data were analysed using 2-way analysis of variance with Bonferroni post-hoc testing.  
* p < 0.05 ** p < 0.01 *** p < 0.001 
Data are shown for all participants with satisfactory screening who went on to attend Visit 1, 
regardless of later withdrawal/exclusion. Following withdrawal/exclusion following diagnosis 
of GDM, group numbers are as follows: 
Lean non-pregnant (n=7); lean pregnant 19 weeks (n=6); lean pregnant 36 weeks (n=4).  











4.3.5. Endogenous Glucose Production & Glucose disposal 
The rate of disappearance (Rd) of glucose and endogenous glucose 
production (EGP) are shown in Figure 4.6 (expressed per kg total body 
weight).  
At baseline, prior to insulin administration, Rd glucose is equivalent to EGP 
as they are in steady state. The time point before insulin administration 
represents fasting conditions. Fasting Rd glucose was significantly greater in 
lean compared to obese women in pregnancy at both gestations and in non-
pregnant women (4.6A). 
Following low dose insulin infusion, Rd glucose was increased compared to 
baseline in all groups (4.6B). Rd glucose was greater in lean compared to 
obese non-pregnant women and in pregnant women at 19 but not 36 weeks. 
Following high dose insulin infusion, Rd glucose was further increased, 
more so in lean compared to obese women (4.6C). The increase in Rd glucose 
in response to high dose insulin was most pronounced in lean women at 19 
weeks, with a smaller response in this group at 36 weeks gestation. No such 
difference in response was observed in obese women. 
Endogenous glucose production was reduced in all groups compared to 
fasting conditions pre-insulin (4.6D). In lean women, there was a small but 
statistically significant increase in EGP at 19 weeks gestation compared to 
non-pregnant women. At this gestation, EGP was greater in lean compared 
to obese women but there were no statistically significant differences 




Rd glucose and EGP can also be expressed per kg fat-free mass, representing 
substrate uptake by non-adipose tissue (Figure 4.7). Under fasting 
conditions, there were no differences in Rd glucose per kg between lean and 
obese non-pregnant subjects or in pregnant subjects at 19 weeks gestation.  
However, by 36 weeks gestation, there was significantly greater glucose 
uptake in both lean and obese pregnant women, although no significant 
differences between lean or obese women (Figure 4.7A). 
Following low dose insulin, glucose uptake was stimulated in both lean and 
obese women, except at 36 weeks gestation where this did not appear to 
occur (Figure 4.7B).  
Following high dose insulin infusion, glucose uptake was increased in lean 
and obese non-pregnant women, and in lean but not obese women in early 
pregnancy (Figure 4.7C). By 36 weeks, there was little further stimulation of 
glucose uptake in both lean and obese women. In lean pregnant women, 
stimulation of glucose uptake was reduced at 36 compared with 19 weeks. 
Endogenous glucose production under fasting conditions is equal to Rd 
glucose (Figure 4.7A) and was almost completely suppressed by low dose 
insulin (Figure 4.7E). At high dose insulin, there is no reliable measure of 
EGP due to artefact from large volumes of non-labelled glucose infused to 





Figure 4.6.  
Rd glucose and endogenous glucose production per kg total bodyweight 
 
Figure 4.6. (A, B and C) Rd glucose per kg total body weight under fasting conditions (A) and 
following low dose (B) and high dose (C) insulin infusion. (D) Endogenous glucose 
production (EGP), following low dose insulin infusion.  
Data are presented as mean ± SEM. * p < 0.05 ** p < 0.01 *** p < 0.001 
Data were analysed using 2-way analysis of variance with Bonferroni post-hoc testing. 
Data are shown for all participants with satisfactory screening who went on to attend Visit 1, 
regardless of later withdrawal/exclusion. Following withdrawal/exclusion following diagnosis 
of GDM, group numbers are as follows: 
Lean non-pregnant (n=7); lean pregnant 19 weeks (n=6); lean pregnant 36 weeks (n=4).  























































































































* p < 0.05
** p < 0.01




Figure 4.7.  
Rd glucose and endogenous glucose production per kg fat-free mass 
 
 
Figure 4.7. (A, B and C) Rd glucose per kg fat-free mass under fasting conditions (A) and 
following low dose (B) and high dose (C) insulin infusion. (D) Endogenous glucose 
production (EGP), following low dose insulin infusion.  
Data are presented as mean ± SEM. * p < 0.05 ** p < 0.01 *** p < 0.001 
Data were analysed using 2-way analysis of variance with Bonferroni post-hoc testing. 
Data are shown for all participants with satisfactory screening who went on to attend Visit 1, 
regardless of later withdrawal/exclusion. Following withdrawal/exclusion following diagnosis 
of GDM, group numbers are as follows: 
Lean non-pregnant (n=7); lean pregnant 19 weeks (n=6); lean pregnant 36 weeks (n=4).  





4.3.6. Lipolysis  
Rate of appearance (Ra) of glycerol per kg fat mass is shown in Figure 4.8 (A, 
B & C). In lean women, baseline pre-insulin rate of lipolysis per kg fat mass 
was greatest in non-pregnant women, reducing in pregnancy and lowest at 
36 weeks (4.8A). In obese women, there was no such response to pregnancy.  
In non-pregnant women, obese women had a much lower rate of lipolysis 
when fasting compared with lean women. In pregnancy, there was no 
difference in glycerol production between lean and obese women. 
Low dose insulin infusion resulted in suppression of Ra glycerol in all 
groups (4.8B). In non-pregnant women, Ra glycerol remained lower in obese 
compared with lean women; there was no difference between pregnant and 
non-pregnant groups.  
High dose insulin infusion resulted in little further suppression of Ra 
glycerol compared with low dose insulin (4.8C). 
At isotopic steady state, the rate of appearance (Ra) glycerol is equal to the 
rate of disappearance (Rd) glycerol. Since adipose tissue is the only source of 
glycerol production, Ra glycerol per kg fat mass is indicative of the rate of 
lipolysis. Rd glycerol is then expressed per kg fat-free mass (Figure 4.8D, E & 
F) and is indicative of substrate utilisation. There is no re-uptake of glycerol 
by adipose tissue, therefore fat-free mass alone is responsible for glycerol 
uptake.  
Under fasting conditions, utilisation of glycerol as a substrate is increased in 
both lean and obese women in response to pregnancy (4.8D) and is slightly 
greater in obese compared to lean women although this is not statistically 
significant. Glycerol utilisation is suppressed in response to insulin infusion 




 The measurements of glycerol enrichment have a high variance, this is due 
to the very low levels of glycerol in these samples, resulting in difficulties 
with the GC-MS assay; this may lead to potential problems with reliability of 
these data, particularly between group analyses in a small cohort. However, 
there is clear suppression of glycerol production by insulin infusion in all 




Figure 4.8. Whole body glycerol production 
 
Figure 4.8.  Ra glycerol per kg fat mass under fasting conditions (A) and following low dose 
(B) and high dose (C) insulin infusion. Rd glycerol per kg fat-free mass under fasting 
conditions (D) and following low dose (E) and high dose (F) insulin infusion. 
Data are presented as mean ± SEM. Data were analysed using 2-way analysis of variance 
with Bonferroni post-hoc testing. 
Data are shown for all participants with satisfactory screening who went on to attend Visit 1, 
regardless of later withdrawal/exclusion. Following withdrawal/exclusion following diagnosis 
of GDM, group numbers are as follows: 
Lean non-pregnant (n=7); lean pregnant 19 weeks (n=6); lean pregnant 36 weeks (n=4).  





4.3.7. Circulating lipids & insulin 
Total cholesterol and triglycerides are shown in Figure 4.9. There was no 
difference in total cholesterol between lean and obese individuals, either 
non-pregnant, at 19 weeks gestation  or at 36 weeks (Figure 4.9A). However, 
there was a significant increase in total cholesterol in lean but not obese 
women from 19 to 36 weeks (p < 0.05). At 36 weeks, triglycerides were 
significantly greater compared with the respective non-pregnant group in 
both lean and obese women (Figure 4.9B). In lean pregnant women, this 
increase occurred late, with a significant increase between 19 and 36 weeks 
gestation (p < 0.05); whereas in obese women, triglycerides were already 
elevated and there was no further significant increase in triglyceride by 36 
weeks gestation.  
Serum NEFA levels are shown in Figure 4.10. In lean women, there were no 
significant differences in mean serum NEFA between non-pregnant and 
pregnant women. In obese women, there was a significant increase in serum 
NEFA from non-pregnant to 19 weeks, with no further increase by 36 weeks 
gestation. At 19 weeks gestation, obese women had significantly greater 
serum NEFA than lean women (p < 0.05); by 36 weeks, there was no 
significant difference between lean and obese women. 
Serum insulin concentrations are shown in Figure 4.11. In lean women, there 
were no significant differences in mean fasting serum insulin between 
pregnant and non-pregnant women. In obese women, mean serum insulin 
increased from non-pregnant to 19 weeks, but there was no further increase 
during the remainder of pregnancy.  
Obese women had greater serum insulin compared to lean women 





























































Figure 4.9 Fasting serum total cholesterol and triglyceride 
 
Data are expressed as mean ± SEM. * p < 0.05 ** p < 0.01 
 
A. Serum total cholesterol.  
B. Serum triglyceride.  
 
Data were analysed using 2-way analysis of variance with Bonferroni post-hoc testing. 
  
Data are shown for all participants with satisfactory screening who went on to attend Visit 1, 
regardless of later withdrawal/exclusion. Following withdrawal/exclusion following diagnosis 
of GDM, group numbers are as follows: 
Lean non-pregnant (n=7); lean pregnant 19 weeks (n=6); lean pregnant 36 weeks (n=4).  






























Figure 4.10 Serum NEFA 
 
Data are expressed as mean ± SEM. * p < 0.05  
 
Data were analysed using 2-way analysis of variance with Bonferroni post-hoc testing. 
  
Data are shown for all participants with satisfactory screening who went on to attend Visit 1, 
regardless of later withdrawal/exclusion. Following withdrawal/exclusion following diagnosis 
of GDM, group numbers are as follows: 
Lean non-pregnant (n=7); lean pregnant 19 weeks (n=6); lean pregnant 36 weeks (n=4).  



































Figure 4.11 Serum insulin 
 
Data are expressed as mean ± SEM. ** p < 0.01 *** p < 0.001 
 
Data were analysed using 2-way analysis of variance with Bonferroni post-hoc testing. 
  
Data are shown for all participants with satisfactory screening who went on to attend Visit 1, 
regardless of later withdrawal/exclusion. Following withdrawal/exclusion following diagnosis 
of GDM, group numbers are as follows: 
Lean non-pregnant (n=7); lean pregnant 19 weeks (n=6); lean pregnant 36 weeks (n=4).  









Plasma leptin and mRNA transcript levels of leptin in abdominal 
subcutaneous adipose tissue are shown in Figure 4.12. Plasma levels of leptin 
were greater in both non-pregnant and pregnant obese compared with 
matched lean subjects with an overall effect of BMI (p < 0.0001) (Figure 
4.12A). Transcript levels of leptin in abdominal subcutaneous adipose tissue 
were significantly greater in obese compared with lean non-pregnant 
subjects (Figure 4.12B) (p < 0.01). In lean subjects, transcript levels of leptin 
were elevated in pregnant compared with non-pregnant subjects, although 
this was not statistically significant. In obese subjects, transcript levels of 
leptin were reduced in pregnant compared with non-pregnant subjects.  
Plasma total adiponectin and transcript levels of adiponectin in abdominal 
subcutaneous adipose tissue are shown in Figure 4.13. In lean women, total 
adiponectin Figure 4.13A) was greater in pregnant compared with non-
pregnant women (at 19 weeks, p < 0.05); however, there was no further 
change between 19 and 36 weeks. In obese women, there was no difference 
between pregnant and non-pregnant subjects. At 19 weeks, obese subjects 
had significantly lower total plasma adiponectin compared with lean 
pregnant subjects (p < 0.01); at 36 weeks, there was no significant difference 
between lean and obese women. Transcript levels of adiponectin (Figure 
4.13B) were lower in obese compared with lean non-pregnant and pregnant 
subjects, with an overall effect of BMI, (p < 0.01). There were no statistically 

























































Figure 4.12 Plasma Leptin & transcript levels of leptin in subcutaneous abdominal adipose 
tissue 
Leptin was measured in plasma by ELISA. Transcript levels of leptin were measured in 
adipose tissue by RT-PCR and normalised to transcript levels of cyclophilin A.  
A. Plasma leptin. 
B. Transcript levels of leptin in subcutaneous abdominal adipose tissue.  
 
Data are expressed as mean ± SEM. ** p < 0.01. Data were analysed using 2-way analysis 
of variance with Bonferroni post-hoc testing.  
 
Data are shown for all participants with satisfactory screening who went on to attend Visit 1, 
regardless of later withdrawal/exclusion. Following withdrawal/exclusion following diagnosis 
of GDM, group numbers are as follows: 
Lean non-pregnant (n=7); lean pregnant 19 weeks (n=6); lean pregnant 36 weeks (n=5, 
plasma; n=4, transcript).  
Obese non-pregnant (n=7); obese pregnant 19 weeks (n=9); obese pregnant 36 weeks (n=4, 
































































Figure 4.13 Plasma Total Adiponectin & transcript levels of adiponectin in subcutaneous 
abdominal adipose tissue 
Adiponectin was measured in plasma by ELISA. Transcript levels of adiponectin were 
measured in adipose tissue by RT-PCR and normalised to transcript levels of cyclophilin A.  
A. Plasma total adiponectin. 
B. Transcript levels of adiponectin in subcutaneous abdominal adipose tissue. 
Data are expressed as mean ± SEM. * p < 0.05 ** p < 0.01. Data were analysed using 2-way 
analysis of variance with Bonferroni post-hoc testing.  
 
Data are shown for all participants with satisfactory screening who went on to attend Visit 1, 
regardless of later withdrawal/exclusion. Following withdrawal/exclusion following diagnosis 
of GDM, group numbers are as follows: 
Lean non-pregnant (n=7); lean pregnant 19 weeks (n=6); lean pregnant 36 weeks (n=5, 
plasma; n=4, transcript).  
Obese non-pregnant (n=7); obese pregnant 19 weeks (n=9); obese pregnant 36 weeks (n=4, 





4.3.9. Circulating plasma cytokines 
 
Plasma IL-6 and IL-1Ra were quantified in plasma (Figure 4.14). In lean 
women, plasma IL-6 levels were greater in pregnant compared with non-
pregnant subjects (Figure 4.14A). In obese women, there was no difference 
between non-pregnant subjects and pregnant women at 19 weeks gestation; 
at 36 weeks, there was an increase in plasma IL-6 though this was not 
statistically significant. 
In lean women, plasma IL-1Ra was greater in pregnant compared with non-
pregnant women, and increased with gestation although this was not 
statistically significant (Figure 4.14B). In obese women, plasma IL-1Ra was 




















































Figure 4.14 Plasma IL-6 (A) and IL-1Ra (B), measured by ELISA 
Data are expressed as mean ± SEM. * p < 0.05 ** p < 0.01 
Data were analysed using 2-way analysis of variance with Bonferroni post-hoc testing.  
Data are shown for all participants with satisfactory screening who went on to attend Visit 1, 
regardless of later withdrawal/exclusion. Following withdrawal/exclusion following diagnosis 
of GDM, group numbers are as follows: 
Lean non-pregnant (n=7); lean pregnant 19 weeks (n=6); lean pregnant 36 weeks (n=5).  





4.3.10. Pro-inflammatory transcripts in abdominal subcutaneous adipose 
tissue 
 Transcript levels of IL-6, MCP-1 and TNFα were quantified in subcutaneous 
adipose tissue using real time RT-PCR (Taqman) (Figure 4.15).  
Transcript levels of IL-6 (Figure 4.15A) were broadly greater in obese 
compared with lean women in both pregnant and non-pregnant groups; in 
both lean and obese women, there appeared to be an increase in IL-6 
transcript levels in response to pregnancy. There was an overall effect of BMI 
(p = 0.05) but there were no significant between-group differences between 
lean or obese women at any specific time points. 
In lean women, transcript levels of MCP1 (Figure 4.15B) increased in 
pregnant compared with non-pregnant women and there was a further 
increase from 19 to 36 weeks, although this was not statistically significant in 
this cohort. In obese women, there was a small but non-significant increase in 
transcript levels of MCP1 in pregnant women at 19 weeks gestation 
compared with non-pregnant obese women but no further increase in 
pregnancy. In non-pregnant women, transcript levels of MCP1 were greater 
in obese compared to lean women, but in pregnancy, there were no 
significant differences between lean and obese women.  
TNFα transcript levels (Figure 4.15C) were significantly increased in lean 
pregnant women at 19 weeks gestation compared with lean non-pregnant 
women (p = 0.05), with no further change during pregnancy. There was no 
effect of pregnancy in obese women. Transcript levels of TNFα were greater 
in obese compared with lean non-pregnant women, although this was not 
statistically significant in this cohort; there was no significant difference 



























































































Figure 4.15 Transcript of pro-inflammatory cytokines 
Transcript levels of IL-6 (A), MCP-1 (B) and TNFα (C) were quantified by real time RT-PCR 
and expressed relative to transcript levels of cyclophilin A.  
 
Data are expressed as mean ± SEM. * p < 0.05 
Data were analysed using 2-way analysis of variance with Bonferroni post-hoc testing.  
 
Data are shown for all participants with satisfactory screening who went on to attend Visit 1, 
regardless of later withdrawal/exclusion. Following withdrawal/exclusion following diagnosis 
of GDM, group numbers are as follows: 
Lean non-pregnant (n=7); lean pregnant 19 weeks (n=6); lean pregnant 36 weeks (n=5).  





4.3.11. Metabolic transcripts in abdominal subcutaneous adipose tissue 
In our group, microarray analysis was carried out to identify potential 
candidate genes whose expression was altered in response to the 
combination of pregnancy and obesity, using adipose tissue from a murine 
model of diet induced obesity (Pedroni, Morton, et al. Unpub. 2012). They 
found that a selection of genes which regulate lipid synthesis and storage 
were specifically upregulated in obese pregnant animals. To validate these 
genes in a human model, transcript levels of 6 of these genes were assayed in 
adipose biopsies from subjects undergoing clamp procedures. Transcript 
levels of stearoyl-CoA desaturase-1 (SCD1), malic enzyme-1 (ME1), retinol 
binding protein-4 (RBP4), fatty acid synthase (FASN), diglycerol acyl 
transferase-2 (DGAT2) and insulin receptor substrate-1 (IRS1) were 
quantified in subcutaneous adipose tissue using quantitative real time RT-
PCR (Taqman) (Figure 4.16).  
In obese women, transcript levels of SCD1 (Figure 4.16A) were decreased in 
early pregnancy compared with non-pregnant (p < 0.05). No such decrease 
was seen at 19 weeks in lean women compared with non-pregnant; however, 
by 36 weeks, SCD1 transcript levels were decreased by approximately 60% to 
levels comparable with obese subjects, though this was not statistically 
significant in this cohort.  
In obese women, ME1 transcript levels (Figure 4.16B) were decreased 
compared with lean women with an overall effect of BMI (p = 0.05). In both 
lean and obese women, there was a decrease in ME1 transcript levels 
associated with pregnancy. 
There was no difference in transcript levels of RBP4 (Figure 4.16C) in lean or 
obese women, nor was there a difference between pregnant and non-




Transcript levels of FASN (Figure 4.16D) were decreased in obese compared 
to lean women, in both pregnant and non-pregnant groups, with an overall 
effect of BMI    (p < 0.0001). There was no specific effect of pregnancy.  
Transcript levels of DGAT2 (Figure 4.16E) were decreased in obese compared 
with lean women at each time point and in pregnant women compared with 
non-pregnant, though this was not statistically significant in this cohort. 
There was no difference between 19 and 36 weeks gestation in either lean or 
obese women. 
Transcript levels of IRS1 (Figure 4.16F) were decreased in obese compared 
with lean women in both pregnant and non-pregnant groups with an overall 
effect of BMI (p = 0.02). In lean women, IRS1 transcript levels were increased 
at 19 weeks compared with non-pregnant but then significantly decreased by 
36 weeks (p < 0.01); there was no change in IRS1 levels in response to 
pregnancy in obese women. IRS1 transcript levels were significantly 
decreased in obese compared to lean pregnant women at 19 weeks gestation 

















































































































































































Figure 4.16 Transcript levels of key genes involved in fatty acid regulation 
Transcript levels of SCD1 (A), ME1 (B), RBP4 (C), FAS (D), DGAT2 (E) and IRS1 (F) were 
quantified by real time RT-PCR and expressed relative to transcript levels of cyclophilin A.  
 
Data are expressed as mean ± SEM; * p < 0.05 ** p < 0.01 *** p < 0.001.  
Data were analysed using 2-way analysis of variance with Bonferroni post-hoc testing.  
 
Data are shown for all participants with satisfactory screening who went on to attend Visit 1, 
regardless of later withdrawal/exclusion. Following withdrawal/exclusion following diagnosis 
of GDM, group numbers are as follows: 
Lean non-pregnant (n=7); lean pregnant 19 weeks (n=6); lean pregnant 36 weeks (n=5).  






In the previous chapter, we showed that obese women were insulin resistant 
throughout pregnancy compare with lean women and that although many 
features consistent with obesity such as excess circulating inflammatory 
markers were present, there were some features of the adipose tissue at term 
in which lean and obese women did not appear to be as divergent as 
expected. In this chapter, we have shown that in early pregnancy many of 
these differences persist, but during pregnancy lean and obese women follow 
a convergent path with advancing gestation, such that by the third trimester, 
there are many similar metabolic characteristics between women of greatly 
differing BMI. Indeed, obese women appear resistant to the metabolic 
changes which occur in lean women during pregnancy. This refutes our 
initial hypothesis that the combination of obesity and pregnancy would lead 
to an exaggerated metabolic profile. 
In healthy pregnancies, there is progressive development of insulin 
resistance, maximal in the third trimester and immediate post-partum period 
(Spellacy, Goetz, et al. 1965; Catalano, Tyzbir, et al,. 1993). A number of 
factors have been shown to be important in the development of pregnancy-
related IR, including TNFα (Kirwan, Haugel-De Mouzon, et al.  2002) and 
adiponectin (Catalano, Hoegh, et al. 2006). One of the main associations of 
obesity outwith pregnancy is systemic resistance to insulin. We therefore 
expected to find an additive effect where obesity and pregnancy co-exist, 
with this effect greatest in the third trimester. 
As expected, in non-pregnant women, obese subjects had greatly reduced 
whole-body insulin sensitivity as assessed by insulin-stimulated whole body 
glucose disposal compared with lean women (Figures 4.5 and 4.6). However, 




pregnancy did not appear to exert as great an effect on maternal insulin 
sensitivity as it did in lean women, and by the third trimester, there were few 
differences between lean and obese pregnant women. Achieved plasma 
insulin during the clamp was slightly greater in obese women, consistent 
with reduced insulin clearance in obese subjects (Mora, Scarfone, et al. 2003). 
However, when insulin sensitivity is expressed as M/I, ie, glucose disposal 
per unit insulin, a similar pattern of IS is observed, with a large decrement in 
IS in lean women in pregnancy and relatively little effect of pregnancy in 
obese women. 
Consistent with previous published studies, there was a decrement in insulin 
sensitivity in lean women of approximately 50-60% between 19 and 36 weeks 
gestation. No such decrement was observed in obese women. Previous 
studies have also shown that in overweight and class I obese (BMI > 30kg/m2) 
women, there is a reduction in the magnitude of change in insulin sensitivity 
compared with lean women, although some degree of response to pregnancy 
is maintained (Catalano & Ehrenberg, 2006), as well as development of a 
greater degree of insulin resistance in obese women who have developed 
gestational diabetes (Catalano, Huston, et al. 1999). This data extends 
previous work to women of even greater pre-pregnancy BMI and 
importantly, excludes those with gestational diabetes. Women who develop 
gestational diabetes are not necessarily those in whom the most severe 
insulin resistance is found, but those women who are unable to sustain a 
compensatory hyperinsulinaemia. Data was included in analysis for those 
women who subsequently developed gestational diabetes (3 x obese, 1 x 
lean) as these women had normal glucose tolerance as defined by an oral 
glucose tolerance test at this time of study although they were subsequently 




any differences in whole body glucose disposal between these women and 
the rest of their cohorts at 19 weeks gestation, although with such limited 
numbers, sub-group analysis is not practical. However, it is possible that 
their inclusion may affect the heterogeneity of the pregnant groups.  
Following diagnosis of GDM, these women were excluded from further 
study for two reasons. Firstly women with GDM handle glucose load 
differently and respond differently to clamp conditions and secondly, 
women with GDM are managed differently in pregnancy compared to 
healthy women in terms of nutritional advice and pharmacological 
interventions including exogenous insulin and metformin.  
A further consideration in this cohort is the discrepant ages of the different 
cohorts (Table 4.1). Increased age is associated with insulin resistance but this 
is often linked to age-associated accumulation of visceral fat (Kohrt, Kirwan, 
et al. 1993; Gabriely, Ma, et al. 2002). While there were statistically significant 
differences in the ages of the four groups, these differences are not likely to 
be clinically relevant, particularly as the groups are otherwise well matched 
in body mass and fat mass. Social class was also not a specific inclusion or 
exclusion criteria in this cohort; although participants were of social class IIIa 
and above on the basis of occupation, DEPCAT scoring was not performed; 
social deprivation is associated with overall poorer health, and risk of 
diabetes (Connolly, Unwin, et al. 2000). In this cohort, it is possible that subtle 
differences in socio-economic status may influence the results. However, 
since the cohort is otherwise matched for other factors which influence 
insulin resistance, particularly body fat and ethnicity, if an effect is present, it 
is likely to be small. 
In Chapter Three, insulin resistance was assessed using fasting measures of 




that obese subjects had greater insulin resistance throughout pregnancy and 
did not demonstrate the same increase in insulin resistance as derived from 
clamp studies in this chapter. While fasting indices are useful in larger 
population studies compared to more intensive clamp studies and provide 
information about fasting beta-cell function, clamp studies have the 
advantage of providing information about the stimulated state ie 
responsiveness to insulin. This explains why clamp studies appear to 
demonstrate a different pattern of insulin sensitivity compared with HOMA-
IR values.  
In addition to information regarding glucose disposal as an index of insulin 
sensitivity, when combined with stable isotope tracers, clamp studies 
provide more detailed information regarding glucose utilisation, endogenous 
glucose production and rates of lipolysis. These values can be expressed per 
kg weight but provide different information depending on whether this is 
expressed per kg total body weight or per kg fat-free mass (FFM), which 
represents the compartment where most glucose disposal occurs. When Rd 
glucose is considered by kg total body weight, there is greater glucose 
disposal under fasting conditions in lean women at all time points. This is 
likely to be due to lean women having proportionately greater lean mass 
compared to obese women; since the majority of glucose disposal is in lean, 
ie fat-free, body mass, lean women will therefore appear to dispose of more 
glucose per kg total body weight. Although lean women gain 
proportionately more fat mass in pregnancy compared with obese women, 
lean women still have a significantly greater proportion of total body weight 
as lean mass compared to obese women, even in the third trimester. 
Therefore lean women will still appear to have greater glucose disposal per 




When Rd glucose expressed per kg FFM is considered however, there is 
increased fasting disposal of glucose in lean and obese women by 36 weeks 
gestation compared to non-pregnant women and pregnant women at 19 
weeks gestation (Figure 4.7). The main contributor to an increase in FFM 
between 19 and 36 weeks of pregnancy is likely to be the fetoplacental unit as 
well as increased fluid mass, therefore the increase in Rd glucose from 19 to 
36 weeks is likely to represent glucose uptake by the fetoplacental unit. It is 
similar in both lean and obese women per kg, indicating similar substrate 
requirements of the fetoplacental unit under both conditions. With 
administration of insulin, lean women retain sensitivity to insulin-stimulated 
glucose uptake at 19 weeks where obese women do not, but by 36 weeks, 
there is little further stimulation of Rd glucose from low dose to high dose 
insulin.  
EGP under fasting conditions is equivalent to Rd glucose under fasting 
conditions as the system is in isotopic steady state and no exogenous glucose 
is being administered. EGP reflects hepatic glucose production and is 
elevated in the third trimester in both lean and obese women as expected 
when expressed per kg FFM (Figure 4.7). While EGP does not appear to be 
increased in the third trimester when expressed per total body weight, 
overall EGP is greater in obese women at this gestation due to greater total 
body mass. EGP was suppressed by low dose insulin in all groups, with 
greatest suppression in the most insulin sensitive groups but appeared to be 
stimulated by high dose insulin, particularly in the most insulin-sensitive 
groups (lean non-pregnant and lean early pregnancy). This may reflect an 
artefact of the tracer conditions due to the high volume of exogenous glucose 




Ra glycerol is indicative of the rate of lipolysis. When this is expressed per kg 
fat mass, it reflects the lipolytic activity of each unit of fat mass, as adipose is 
the only tissue which exports glycerol. Ra glycerol is greater in lean 
compared with obese non-pregnant women under fasting conditions as 
lipolysis is activated to supply NEFA and glycerol for beta-oxidation and 
gluconeogenesis; while obese women appear to have a lower rate of Ra 
glycerol per kg fat mass, approximately 50% that of lean women, they have a 
much greater overall fat mass, approximately 50% greater than lean women, 
therefore whole body rate of lipolysis are similar. In pregnancy lean women 
appear to have much lower fasting Ra glycerol per kg fat mass compared 
with non-pregnant women, with a further small reduction with advancing 
gestation whereas obese women do not show such a response to pregnancy. 
Again, if total body fat mass is taken into consideration, this leads to overall 
greater total rates of lipolysis in obese compared to lean women throughout 
pregnancy.   
Since Ra glycerol is equal to Rd glycerol under isotopic steady state 
conditions, this data can also be used to indicate substrate utilisation. 
Glycerol is primarily taken up by liver and skeletal muscle, the major 
components of fat-free mass. Therefore where Rd glycerol is expressed per 
kg FFM, this is indicative of the rate at which glycerol is utilised by these 
tissues. In Figure 4.8, fasting glycerol utilisation is no different in lean and 
obese non-pregnant women per kg FFM; and is increased in both lean and 
obese women by the third trimester. However, while in lean women, there is 
no increase in glycerol utilisation until 36 weeks gestation, in obese women, 
the rate of glycerol utilisation begins to increase by 19 weeks gestation, 




Accurate measurement of glycerol by GC-MS is notoriously difficult and is 
reflected by moderately high variances in glycerol measurement. While Ra 
glycerol is a more accurate measure of lipolysis as this pathway is the only 
source of glycerol and is not affected by reuptake by adipocse tissue, 
technical difficulties with the assay can limit the accuracy with which rates of 
lipolysis can be assessed. An alternative means of assessing lipolysis would 
be by measurement of the rate of appearance of fatty acids; three moles of 
fatty acid are released with one mole of glycerol by complete lipolysis of one 
mole of triglyceride. However, it is not possible to assess fatty acid release 
using stable isotope tracers in pregnant women as the fatty acid tracers come 
complexed with albumin which is not approved for use in pregnancy in this 
context. A further issue is that incomplete lipolysis of triglyceride will also 
release fatty acids and there is also reuptake of fatty acids by adipocytes 
following lipolysis. Therefore, while on one hand, Ra glycerol is the better 
measure of the true rate of lipolysis, it is limited by technical aspects of the 
assay. On the other hand, measurement of fatty acids is a more reliable assay 
but is limited by the physiology of fatty acid release. Use of both indices may 
therefore help to provide more reliable information. 
As discussed, in non-pregnant women, total rates of lipolysis appear to be 
similar when body fat content is accounted for. This is supported by similar 
levels of fasting NEFA in lean and obese non-pregnant women (Figure 4.9). 
In pregnancy, it would appear that there is overall total greater lipolysis in 
obese compared with lean women due to a much greater fat mass, given 
similar rates of lipolysis per kg fat. This is also supported by an early rise in 
fasting NEFA and triglyceride in obese pregnant women at 19 weeks 
gestation, compared with lean women of the same gestation. By 36 weeks, 




suggest that total lipolysis is greater in obese women. However, by 36 weeks, 
fasting NEFA are similar in obese and lean women. This may reflect 
concomitant greater reuptake of NEFA in obese women, or deposition of 
NEFA elsewhere as ectopic lipid, resulting in a similar plasma pool of NEFA 
or it may reflect lack of reliability of Ra glycerol as an accurate assessment of 
lipolysis in the third trimester. 
The lipolytic pathway retained sensitivity to insulin in all subjects. In all 
groups almost maximal suppression of Ra glycerol was achieved by low dose 
insulin; lipolysis was not completely suppressed in any group however, this 
may reflect basal, non-insulin regulated lipolysis. This is consistent with 
previous studies in pregnant women where maximal suppression was 
approximately 50% of basal (Sivan, Homko, et al. 1999).   
In lean women, suppression of lipolysis by low dose insulin was greatest in 
non-pregnant women, with least suppression in the third trimester of 
pregnancy. In contrast, in obese women, there were no such changes in 
response to pregnancy. Utilisation of glycerol was consistently suppressed to 
a greater extent in lean compared with obese women in pregnancy which 
may reflect greater basal use of glycerol as a gluconeogenic substrate. 
Elevated rates of lipolysis are thought to be important in the third trimester 
in normal pregnancy to provide maternal sources for gluconeogenesis and 
triglyceride synthesis and facilitate normal fetal growth and supply of 
necessary fatty acids to the fetus; reduced third trimester lipolysis is 
associated with fetal growth restriction (Diderholm, Stridsberg, et al, 2006). 
Maternal triglyceride is hydrolysed by placental lipases and the released 
fatty acids as well as any circulating maternal NEFA are transported across 
the placenta by diffusion, and also by selective transport using proteins such 




protein (FATP) and Fatty Acid Translocase (FAT) (Campbell, Taffesse, et al. 
1995; Campbell, Bush, et al.  1998; Herrera, Amusquivar, et al. 2006; Haggerty, 
2010). In obese women, higher rates of maternal lipolysis from earlier on in 
pregnancy lead to prolonged placental exposure to elevated NEFA as well as 
triglyceride and may drive elevated supply of NEFA to the fetus. Recent 
studies have reported altered expression of placental fatty acid transport 
proteins and lipoprotein lipase activity in obese compared with lean women 
although this did not correlate with elevated fetal fatty acid concentrations at 
the time of delivery (Dubé, Gravel, et al.  2012). It is possible that prolonged 
exposure of the fetus to excess NEFA leads to more subtle or long-term 
changes in fetal metabolism than is reflected by a snapshot of cord blood or 
birthweight. 
From a maternal perspective, prolonged exposure to NEFA may contribute 
to the pathogenesis of other conditions associated with obese pregnancies, 
particularly hypertensive disorders. In non-pregnant obese individuals, 
abnormal NEFA turnover has been suggested to have an independent link 
with hypertension in addition to effects of insulin resistance and abnormal 
glucose metabolism (Egan, Hennes, et al.  1996; Sarafidis and Bakris, 2010). 
Similarly, elevated NEFA have been implicated in the pathogenesis of pre-
eclampsia, (Hubel, McLaughlin, et al. 1996; Vigne, Murai, et al. 1997).  While 
there were no significant differences between lean and obese subjects in 
blood pressure in this cohort, there were significant elevations in both 
systolic and diastolic blood pressure observed in a larger cohort, (Chapter 3, 
Table 3.1). Although this was still within normal limits of blood pressure, it 
may represent a subtle right-shift in the distribution of blood pressure in the 
obese pregnant population, which would contribute to the higher proportion 




Both inflammatory cytokines and altered adipokine expression have been 
implicated as drivers of altered maternal metabolism. Consistent with this, 
we have shown elevated circulating IL-6 in obese compared with lean 
women, greatest in the third trimester, as well elevated leptin throughout 
pregnancy. In adipose tissue, in lean women, there was elevated expression 
of pro-inflammatory cytokine transcripts in pregnant compared with non-
pregnant women; in contrast, pro-inflammatory cytokine transcripts were 
broadly elevated in both pregnant and non-pregnant obese women. TNFα in 
particular has been implicated as having a role in the insulin resistance of 
pregnancy (Kirwan, Haugel-De Mouzon, et al.  2002), this is supported by 
our observation of increased TNFα transcript in adipose tissue of lean 
pregnant women compared with non-pregnant women. However, it may be 
that in the context of obesity, TNFα expression is already maximal, given 
that there is no further increase in response to pregnancy in obese pregnant 
women. 
Other increases in the expression of pro-inflammatory cytokines observed in 
lean pregnant women may reflect a response to expansion of adipose tissue 
mass as lean women lay down fat stores in pregnancy. MCP-1 mRNA in 
particular is elevated in lean pregnant compared with non-pregnant women, 
with a similar though smaller magnitude increase in IL-6 mRNA levels. 
However, there was a similar though not statistically significant increase in 
IL-6 mRNA levels in obese pregnant compared with non-pregnant women, 
suggesting that there may be an additional effect of pregnancy rather than 
simply fat mass expansion, given that obese women tend to put on less fat 
mass compared with lean women.  
With respect to adipokines, circulating levels of leptin are increased in obese 




with lean non-pregnant women. Transcript levels of leptin are also increased 
in adipose tissue of lean women in pregnancy to a similar level as that 
observed in obese pregnant women. This would be consistent with expected 
changes in adipose tissue mass. In particular, at 36 weeks there is no 
difference in transcript levels of leptin between lean and obese pregnant 
women, which is in keeping with our unexpected findings in Chapter 3 
(Figure 3.3). However in this study, we also found that lean women 
appeared to increase circulating adiponectin in response to pregnancy; this is 
in contrast to data from our larger cohort in Chapter 3 (Figure 3.4) and to 
previous published studies, which showed maintenance of plasma 
adiponectin from pre-pregnancy to early pregnancy, but a significant 
reduction in the third trimester, associated with reduced white adipose tissue 
adiponectin mRNA levels (Catalano, Hoegh, et al. 2006). Additionally, there 
did not appear to be any difference in total adiponectin levels between lean 
and obese non-pregnant women, where a reduction in obese women would 
be expected. However, the pattern of adiponectin transcript levels in adipose 
tissue is more consistent, with reduced mRNA levels in the tissues of obese 
compared to lean women. Broadly, obese women appear to have lower 
plasma adiponectin than lean women, which is consistent with the literature, 
despite an apparent lack of difference in the non-pregnant group, which may 
be an effect of the small numbers and therefore caution is needed in 
interpretation. Data from the larger cohort in Chapter three is more 
consistent with previously reported adiponectin levels in pregnancy.    
Within adipose tissue, there were some differences between obese and lean 
pregnant women in transcript levels of genes regulating lipid synthesis and 
storage. Due to the small numbers in this cohort, few of these differences 




between lean and obese women in some key genes controlling lipid synthesis 
and insulin regulation, particularly decreased stearoyl desaturase-1 (SCD1), 
fatty acid synthase (FASN) and insulin receptor substrate 1 (IRS1) (Figure 
4.16), possibly reflecting an earlier suppression of lipid storage in obese 
women compared with lean. For transcripts where statistical significance 
was not reached, there was a similar pattern of reduction in transcript level at 
an earlier gestation in obese compared to lean women, eg. malic enzyme 1 
(ME1), which is important for generation of NADPH for lipid synthesis.  It is 
tempting to speculate that these expression patterns are consistent with an 
earlier shift in the adipose tissue of obese subjects away from lipid storage in 
early pregnancy, while this shift occurs later in lean subjects. However, a 
larger cohort of samples would be required to verify this, potentially also 
supported by assessment of enzyme quantity and function at protein level as 
protein function does not always correlate well with transcript levels. 
We have shown that lean women have a relatively late decrement in insulin 
sensitivity and other metabolic adaptations to pregnancy such as increase in 
triglyceride and NEFA, whereas obese women appear to be in this state pre-
pregnancy and do not mount much further response to pregnancy. This is 
important in two respects: firstly, it implies that the metabolic adaptations of 
pregnancy may be overridden by the pre-existing effects of obesity or 
secondly, that there may be a limit beyond which further development of 
insulin resistance is not possible or desirable. 
With respect to pre-gravid obesity over-riding the metabolic demands of 
pregnancy, this may affect some but not all aspects of maternal metabolism. 
There are still some differences in the metabolic profile of obese pregnant 
women compared with non-pregnant obese women, particularly with 




with lean women, these changes occur at an earlier gestation. This may 
represent utilisation of what little reserve such patients have to respond to 
the various hormonal stimuli of pregnancy. The consequence of this is 
prolonged exposure of both the maternal and fetal systems to an 
environment which normally only exists in the third trimester.  
Following on from this, why does the maternal environment not simply 
continue to deteriorate, and become more insulin-resistant, with further 
hypertriglyceridemia? To avoid this further deterioration, there may be 
activation of counter-acting pathways. Evidence in support of this hypothesis 
includes increased expression of circulating anti-inflammatory cytokines in 
the plasma of obese pregnant women (Figure 4.12). Elevated IL-1Ra has been 
reported in both murine and human obesity, both circulating cytokine and 
white adipose tissue expression (Meier, Bobbioni, et al. 2002; Juge-Aubry, 
Somm, et al. 2003). In pregnant rats, IL1-Ra levels were no different to that of 
non-pregnant animals although their responses to injected 
lipopolysaccharide differed (Fofie, Fewell, et al. 2004; Ashdown, Poole, et al. 
2006); in human pregnancy however, an increase in IL-1Ra has been reported 
(Østensen, Förger, et al.  2004) including a potential link between fasting 
glucose, BMI and birthweight (Friis, Frøslie, et al.  2010). A further rise in IL-
1Ra in obese pregnant women may represent a potential mechanism to 
attenuate the adverse effects of excess pro-inflammatory cytokines.  
The concept of allostatic regulation of metabolism and allostatic load has 
been applied to obesity to account for the pathological processes observed in 
an obese non-pregnant population. Allostasis is the maintenance of 
normality through change and involves activation of compensatory 
mechanisms during periods of internal or external stress to promote 




activated or inactivated, this leads to allostatic load, which contributes to 
pathological changes and disease progression (McEwen, 1998). Normal 
pregnancy could be viewed as a temporary state of increased demand and 
change to maternal physiology, where certain pathways are activated to 
provide the required protection of maternal physiology during pregnancy, 
but which are then returned to normal after pregnancy is complete. In 
obesity, if some of these pathways are already maximally or constitutively 
activated, then this may result in an inability to mount the normal response 
to pregnancy (Power & Schulkin, 2012). Therefore some of the features we 
observe in obese pregnant women may be secondary to activation of 
adaptive responses and ultimately a limitation of plasticity within their 
physiology, where a normal allostatic response becomes pathological due to 





In this chapter it has been shown that obese pregnant women have profound 
insulin resistance, elevated triglyceride, NEFA, pro-inflammatory cytokines 
and dysregulated adipokine profile compared with lean pregnant women. 
We expected to find exaggeration of such metabolic features in these women 
as a result of the presence of the dual stressors of pre-gravid obesity and 
pregnancy; however, we instead found that by the third trimester, there were 
fewer differences between lean and obese women, particularly with respect 
to adipose tissue. Therefore, it may be that the adverse outcomes associated 
with obese pregnancies are due to duration or timing of exposure to an 
adverse metabolic profile rather than severity of exposure per se, and may 
reflect a greater pre-existing allostatic load in obese pregnant women 
compared with lean women. Therapeutic interventions may therefore be of 
most benefit if targeted to early pregnancy, though ideally pre-pregnancy, 
with the aim of improving maternal metabolic status at earlier gestations and 
reducing fetal exposure. However, the difficulty with such interventions 
would be in identification of an optimal target which would permit 
improvement in outcome without restricting the degree of adaptation which 
is required for a healthy pregnancy.  
The consequences of prolonged duration of exposure to a period of insulin 
resistance in obese women might be reflected in part in altered adipose tissue 
distribution with excess ectopic lipid in liver and skeletal muscle as well as in 
a differing pattern of adipose tissue accumulation in pregnancy between lean 
and obese women; in the next chapter, magnetic resonance imaging 





Chapter 5  
 
AMPOP study: Adipose distribution in the third trimester 




Adipose tissue distribution patterns have been associated with variations in 
risk of cardiovascular disease, notably an increased risk of insulin resistance, 
metabolic syndrome and type II diabetes mellitus in subjects with 
predominantly centrally distributed obesity (Lapidus, Bengtsson et al.  1984; 
Kissebah and Krakower. 1994; Canoy, Boekholdt et al. 2007; Fox, Massaro, et 
al., 2007; Demerath, Reed et al., 2008). This has led to the ‘portal’ theory of 
central obesity, where increased exposure of the liver to elevated levels of 
inflammatory cytokines, NEFA and other metabolites from omental adipose 
is thought to lead to hepatic insulin resistance (Kabir, Catalano, et al. 2008; 
Catalano, Stefanovski et al. 2010; Rytka, Wueest et al. 2011). However, the 
evidence for this being the dominant mechanism to account for the observed 
associations between adipose tissue distribution and metabolic disease is not 
strong. 
 
Obesity is also associated with accumulation of ectopic lipid outwith specific 
adipose tissue depots typically in liver (Bozzetto, Prinster et al. 2010) and 
skeletal muscle (Goodpaster, Theriault, et al., 2000), and particularly in 
association with abdominal obesity (Jakobsen, Berentzen et al.,  2007) and is 
thought to reflect saturation of the storage capacity of the adipose depot. 
However, in patients with lipodystrophy, there is liver lipid accumulation 




adipose tissue (Reitman, Arioglu et al., 2000). In animal models of this 
condition, transplantation of subcutaneous adipose reverses the insulin 
resistance (Gavrilova, Marcus-Samuels et al., 2000) as does treatment with 
leptin in humans (Petersen, Oral et al., 2002). Therefore it is not simply the 
presence of excess adipose, or more specifically excess subcutaneous adipose, 
which drives ectopic lipid accumulation.  
 
With respect to obesity, at any given level of obesity, there is a wide variance 
in insulin sensitivity (Ferranini, Natali et al., 1997) and the severity of 
observed hepatic steatosis is thought to reflect the degree of underlying 
insulin resistance rather than body fat content alone (Seppälä-Lindroos, 
Vehkavaara et al., 2002). The relationship between insulin resistance and 
ectopic lipid accumulation is less clear, ie. whether lipid accumulation is a 
cause or a consequence of insulin resistance. Hepatic lipid accumulation is 
associated with elevated inflammation and oxidative stress (Day and James,. 
1998). Thus, liver lipid accumulation initiates a cycle of worsening IR and 
enhanced lipid deposition, culminating in hepatic inflammation, fibrosis and 
hepatocellular damage. Clinically this manifests as non-alcoholic steato-
hepatitis, with deranged liver enzymes and hepatic dysfunction. Similarly, 
Intramyocellular lipid accumulation is associated with impaired IRS1 and 
PI3K action in human males (Virkamäki, Korsheninnikova et al., 2001). 
 
The relative contributions to the metabolic requirements of pregnancy of the 
pattern of fat accumulation or of the different adipose depots are not clear. 
We have already shown that obese women tend to gain less weight in 
pregnancy that lean women (Chapter 3 & 4), which is consistent with 




peripherally in contrast to obese women as assessed by skinfold thickness 
(Ehrenberg, Huston-Presley et al. 2003). However, there have not been any 
studies of intra-abdominal adipose tissue distribution to date. 
 
Similarly, hepatic and skeletal muscle lipid content have not previously been 
quantified in healthy pregnant women, although the rare condition of acute 
fatty liver of pregnancy is recognised (Moore, 1956; Ch’ng, Morgan, et al. 
2002; Knight, Nelson-Piercy, et al.  2008). The aetiology of this condition is not 
known but it is associated with rapid fat accumulation in the liver, in 
conjunction with elevated transaminases and hepatocyte damage. We have 
already shown in Chapter 4 that in the third trimester, lean women are 
significantly more insulin resistant than in the first half of pregnancy. 
Whether this manifests in hepatic lipid accumulation is not known. We have 
also shown that obese pregnant women have prolonged exposure to insulin 
resistance compared with lean women; this might be expected to be reflected 
by excess ectopic accumulation of lipid.  
 
Assessment of body fat distribution in pregnancy is technically challenging, 
particularly where the visceral component is concerned, and requires the use 
of imaging techniques.  To date, no other studies have made use of magnetic 
resonance imaging to assess body fat distribution in pregnancy, although this 
is a recognised approach in the non-pregnant population. It has the obvious 
advantage of avoiding the use of ionising radiation necessary with CT 
imaging and provides a much clearer definition of tissue margins than 
ultrasound, a widely used imaging modality in obstetrics.  Similarly, the use 




quantify ectopic lipid accumulation, in a population in whom the gold 
standard liver biopsy is clearly neither safe, practical or acceptable. 
 
We hypothesised that: 
1. MR imaging is practical to conduct in pregnancy in the third trimester at 
3T. 
2. MR imaging can be used to quantify intra-abdominal fat distribution. 
3. Hepatic and skeletal muscle lipid content is elevated in obese compared 
with lean pregnant women in the third trimester. 
4. An increase in intra-abdominal adipose tissue accounts for the majority 
of the difference in adipose tissue mass between lean and obese women. 
 
In this study we aimed to: 
 
1. Optimise an imaging protocol for measurement of (a) intra-abdominal 
adipose distribution and (b) hepatic and skeletal muscle lipid content in 
pregnant women in the third trimester. 
2. Quantify and compare adipose tissue distribution in lean and obese 
pregnancy women at 36 weeks gestation. 
3. Quantify and compare hepatic and skeletal muscle lipid in lean and obese 






5.2.1. Patient recruitment, exclusion and inclusion criteria 
 
Pregnant women were recruited from the Metabolic Antenatal Clinic and 
control cohort as described previously and were imaged at approximately 36 
weeks gestation. Lean women had a booking BMI between 20.0 and 25.0 
kg/m2; obese women had a booking BMI > 40.0 kg/m2. 
 
All women had healthy singleton pregnancies, a normal OGTT at 28 weeks 
and no contra-indications to MR scanning. Demographic characteristics are 
shown in Table 5.1. A fasting blood sample was obtained at the study visit 
for quantification of glucose, and anthropometric measurements made, 
including estimation of fat mass using bioelectrical impedance.  
 
5.2.2. Scanning protocol 
 
Patients were imaged at the Clinical Research Imaging Centre at the Royal 
Infirmary of Edinburgh on a Siemens Magnetom Verio 3T Whole Body MRI 
scanner (Siemens Medical, Erlangen, Germany). Patients were positioned in 
the scanner in a left lateral position to prevent aorto-caval compression. MRI 
data was obtained using a combination of body matrix and spine matrix coil 
elements.  The body matrix coil was positioned over the maternal liver and 
thigh. Aural protection was provided by use of ear plugs and headphones. 
Contact was maintained with the scanning staff at all times through the use 




scan process; blood pressure was recorded prior to commencing scanning 
and every 10 minutes thereafter. 
 
Scanning was carried out by Annette Cooper (radiologist) and Scott Semple 
(MR physicist). Image analysis was carried out by the investigator (SB), 
Carolyn Chiswick (clinical research fellow) and Calum Gray (physicist). 
Landmarking of images was carried out by SB, CG and Jane Walker 
(consultant radiologist).  
 
5.2.3. Scanning sequences 
 
MRI and MRS were acquired with a combination of body matrix and spine 
matrix elements. Two dimension (2D) multi-slice FLASH images were 
acquired axially central to the right lobe of the maternal liver with water and 
lipid signals in and out of phase, using echo times of 2.46, 4.92, and 8.61ms. 
MRI and MRS were also acquired in maternal right quadriceps. 
 
5.2.4. Quantification of intra-hepatic and skeletal muscle lipid 
concentration 
 
5.2.4.1. 1H-MR Spectroscopy 
 
1H MR spectroscopy (1H-MRS) is a technique which can be used to detect and 
quantify specific metabolites in a region of interest based on differing 
resonant frequencies of protons depending on the structure of the molecule 
they are present in. Thus different metabolites, in this case triglyceride, are 




spectrum. 1H-MRS can be used to quantify intracellular lipid as well as the 
total lipid content in a region of interest (Szczepaniak, Nurenberg et al. 2004; 
Springer, Machann et al., 2010) 
 
1H proton MRS PRESS single voxel spectra were obtained in the right lobe of 
the liver remote from any large vessels or subcutaneous adipose using an 
echo time of 30 ms and a voxel size of 3cm3. Spectra were also obtained in the 
right quadriceps muscle using the same echo time and a voxel size of 2cm3. 
Exemplar hepatic spectra are shown in Figure 5.1 below. 
 
Spectra were obtained with and without water suppression, and lipid 
concentration was calculated from the water-suppressed acquisition using 
the spectroscopy analysis tool JMRUI. This step is necessary in tissues with 
low lipid content, as in such tissues the water peak of the spectrum is much 
larger and wider than the lipid peak, which is thus more difficult to resolve. 
 
Figure 5.1 Representative hepatic spectra from lean and obese subjects 
 
Figure 5.1 Representative hepatic spectra from a lean subject (A) (BMI at 36 weeks 
26.3kg/m
2







5.2.4.2. In- and out-of-phase imaging 
 
In some subjects, it was not possible to obtain satisfactory hepatic 1H-MRS 
data. This occurred most commonly in subjects with the highest BMI, in 
whom there were issues with loading of the subject within the bore of the 
scanner, limiting spectroscopy data acquisition. This occurred for two 
reasons: firstly, significant distortion of the magnetic field led to difficulty 
with a process required to compensate for such lack of homogeneity 
(shimming); secondly, the region of interest (eg. liver) was physically further 
away from the coil therefore less signal was detected. 
 
Intrahepatic lipid signal contribution was therefore also calculated by the 
Dixon method through subtraction of in and out of phase images (2.46ms 
and 8.61ms), and T2* decay during this time corrected using the two in-phase 
images (2.46ms and 4.92ms) according to a well-established protocol 






5.2.5. Assessment of Abdominal Adipose 
 
5.2.5.1. Data acquisition 
 
To define subcutaneous and intra-abdominal fat, a 3D T1-weighted VIBE 
sequence was acquired axially through the liver with in and out phase 
images, and lipid signals defined using a combination of the in and out of 
phase images with a semi-automated thresholding technique employed 
using the commercial software SliceOmatic™ (TomoVision, Quebec, 
Canada).  
 
Adipose tissue appears bright on T1-weighted images. Regions of interest 
with attenuation above an investigator-defined threshold were coloured to 
delineate intra-abdominal adipose (red) and subcutaneous adipose (green). 
The area of the coloured regions was extracted, converted into a unit of 
volume (mm3) and expressed as a percentage of the total abdominal volume 
being examined. Intra-abdominal adipose was defined as all adipose tissue 
below the abdominal wall musculature; this includes omental, mesenteric 
and paranephric deposits but does not distinguish between intra- and retro-
peritoneal deposits. Subcutaneous adipose was defined as all adipose inferior 
to skin but outwith the abdominal cavity. Adipose tissue depots which were 
not definably subcutaneous but were obviously outwith the abdominal 
cavity were coloured blue and defined as paraspinal adipose. Where breast 
tissue was in the field of view, this was excluded from analysis.  Example 





Adipose tissue volumes were calculated using the extracted areas of the 
regions of interest (mm2) multiplied by the width of each slice (2mm); this 
was expressed as a volume in litres by dividing the volume in mm3 by 1x106. 
Adipose tissue mass was then be calculated using an estimate of adipose 
tissue density of 0.9kg/L.  
 




Figure 5.2 Representative abdominal slices from lean (A) (BMI at 36 weeks, 23.4kg/m
2
) and 
obese (B) (BMI at 36 weeks 43.7 kg/m
2
).  




5.2.5.2. Region selection 
 
A multi-slice approach was used as described in Chapter Two (2.7.3). Briefly, 
MR imaging facilitates acquisition of 2D image data as well as single or 
multiple slice 3D image data. Single slice data has the advantage of being 
rapid to acquire and analyse, but is limited in how representative it is of the 
region of interest. Multi-slice data takes longer to acquire and analyse but is 
thought to be more representative. Images were landmarked by the 
investigator (SB) and a consultant radiologist (Dr Jane Walker). The left renal 
pelvis was identified in all patients. Regions of adipose tissue were marked 




Intra-observer variability was assessed by the same observer (SB) defining all 
three regions on 5 slices from 9 subjects (n = 45 comparisons per depot) on 
two separate occasions. Inter-observer variability was assessed by 
comparison of data from 21 slices from 10 patients (n = 210 comparisons for 3 
depots) by two independent observers (SB and CC).  
 
For each set of paired data, two approaches were used to assess agreement. 
Firstly, readings were plotted pairwise, M1 vs M2, where M1 was the initial 
measurement and M2 was the repeated measure (Figure 5.4 and 5.6). The 
line of agreement was also plotted, representing expected values for M2 if 
there were 100% agreement between M1 and M2. Linear regression was 




better the agreement between the 2 measures.  M1 and M2 were correlated 
using Pearson correlation. 
 
Secondly, Bland Altman plots were constructed for each set of data (Bland 
and Altman, Lancet, 1986); this is a plot of the mean of M1 and M2 against 
the difference between them (M1-M2) (Figure 5.5 and 5.7). Ninety-five per 









5.3.1. Patient Demographic Characteristics 
  
Demographic characteristics of participants are shown in Table 5.1. Details 
are given for subjects whose data was used for the main analysis, excluding 
subjects scanned as part of protocol development. 
 
The mean age of women in the obese cohort was slightly lower than the lean 
cohort (28.4 ± 1.1 vs 32.5 ± 1.4 years, p = 0.04). While this is statistically 
significant, this four year difference does not represent a clinically significant 
difference in age. This perhaps represents the socioeconomic circumstances 
of the population of women from whom recruitment was drawn. There were 





Table 5.1 Demographic characteristics of study cohort 
 
 Lean (n = 10) Obese (n = 10) p 
Age (years) 32.5 ± 1.4 28.4 ± 1.1 0.04 




p, Visit 1 vs Visit 2 
 
61.95 ± 1.6 
73.3 ± 2.2 
< 0.0001a 
 
117.9 ± 4.7 








p, Visit 1 vs Visit 2 
 
22.8 ± 0.4 
27.0 ± 0.8 
< 0.0001 
 
44.2 ± 1.3 


















(Nulliparous/Total n) 6/10 3/10 0.37 
SBP at 36 weeks (mmHg) 108.9 ± 2.4 124.4 ± 3.2 0.001 
DBP at 36 weeks (mmHg) 64.0 ± 2.7 73.4 ± 2.1 0.01 
Mean ∆ weight (kg) 11.4 ± 1.4 5.3 ± 1.2 0.004  
Fat mass at 36 weeks (kg) 24.7 ± 1.3 60.8 ± 3.6 < 0.0001 
Fasting glucose at 36 weeks 
(mmol/L) 
4.1 ± 0.1 4.5 ± 0.2 
(n=6b) 
0.03 












Median gestation at delivery 
(weeks+days) 
40+4 40+4 0.60 
Birthweight (g) 3665 ± 113 3963 ± 194 0.18 
 
Data are expressed as mean ± SEM unless otherwise specified.  
Groups are compared using Students’ unpaired t-test unless otherwise specified. 
 
a. Data were compared between visit 1 and visit 2 using paired Students’ t-test 
b. Fasting blood glucose values at 36 weeks were only available for 6 of the women in the 
obese cohort as 4 women did not attend for blood sampling at this gestation.  
c. Delivery data were compared using Fisher’s exact test. Vaginal delivery includes 




5.3.2. Total abdominal volumes 
 
Total abdominal volumes within the 20-slice region analysed are shown in 
Figure 5.3. At 36 weeks gestation, obese women had significantly greater 
abdominal volumes compared with lean women in the same region. (6.63 ± 
0.3 vs 3.78 ± 0.2 litres, p < 0.0001). 
 
 























Figure 5.3 Total abdominal volumes within 20 x 2mm slice region of interest. 
Data are expressed as mean ± SEM; n = 10 per group. *** p <  0.0001 




5.3.3. Reproducibility of measurements 
 
Following repeated measurements by the same investigator (intra-rater) and 
of the same images by 2 investigators (inter-rater), correlative analysis was 
performed (Figure 5.4 and Figure 5.6). Measurements were highly correlated 
for pairs of measurements for each depot, Pearson r was greater than 0.97 for 
each depot.  
 
Bland-Altman analysis was carried out to illustrate the agreement between 
the pairs of measurements (Figure 5.5 and 5.7). Overall, on repeated 
measurement by both the same investigator and by another investigator 



























Paired subcutaneous adipose measurements


















Paired intra-abdominal adipose measurements

















Paired paraspinal adipose measurements





















Figure 5.4 Initial (M1) and repeated (M2) measurements of adipose volume per slice were 
plotted (cm
3
).  The line of equality in each plot has slope = 1, where M1 = M2.  
(A) All pairs of data; n = 135. Slope = 1.00± 0.005. Pearson r = 0.99 
(B) Paired SC data; n = 45. Slope = 1.02 ±0.006. Pearson r = 0.99 
(C) Paired intra-abdominal data; n=45. Slope = 0.97 ± 0.03. Pearson r = 0.98 

















Figure 5.5. Bland Altman plots of paired measurements.  
(A) All pairs of measurements (n = 130); Mean difference (Lower – upper 95% limits of 
agreement) = -1.79 (-7.26 – 3.68) cm
3
. 
(B) Paired subcutaneous measurements (n = 45); Mean difference (Lower – upper 95% 
limits of agreement) = -1.79 (-7.91 – 4.34) cm
3
. 
(C) Paired intra-abdominal measurements (n = 45); Mean difference (Lower – upper 
95% limits of agreement) = -2.55 (-8.77 – 3.68) cm
3
. 
(D) Paired paraspinal measurements (n = 45); Mean difference (Lower – upper 95% 
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Paired Intra-abdominal fat measurements
























Paired paraspinal adipose measurements





































Figure 5.6 Initial (M1) and repeated (M2) measurements of adipose volume per slice were 
plotted (cm
3
).  The line of equality in each plot has slope = 1, where M1 = M2.  
(A) All pairs of data; n = 672. Slope = 1.04 ± 0.004. Pearson r = 0.99 
(B) Paired SC data; n = 231. Slope = 1.01 ± 0.006. Pearson r = 0.99 
(C) Paired intra-abdominal data; n=231. Slope = 1.02 ± 0.02. Pearson r = 0.95 
(D) Paired paraspinal data; n = 210. Slope = 1.09 ± 0.03. Pearson r = 0.91 
 
All pairs

















Paired subcutaneous adipose measurements

















Paired intra-abdominal adipose measurements
















Paired paraspinal adipose measurements
























Figure 5.7 Inter-rater reproducibility: Bland Altman analysis  
 
 
Figure 5.7. Bland Altman plots of paired measurements.  
(A) All pairs of measurements (n = 672); Mean difference (Lower – upper 95% limits of 
agreement) = -1.80 (-10.16 – 6.56) cm
3
. 
(B) Paired subcutaneous measurements (n = 231); Mean difference (Lower – upper 
95% limits of agreement) = -4.9 (-11.9 – 2.0) cm
3
. 
(C) Paired intra-abdominal measurements (n =231); Mean difference (Lower – upper 
95% limits of agreement) = -1.5 (-10.0 – 6.9) cm
3
. 
(D) Paired paraspinal measurements (n = 210); Mean difference (Lower – upper 95% 






5.3.4. Subcutaneous, intra-abdominal and paraspinal fat masses 
 
Fat masses in the subcutaneous, intra-abdominal and paraspinal adipose 
depots are shown in Figure 5.8. Obese women had significantly greater fat 
masses in all 3 depots compared with lean women (subcutaneous, 2308 ± 197 
vs 539.9 ± 68.8 g, p < 0.0001, Figure 5.8A; intra-abdominal, 534.3 ± 64.8 vs 
128.8 ± 29.9 g, p < 0.0001, Figure 5.8B; paraspinal, 57.1 ± 15.6 vs 6.7 ± 1.8 g p = 










































































Fat mass in subcutaneous, intr-abdominal and paraspinal adipose depots. 
Data are expressed as mean ± SEM; n = 10 per group. ** p < 0.01 *** p < 0.0001 





5.3.5. Intra-hepatic and Intra-myocellular fat fraction 
 
Hepatic fat fraction was calculated using the Dixon method as described and 
expressed as a percentage of total liver volume. There was no significant 
difference between obese and lean women in hepatic fat fraction (1.2 ± 0.3 vs 
1.6 ± 0.4 %, p = 0.34, Figure 5.9). 
 
Intramyocellular lipid fraction was calculated using 1H-MR spectroscopy 
from a 2cm3 voxel placed in the right quadriceps muscle as described. Obese 
women had significantly greater intramyocellular lipid compared with lean 








Figure 5.9 Hepatic fat fraction.  







Figure 5.10 Intramyocellular lipid content of quadriceps muscle in lean 
and obese pregnant women at 36 weeks gestation 
 
 
Figure 5.10 Intramyocellular lipid content of quadriceps muscle 
Data are expressed as mean ± SEM (%) and compared using Students’ t-test.  






5.4.1. Validation of experimental protocol 
 
5.4.1.1. Evaluation of MR imaging as a means of assessing intra-abdominal 
adipose tissue volume 
 
In this chapter we have shown that adipose tissue can be identified and 
quantified using MR imaging techniques.  
 
Data acquisition for measurement of adipose tissue volumes was possible for 
all patients; however, for participants with very high BMI, data were limited 
by the full abdominal circumference occasionally not being included in the 
largest field of view available for every slice analysed. Since the scan 
machine used has a bore of 70cm, the largest scanner bore currently available 
for human clinical use in the UK, there are implications for imaging our 
increasingly obese population. However, the main limiting factor is the 
ability to generate an accurate and stable magnetic field (in this study, 
approximately 50cm diameter); beyond this, there is significant image 
distortion at the peripheries. Therefore it is not simply a matter of physically 
fitting the subjects within the scanner bore but also within a reliable and 
accurate field of view.  
 
MRI techniques have been validated for measurement of adipose tissue in 
animal models (Fowler, Fuller et al., 1992) and human cadaveric studies 
(Abate, Burns et al. 1994) as well as showing high agreement with other 




Fowler et al. 1991). In our study, adipose tissue depots were quantified using 
the SliceOmatic™ semi-automated thresholding technique which has been 
evaluated in comparison with other methods and has been found to be 
reliable (Bonekamp, Ghosh et al. 2008).  In this cohort, identification of 
adipose tissue was straightforward for the subcutaneous depot, as the 
boundaries of the abdominal cavity were clear. Limitations in identifying this 
region lies in occasional slices not having the full abdominal circumference in 
the field of view as a result of subject habitus as discussed above. Thus, 
estimation of subcutaneous adipose volumes may be underestimated in the 
high BMI cohort. The intra-abdominal deposits were less clearly defined. 
Definition of a paraspinal depot was included as extracellular lipid was 
identifiable in some participants distinct from subcutaneous or intra-
abdominal adipose. 
 
With respect to reproducibility of measurements of adipose tissue volume, 
we have shown that there is a high level of inter and intra-rater correlation 
(Figures 5.4-7). This is greatest for measurements of subcutaneous adipose 
tissue, and least for measurements of paraspinal adipose deposits. 
Subcutaneous adipose volumes were largest therefore small differences in 
delineating a region of interest had a negligible effect, whereas the paraspinal 
deposits were very small, with the largest measurement less than 100ml, thus 
variations in measurement had a greater effect. Additionally, the 
subcutaneous region was the most easily identifiable, with clear margins, 
whereas definition of regions of intra-abdominal or paraspinal adipose 
required greater individual interpretation. That there were high levels of 
inter-rater agreement for the intra-abdominal depot despite this, suggests 




volumes of adipose tissue, including subcutaneous and intra-abdominal, it is 
not yet a satisfactory means of quantifying small deposits of adipose.  
 
With respect to defining a region of abdomen in which to quantify fat 
content, a number of approaches have been applied in the literature (Han, 
Kelly et al., 1997; Thomas and Bell, 2003; Demerath, Shen, et al., 2007). These 
include either use of a single representative slice or use of multiple slices to 
assess intra-abdominal adipose, both at a fixed anatomical landmark, 
typically L2/3 or L4/5 diskspaces. The former approach is less time-
consuming, both for image acquisition and analysis. However, single slices 
are less representative of an abdomen, as lipid distribution is highly 
dependent on patient and organ positioning. Omental adipose contributes 
the majority of intra-abdominal adipose and is a highly mobile organ. The 
latter approach covers a wider region of interest allowing more accurate 
quantification which is more representative of intra-abdominal adipose 
distribution, although single slice estimates correlate closely with multiple-
slice data (Ross, Léger et al., 1992).  
 
In this study, there were several factors influencing our approach. Firstly, 
patients were positioned in a left-lateral tilt rather than supine to prevent 
aorto-caval compression. Secondly, at 36 weeks gestation, the gravid uterus 
takes up a large proportion of intra-abdominal volume. Both of these 
contribute to a significant distortion of the normal female intra-abdominal 
anatomy, with both compression and elevation of organs in a variable 
distribution. This leads to issues with defining a region of interest. Firstly, the 
routine landmarks used for the non-pregnant population, while fixed, lie in 




the field of view at this level will be composed of uterus and uterine contents 
rather than intra-abdominal organs. Secondly, acquisition of MR data is 
affected by motion artefact; contributions from fetal movement and amniotic 
fluid thus limit the usefulness of data in this region. We therefore 
endeavoured to identify a fixed landmark cranial to this.  The left renal pelvis 
was chosen as a suitable landmark (a) as it was clearly identifiable in all 
patients, (b) since it is a retro-peritoneal organ, it is less affected by the 
presence of a gravid uterus and (c) it is sufficiently cranial to uterine fundus 
that acceptable data quality is maintained. Following identification of a fixed 
anatomical landmark, a multi-slice approach was used and a region 
composed of 20 x 2mm consecutive slices cranial to left renal pelvis were 
analysed using SliceOmatic™ as described.  
 
It was felt that a single-slice approach would be insufficiently representative 
in this population and that this would outweigh the validity of data 
acquired. However, a multi-slice approach which included the uterus would 
be sufficiently affected by artefact that the additional data would not be 
reliable. We believe that our approach is suitable for comparison of 
abdominal fat content in lean and obese pregnant women. However, it is not 
possible to determine whether these measurements are comparable to the 
general non-pregnant population and further imaging of an age- and BMI-





5.4.1.2. Evaluation of MR imaging modalities as a means of assessing intra-
organ lipid content in pregnant women 
 
While liver biopsy is considered the gold standard method for determining 
organ lipid content in vivo, the need for non-invasive methods of 
quantification has led to the development of a number of alternative imaging 
techniques, such as ultrasound, CT imaging and MR methods such as 1H-
MRS. 1H-MRS allows accurate determination of lipid content and has been 
validated against histological measurement of organ lipid content 
(Szczepaniak, Babcock et al., 1999) but is predicated on acquisition of 
satisfactory spectra. In this cohort, practical considerations limited spectra 
acquisition, predominantly in the high BMI cohort. Asymmetric loading of 
the subjects into the scanner bore and distortion of the magnetic field by high 
body mass led to inadequate spectra acquisition.  
 
A further issue limiting the use of spectroscopy in the liver was that of voxel 
placement. Voxels are required to be placed in a homogenous region of liver, 
free of vessels or obvious fat deposits, distant from lung and subcutaneous or 
visceral adipose; in this cohort, we found that hepatic vessels were generally 
very prominent in all subjects, which may reflect physiological 
cardiovascular adaptation of pregnancy, and thus satisfactory voxel 
placement was difficult, contributing to suboptimal spectra acquisition. The 
presence of flowing blood within a voxel is likely to cause a degree of 






An alternative method for determining the lipid content of an organ is the 
Dixon technique, which makes use of the differing relaxation times of water 
and fat and applies post-processing algorithms to MR images acquired with 
water and fat signals in phase, and at 180o out of phase. By using subtraction 
of these in and out of phase images, the proportion of fat and water in the 
region of interest can be obtained. This method has the advantage of not 
being influenced by voxel placement or patient positioning in the scanner; 
however, sequence acquisition time is considerably longer for each subject 
compared with that for 1H-MRS, and requires a breath-hold technique, 
limiting its acceptability to some subjects.  
 
In this study, we found that while 1H-MRS was possible in skeletal muscle, it 
was not possible to reliably acquire satisfactory hepatic spectra in the very 
obese subjects. We therefore used the Dixon method to determine liver fat 




5.4.2.  Adipose accumulation in the third trimester in healthy pregnant 
women  
 
5.4.2.1. Adipose tissue distribution in the third trimester in healthy pregnant 
women  
 
Excess visceral fat accumulation has been associated with reduced insulin 
sensitivity and increased risk of metabolic syndrome and type II diabetes 
(Nguyen-Duy, Nichaman et al. 2003). We have shown that in the third 
trimester, obese pregnant women have significantly greater subcutaneous, 
intra-abdominal and para-spinal adipose depots compared with lean women 
of the same gestation.  
 
The reliability of quantification and significance of paraspinal adipose 
accumulation is uncertain. It was observed more commonly in obese 
compared to lean women but may reflect increased ectopic lipid 
accumulation, rather than a specific adipose depot, and certainly is very 
small compared to the larger subcutaneous and intra-abdominal depots. 
 
The mechanism by which visceral adipose is thought to contribute to hepatic 
insulin resistance possibly involves exposure to cytokines and metabolic 
intermediaries via the portal circulation (Kabir, Catalano et al. 2008; Catalano, 
Stefanovski et al. 2010; Rytka, Wueest et al. 2011). Plainly, the mass of adipose 
tissue alone does not account for the development of insulin resistance in 
pregnancy: at this gestation, lean and obese women have equivalent insulin 
sensitivities, as we have shown in Chapter 4. While increased adipose tissue 




direct causation. However, removal of visceral fat in rats has been shown to 
improve insulin sensitivity (Gabriely, Ma et al. 2002) and weight loss in 
humans is also associated with improvement in metabolic and inflammatory 
parameters and insulin sensitivity (Holte, Bergh et al.  1995; Dandona, 
Weinstock et al. 1998; Halle, Berg et al.  1999; Christiansen, Richelsen, et al. 
2004). 
 
A more useful measure could be the relative changes in adipose depots in 
pregnancy ie if pregnancy-associated weight gain is preferentially 
subcutaneous or visceral. Both lean and obese women have approximately 
four times more subcutaneous than intra-abdominal adipose, and obese 
women have approximately four times more subcutaneous and intra-
abdominal adipose than lean women. However, given that lean women 
expand their fat mass more than obese women during pregnancy, whether 
this is equal over both depots is not known.  In a murine model of high-fat 
feeding in our laboratory, high-fat fed mice had decreased fat mass in the 
mesenteric depot in response to pregnancy, converging with similar depot 
size as control mice by the end of pregnancy. Additionally, high-fat fed 
pregnant mice had decreased subcutaneous fat compared with high-fat fed 
non-pregnant mice. Compared with control mice, high-fat fed mice always 
had a greater subcutaneous depot in non-pregnant and pregnant animals; 
however, control animals preferentially gained subcutaneous fat in response 





5.4.2.2. Ectopic lipid accumulation in the third trimester in healthy pregnant 
women 
 
Accumulation of liver and skeletal muscle lipid has been associated with 
metabolic syndrome, global insulin resistance and obesity, and may reflect 
ectopic lipid deposition. Hepatic lipid accumulation correlates inversely with 
insulin sensitivity in subjects with type II diabetes (Ryysy, Häkkinen et al, 
2000) and is associated with markers of metabolic dysfunction such as 
increased insulin concentrations, triglycerides and fasting glucose 
concentrations (Kotronen, Juurinen et al.,  2008). While obesity is an 
independent risk factor for enhanced insulin resistance, for any given level of 
obesity, there is great variability in the degree of insulin resistance (EGIR 
data) and associated hepatic lipid deposition.   
 
In a study of obese women with a history of gestational diabetes, women 
with higher levels of liver fat (~9%) as quantified by 1H-MRS had 
significantly lower whole body insulin sensitivity compared to women of 
similar BMI but with lower liver fat content (3.2%). Liver fat content was 
correlated with fasting insulin, triglyceride levels and systolic blood 
pressure, even after adjusting for sc adipose depot size and BMI (Tiikainen, 
Tamminen et al, 2002).  In our cohort, pregnant women in the third trimester 
had even lower liver fat content compared to those in the Tiikainen study, 
regardless of BMI and despite profound insulin resistance, suggesting a 






In Sprague-Dawley rats, liver weight increases in pregnancy and lactation 
compared to non-pregnant animals (Cunnane and Armstrong, 1989). Hepatic 
total lipid concentration increased in late pregnancy but triglyceride content 
had a different pattern, first decreasing by mid-pregnancy, then increasing to 
non-pregnant levels, followed by a further increase with lactation. In fatty 
liver of pregnancy, there is an acute accumulation of free fatty acids (Eisele et 
al, 1975); this contrasts to nutritional fatty liver, where the majority of 
accumulation of hepatic lipid is triglyceride. 
 
We have shown in Chapter 4 that in healthy pregnant women, there is no 
significant difference between lean and obese women in systemic insulin 
sensitivity as assessed by whole body glucose disposal in the third trimester. 
This may account for lack of observed difference in hepatic lipid 
accumulation between lean and obese women at the same gestation, if lipid 
accumulation is driven by reduced insulin sensitivity.  
 
However, we have also shown that morbidly obese and lean pregnant 
women in the third trimester have insulin sensitivities approximately 30% 
lower than that of lean non-pregnant women. Despite this greatly reduced 
insulin sensitivity, hepatic lipid accumulation is globally low in lean and 
obese women, approximately 1.5%. This contrasts with reported hepatic fat 
contents of 3-25% in other obese populations (Fabbrini, Magkos et al. 2009; 
Sijen, Edens et al. 2010). Calculated liver fat content in this cohort of patients 
is very low. Typically, insulin resistant, diabetic subjects have liver fat 
contents exceeding 5%, the diagnostic cutoff for hepatic steatosis 
(Szczepaniak, Nurenberg et al, 2004). However, in quadriceps muscle, there 




with lean women in the third trimester, which is consistent with elevated 
intramyocellular lipid observed in non-pregnant insulin resistant 
populations (Krssak, Petersen et al. 1999; Kuhlmann, Neumann-Haefelin et al. 
2003). Intramyocellular lipid content has been estimated at approximately 2% 
in 1H-MRS studies of lean subjects (Krssak, Falk Petersen, et al. 1998) which is 
in keeping with our findings in lean pregnant women.  
 
If ectopic lipid accumulation is simply a function of insulin 
resistance/sensitivity, then we may expect either (a) that obese women in the 
third trimester will have greater hepatic and skeletal muscle lipid 
accumulation compared with lean women, perhaps secondary to prolonged 
exposure to reduced IS, or (b) that there is no significant difference between 
lean and obese women in the third trimester in either hepatic or skeletal 
muscle accumulation, as they have equivalent global insulin sensitivities at 
this gestation. That they have differential accumulation of ectopic lipid in 
these sites despite equivalent IS points to a potential pregnancy-specific 
mechanism limiting hepatic lipid accumulation in the face of reduced IS in 
lean women, and in over-riding the effect of obesity on hepatic but not 
skeletal muscle lipid accumulation.  
 
In Chapter Three, we showed that ALT normalises in obese pregnant women 
with advancing gestation (Figure 3.11). ALT can be used as an indicator of 
the presence of hepatic steatosis, although there are some limitations to this 
(Clark, Brancati, et al. 2003). The reduction in ALT observed in obese 
pregnant women may reflect improvement in hepatic lipid content in 
pregnancy, although imaging at an earlier gestation would be required to 




hepatic fat contributes significantly to systemic insulin resistance. In 
pregnant women, firstly, despite profound insulin resistance, lean and obese 
women have apparently normal liver function and low levels of hepatic fat. 
This would suggest that the insulin resistance of pregnancy is brought about 
by different mechanisms to those seen in obesity and type II diabetes 
mellitus. Secondly, obese women, in the presence of both pregnancy and 
obesity, appear to shown an improvement in transaminase levels as well as 
low liver fat in the third trimester which is suggestive not only of discrete 
mechanisms driving pregnancy-related insulin resistance but also of 
mechanisms specifically protecting the liver from lipid accumulation.  
 
If not hepatic lipid as a driver of pregnancy-related insulin resistance, then 
perhaps intramyocellular lipid? There is greater myocellular lipid content in 
both lean and obese women compared to liver but muscle lipid content is in 
keeping with reported values in the literature on non-pregnant individuals. 
This would suggest that ectopic lipid is perhaps less important in the 
development of pregnancy-related insulin resistance than it is in other 
circumstances and that while in muscle at least, the effect of obesity persists, 






We have shown that MRI is a satisfactory means of obtaining information 
regarding adipose tissue distribution and ectopic lipid accumulation in 
pregnant women in the third trimester and that while established techniques 
are possible in such women, there are significant practical limitations on the 
use of such techniques, such as 1H-MRS in morbidly obese women.  
 
We have also shown that in the third trimester, while morbidly obese women 
have significantly greater subcutaneous and visceral adipose tissue depots, 
this is associated with greater skeletal muscle lipid content but no significant 
difference in hepatic ectopic lipid content, despite similar degrees of insulin 
sensitivity in lean and obese women at this gestation. This points to a 
pregnancy-specific mechanism which possibly overrides the effects of 





Chapter 6 General Conclusions 
6.1.  Summary of Findings 
In this thesis we have described the anthropometric and metabolic 
phenotype of Class III obese pregnant women. We initially hypothesised that 
obesity and pregnancy would interact to cause an exaggerated adverse 
metabolic profile, thus contributing to the pathophysiology seen in such 
pregnancies. Instead, we have observed that although some features 
characteristic of obesity outwith pregnancy (such as profound insulin 
resistance, a pro-inflammatory circulating environment and dyslipidaemia) 
are maintained the surprising finding was that in many cases, lean women, 
with almost half the adipose tissue mass, had very similar metabolic 
characteristics by the third trimester as obese women. Indeed, the key 
finding appeared to be a lack of an additive effect of pregnancy and obesity, 
i.e. an apparent limit of metabolic adaptation beyond which obese women do 
not deteriorate further but appear to reach more quickly compared with 
normal weight women. Thus, these data suggest that the main driver of 
many of the adverse outcomes in obese pregnant women is not the severity 
of these metabolic adaptations but could be the duration for which the 
pregnant woman and offspring are exposed to them.  
This has three implications. Firstly, quantification of an acceptable limit of 
metabolic adaptation in pregnancy would be essential in development of any 
potential new therapies designed to counter the effect of obesity in 
pregnancy, as clearly, some degree of metabolic adaptation is required for 
normal pregnancy. Secondly, a means of quantifying the degree of pre-
existing metabolic disturbance would be of use to potentially identify those 




identification of the mechanisms or pathways which contribute to improving 
metabolic function may provide new therapies for obese pregnant women. 
In Chapter Three, we described firstly the longitudinal inflammatory and 
metabolic characteristics of healthy lean and obese women and secondly 
some of the adipose tissue characteristics in term pregnancies. We showed 
that there appeared to be a convergent path followed by lean and obese 
women in pregnancy. We expected to show an exaggerated pro-
inflammatory environment with dysregulated metabolic features in obese 
pregnant women; however, many of the adipose tissue characteristics 
expected at term were not observed, notably any upregulation of leptin 
transcripts in correlation with BMI, or a clear pro-inflammatory phenotype. 
Some non-pregnant characteristics were preserved: circulating leptin was 
greater in obese women throughout pregnancy, there was evidence of mildly 
elevated pro-inflammatory cytokines such as IL-6 and MCP-1, and fasting 
insulin was also greater. However, these differences were significantly 
blunted compared to what we had initially hypothesised. This work had two 
main weaknesses. Firstly, there was no non-pregnant control group. This 
meant that it was not possible to say whether the lean women showed 
deterioration in metabolic and inflammatory parameters, or whether instead, 
pregnancy conferred a protective effect on very obese women. Secondly, BMI 
was always considered as a function of early pregnancy BMI, despite this 
being an observation made in some cases nearly 6 months prior to samples 
being obtained at delivery. Weight gain or weight change in pregnancy was 
therefore a potential confounding factor.  
The first of these considerations was addressed by the design of the AMPOP 
study (Chapter Four). In this study, both lean and obese pregnant women 




afforded the opportunity to dissect the relative contributions of pregnancy 
and obesity. In this chapter, we showed that in pregnancy, lean women do 
appear to converge with obese women, such that in the third trimester, there 
are many metabolic similarities between lean and obese women, notably in 
terms of their profound insulin resistance as assessed by hyperinsulinaemic 
euglycaemic clamp. While this study was limited by the small numbers of 
subjects, each participant was carefully characterised in detail, and the 
observed differences between groups were of sufficient magnitude to be 
detected even in a small group. The AMPOP study also clearly showed that 
in obese women, pregnancy does not appear to be able to exert the same 
magnitude of effect as occurs in lean women. This suggests either that in 
severe obesity, there is a limit of metabolic reserve or dysfunction which 
cannot be overridden by the additional stimulus of pregnancy, or that in 
pregnancy, there is an ability to ‘sense’ the pre-existing metabolic 
environment and either switch off the normal adaptive mechanisms or even 
activate some protective mechanisms which maintain the correct metabolic 
environment required for a successful pregnancy.  
Evidence for extra-adipose manipulation of metabolic changes in pregnancy 
in the context of obesity is indirect. In both Chapters Three and Four, we 
observed that while a degree of metabolic dysfunction remained in obese 
compared with lean women in the third trimester, some of the adipose tissue 
characteristics that might have been expected to account for these differences 
were not present. For example, obese women had elevated circulating leptin 
throughout pregnancy. However, by the end of pregnancy, transcript levels 
of leptin were not elevated in obese compared women in either subcutaneous 
or omental adipose and instead appeared to have decreased compared to 




source of leptin, but also a mechanism by which adipose tissue can 
potentially ‘normalise’. In contrast, excess inflammation persisted in obese 
pregnant women by the end of pregnancy compared to lean women. 
However, transcript levels of pro-inflammatory cytokines increased in 
response to pregnancy in both lean and obese women, by the third trimester, 
the effect of BMI was only seen to a small degree in subcutaneous adipose 
and abolished in omental adipose and there was an increase in circulating 
pro-resolution cytokines in obese pregnant women.  Together, these data 
suggest a potential dampening of the adipose tissue response to obesity in 
the context of pregnancy both by an alternative source of adipose tissue 
products eg. placenta and an activation of a potential pathway which would 
improve the maternal environment. 
The role of different adipose depots is also important. In Chapter Five, MR 
imaging was employed to address the question of preferential accumulation 
of adipose in specific depots. From skinfold data in Chapter Three, it 
appeared that obese pregnant women lost subcutaneous adipose mass, 
particularly in the biceps and triceps, while lean women had relatively little 
change in any of their peripheral skinfolds. We therefore hypothesised that 
changes in the intra-abdominal depot may be more important. From the data 
in Chapter Five, we showed that obese women have greater adipose 
accumulation in both subcutaneous and intra-abdominal adipose but that 
there did not appear to be preferential accumulation at any one particular 
site compared with lean women. Finally, we have shown that in the third 
trimester, despite profound insulin resistance comparable to obese non-
pregnant individuals, that hepatic lipid accumulation is low in both lean and 
obese pregnant women, despite persistence of skeletal muscle lipid 




was not included in this part of the study, the techniques applied were 
comparable to those used widely in the non-pregnant literature. If this is a 
true representation of liver lipid accumulation in pregnancy, then there must 
exist some pregnancy-specific mechanism to account for this in the presence 
of systemic insulin resistance. Other markers of liver health such as 
measurement of transaminases showed an apparent improvement in 
severely obese women with advancing gestation (Chapter Three, Figure 
3.11). Together, these data suggest that liver remains healthy throughout 
pregnancy despite significant alterations to systemic insulin sensitivity, and 
that pregnancy may actually have a beneficial effect on the liver by reducing 
metabolic stress in the context of obesity. While in non-pregnant individuals, 
the liver is central to regulation of insulin sensitivity and intermediary 
metabolism, this seems to be less important in pregnancy.  
Given the apparent diminution of the role of both adipose tissue and liver in 
driving insulin resistance in pregnancy regardless of the presence of obesity, 
the role of the placenta in manipulating the maternal environment is key. The 
feto-placental unit is the only difference between pregnant and non-pregnant 
women and it seems logical that the stimulus for adaptation of maternal 
metabolism originates at this site at the interface between maternal and fetal 
compartments. This temporary organ has the capacity to sense both the 
maternal and the fetal environment as well as to secrete hormonal mediators 






6.2. Clinical Applications 
Interventions to improve outcomes in obese pregnancies are currently 
limited, in part due to lack of any specific therapeutic targets and also in part 
due to the unknown implications of antenatal interventions on the long term 
health of the offspring. It is becoming clear that the in utero environment is 
not only highly important in determining the risk of the offspring developing 
later disease, but that, particularly in the case of female offspring, there is 
also an impact on the subsequent generation through effects on developing 
gametes.  
The main therapies currently in routine clinical practice are largely those 
designed to identify pregnancy complications as early as possible eg. 
screening for GDM and pre-eclampsia, and treat them once they have 
already occurred. There are also strategies to try to improve overall health 
during pregnancy by the advocacy of healthy diet, minimising weight gain 
and increasing exercise. Such lifestyle measures meet with limited success on 
an individual basis (Nelson, Matthews, et al., 2010), but have the advantage 
of having the potential to influence more than just the patient, including the 
patient's family though health promotion, and an as yet unquantified effect 
on the offspring. Specific pharmacological interventions are few and are 
currently at trial stage, for example, the EmPOWAR trial, a randomised 
controlled trial of the use of metformin in obese women as a means of 
improving insulin sensitivity. 
In this study, we have shown that there may be two possible avenues to be 
exploited: firstly, identification of those with an adverse baseline metabolism, 
who may be most at risk of crossing a threshold from compensation to overt 
disease; and secondly, that pregnancy itself may have potential mechanisms 




in obese women, what little metabolic adaptation occurs happens early in 
pregnancy, and therefore the timing of any such interventions to early in 
pregnancy may be most beneficial. 
6.2.1. Identification of Physiological Reserve 
In non-pregnant individuals, it has long been recognised that for a given 
degree of obesity, there is a high level of heterogeneity in the corresponding 
degree of insulin resistance (Ferrannini, Natali et al.  1997), leading to the 
concept of the ‘metabolically healthy obese’ phenotype.  Therefore, there are 
likely to be mechanisms in such individuals which confer protection from the 
normally detrimental effects of excess adiposity. It may be that in the 
obstetric population, such individuals are more commonly represented, in 
that the obstetric population is made up of individuals who have managed to 
maintain a successful conception and pregnancy. Obesity has been associated 
with reduced fertility (Maheshwari, Stofberg, et al. 2007; Bellver, Melo, et al. 
2007); it is a risk factor in individuals with PCOS, who are more likely to 
have anovulatory cycles and difficulty conceiving, and weight loss has been 
shown to improve reproductive potential (Huber-Buchholz, Carey, et al. 
1999). Once conception has occurred, obesity is also associated with an 
increased risk of miscarriage (Lashen, Fear, et al. 2004). By studying the 
obstetric population, we may already be selecting out those obese 
individuals who have the most severely affected phenotype, or who do not 
have the reserve to maintain even a very early pregnancy.  
However, within the obese obstetric population, there are clearly still those 
who go on to develop complications in pregnancy, largely related to 
metabolic or vascular pathologies. One of the common conditions associated 
with obese pregnancies is gestational diabetes. This condition has many 




women who develop gestational diabetes will go on to develop type II 
diabetes in later life (Kim, Newton, et al. 2002) However, this is not a 
condition of insulin sensitivity reserve so much as that of pancreatic reserve, 
in that GDM develops in women unable to maintain the requisite 
compensatory hyperinsulinaemia. Ideally then, a marker of beta cell reserve 
could be of use in predicting those women at high risk of developing GDM. 
Similarly it could be anticipated that there should exist a putative marker, or 
markers, of vascular reserve function, which could identify those obese 
women at high risk of developing pregnancy induced hypertension or pre-
eclampsia.  
In the AMPOP study, we showed that although by the third trimester obese 
women do not appear to be any worse than lean women in terms of insulin 
sensitivity, instead, they appear to maintain this environment throughout 
pregnancy, and that it is therefore potentially duration of exposure rather 
than severity of exposure which is important in defining risk of adverse 
outcomes. Markers of adverse baseline metabolism could be therefore 
potentially be used to identify those women at highest risk early on in 
pregnancy and manage them accordingly if it could be shown in larger 
population studies that these markers were predictive of adverse pregnancy 
outcomes. Whether this would truly be of benefit is uncertain given the 




6.2.2. Potential Protective mechanisms in obese pregnancies 
The role of placenta is crucial in that it is ideally placed as an interface 
between the maternal and fetal environment, and is therefore able to detect 
or sample the maternal environment as well as act as a selective barrier 
limiting exposure of the fetus to a potentially harmful metabolic milieu. We 
have previously shown some differences in expression of pro-inflammatory 
genes between placentae of lean and obese women although many other 
characteristics were unchanged (Roberts, Riley, et al. 2010). Placenta of lean 
and obese subjects have also been shown to have altered placental nutrient 
transport and GLUT1 expression (Hahn, Barth, et al. 1998; Dubé, Gravel et al. 
2012); such changes may reflect placental adaptation to the maternal 
inflammatory and metabolic environment, acting as a buffer between 
maternal and fetal circulation. However, while maternal obesity clearly can 
affect fetal growth and likely later life metabolic responses, it is possible that 
this effect is attenuated by placental mechanisms. While adipose tissue 
pathways are clearly important in driving obesity-related metabolic 
dysfunction, they do not appear to be as important where obesity and 
pregnancy co-exist. Placental signalling to the maternal environment then 
becomes a strong candidate to account for the apparent convergence of obese 
pregnancies with the lean phenotype.  
Such a potential protective mechanism is the role of anti-inflammatory or 
pro-resolution pathways. We showed in Chapter Four, that obese pregnant 
women have elevated levels of interleukin 1-Ra, a key anti-inflammatory 
cytokine. It is possible that these pathways are activated to counter the pro-
inflammatory drive of obesity, and indeed anti-inflammatory activity has 
been observed in obese subjects (Meier, Bobbioni, et al. 2002; Charles, 




se, which is then exploited in pregnancy, potentially secreted from the 
placenta, is not known, but may offer a potential opportunity both as a 
marker of severity of adverse metabolic environment or as a potential 




6.3. Final conclusions 
In this thesis, it has been shown that in pregnancy, there appears to be a 
maximal limit to the required metabolic adaptation which is reached by lean 
women in the third trimester but that this may pre-exist in obese women, 
who are already at or close to this limit prior to pregnancy. Secondly, there 
does not appear to be a further drive to worsen the metabolic environment of 
obese pregnant women, who appear to reach a ‘third trimester’ environment 
early on in pregnancy, and then maintain it. Thirdly, there may exist 
pregnancy-specific mechanisms which serve to adapt maternal metabolism 
proportionately to the pre-existing environment, and may even extend to 
ameliorating some of the adverse effects of pre-gravid obesity, such as 
ectopic hepatic lipid accumulation. 
Future work focussing on early pregnancy metabolic adaptation and 
placental function may thus identify some of these protective mechanisms 
and facilitate the development of focussed interventions to improve the 
health of obese pregnant women, their offspring, and potentially the obese 
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